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 ABSTRACT 1 
ABSTRACT 
The gastric pathogen Helicobacter pylori infects approximately half of the world population. 
It colonizes the gastric mucosa persistently, causing various diseases including gastric cancer. 
As H. pylori becomes increasingly resistant to the current therapeutic antibiotics, alternative 
treatment strategies are urgently required. The development of gastric disorders is at least 
partly due to the H. pylori Cag type IV secretion system. This molecular machine transfers the 
bacterial oncoprotein CagA (cytotoxin-associated gene product A) into gastric cells. Inside 
the host cell, CagA hijacks intracellular signaling cascades, finally promoting gastric 
carcinogenesis. This work aimed to elucidate mechanisms of CagA translocation as well as to 
find substances which inhibit this process.  
As alternative methods for analyzing CagA translocation are time-consuming and labor-
intensive, a novel reporter system was established, which is based on the fusion of a TEM-1 
β-lactamase to full-length CagA (TEM-CagA). TEM-CagA translocation by H. pylori into 
target cells can be monitored by TEM-1-mediated cleavage of the fluorescent β-lactam 
derivative CCF4. This fast, sensitive and highly specific method enables quantitative CagA 
translocation analysis by any fluorescence-assisted device. Applying this assay, CagA 
translocation dynamics as well as the type IV signal recognition and secretion process were 
investigated. Specifically, the impact of partially uncharacterized Cag components on CagA 
translocation efficiency was determined, and the stabilizing role of the CagA chaperone, 
CagF, further defined. It could be shown that the C-terminal secretion signal of CagA is 
defined rather by its minimal length than by a distinct signal sequence. A contribution of the 
foremost CagA N-terminus for signal recognition was excluded, while an extensive internal 
CagA domain was indispensable for CagA delivery. Moreover, CagA translocation was 
proven to depend on bacterial de novo protein synthesis and active host cellular processes. 
To prevent CagA-induced carcinogenesis, anti-infectives which directly block CagA 
translocation into host cells would be most effective. Hence, the TEM-CagA assay was 
downscaled for screenings of compound libraries to identify specific Cag type IV secretion 
inhibitors for usage as therapeutic pathoblockers. This procedure resulted in preliminary 
identification of two related compounds that were able to specifically inhibit CagA 
translocation in vitro. In addition, these screening studies yielded other substances which were 
shown to specifically inhibit H. pylori growth in vitro by targeting its respiratory chain, and 
two of these substances were provisionally validated as potential new antibiotics. Thus, this 
work did not only contribute novel mechanistic insights into CagA translocation, but further 
revealed two promising approaches to treat infection with H. pylori. 
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ZUSAMMENFASSUNG 
Etwa die Hälfte der Weltbevölkerung ist mit dem Magenkeim Helicobacter pylori infiziert. 
Dieses Bakterium persistiert in der Magenschleimhaut und ist Auslöser verschiedener 
Krankheiten, einschließlich Magenkrebs. Da H. pylori zunehmend Resistenzen gegen die 
derzeitigen therapeutischen Antibiotika ausbildet, werden alternative Behandlungsstrategien 
dringend benötigt. Ein maßgeblicher Faktor für die Entstehung der H. pylori-assoziierten 
Krankheitsbilder ist das Cag-Typ IV-Sekretionssystem. Diese molekulare Maschine trans-
feriert das bakterielle Onkoprotein CagA (Zytotoxin-assoziiertes Genprodukt A) in 
Magenzellen. CagA übernimmt innerhalb der Wirtszelle die Kontrolle über intrazelluläre 
Signalkaskaden, was schließlich zur Karzinogenese führt. Diese Arbeit hatte zum Ziel, die 
Mechanismen der CagA-Translokation weiterführend aufzuklären und Substanzen zu finden, 
die diesen Prozess hemmen. 
Bisherige Methoden zur Analyse der CagA-Translokation sind sehr zeit- und arbeitsintensiv. 
Daher wurde ein neues Reportersystem etabliert, welches auf einer Fusion der TEM-1 β-
Laktamase an das CagA-Protein basiert (TEM-CagA). Die Translokation von TEM-CagA aus 
H. pylori in Zielzellen kann mittels der Spaltung des fluoreszierenden β-Laktam-Derivats 
CCF4 durch TEM-1 verfolgt werden. Dieses Prinzip ermöglicht eine Quantifizierung der 
CagA-Translokation durch Fluoreszenzmessung auf eine schnelle, sensitive und hoch-
spezifische Weise. Mit Hilfe dieses Verfahrens wurden die Dynamik der CagA-Translokation 
und der Typ IV-Signalerkennungs- und Sekretionsprozess untersucht. Dabei wurde der 
Einfluss einiger wenig charakterisierter Komponenten auf die CagA-Translokation überprüft 
und die stabilisierende Rolle des CagA Chaperons CagF weitergehend definiert. Es konnte 
gezeigt werden, dass das C-terminale Sekretionssignal von CagA eher durch eine minimale 
Länge als durch eine spezifische Signalsequenz bestimmt wird. Eine Beteiligung des 
äußersten N-terminus von CagA bei der Signalerkennung wurde ausgeschlossen, während die 
Notwendigkeit eines ausgedehnten internen CagA-Bereichs für die CagA-Sekretion gezeigt 
wurde. Zudem wurde nachgewiesen, dass die Translokation von CagA von der bakteriellen de 
novo-Proteinsynthese und von aktiven Wirtszellprozessen abhängt. 
Neue Anti-Infektiva, welche die CagA-Übertragung in die Wirtszelle unterbinden, könnten 
eine äußerst effiziente Maßnahme gegen die von CagA induzierte Karzinogenese sein. Zur 
Identifizierung derartiger therapeutischer Pathoblocker wurde das TEM-CagA-Reporter-
system zum Screening von Substanzbibliotheken verwendet. Dabei wurden zwei verwandte 
Substanzen gefunden, welche den CagA-Translokationsprozess gezielt in vitro blockieren. 
Zudem wurden während des Screeningprozesses weitere Substanzen entdeckt, die spezifisch 
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das Wachstum von H. pylori hemmen. Diese Inhibition wurde auf eine Beeinträchtigung der 
bakteriellen Atmung zurückgeführt, und zwei dieser Substanzen wurden vorläufig als 
potentielle neue Antibiotika validiert. Diese Arbeit hat daher nicht nur zu neuen 
Erkenntnissen im Hinblick auf die CagA-Translokation geführt, sondern auch zu zwei 
möglichen Behandlungsansätzen der Infektion mit H. pylori beigetragen. 
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I. INTRODUCTION 
1. Helicobacter pylori: a gastric pathogen 
1.1 Discovery of H. pylori and epidemiology of infection 
Helicobacter pylori is a gram-negative, microaerophilic bacterium that colonizes the human 
gastric mucosa persistently, which leads to various malignancies including gastric cancer. 
Modern research of H. pylori started in the early 1980s by the Australian pathologists Robin 
Warren and Barry J. Marshall. They were the first to isolate H. pylori [1] and the first to 
establish a link between infection with this bacterium and gastritis as well as peptic ulcers [2]. 
However, at this time, the gastric environment was assumed to be sterile due to its harsh 
acidic conditions. To finally convince the medical community, Marshall performed a self-
experiment and drank a H. pylori suspension which actually caused an acute gastritis [3]. 
Since then, H. pylori is in the worldwide focus of medical research and to honor its discovery, 
Marshall & Warren were awarded the Nobel Prize for Medicine and Physiology in 2005.  
Approximately 50% of the world population is chronically infected with H. pylori. The 
prevalence of infection varies immensely between countries. While the infection rate in many 
developing countries is over 80%, the prevalence in industrialized countries ranges between 
20 to 40% [4, 5]. However, H. pylori infections seem to decrease in Western countries with 
the socioeconomic development including higher hygiene standards. It is assumed that 
H. pylori is transmitted via the oral-oral or fecal-oral route during early childhood and persists 
without antibiotic treatment for a life-time in its gastric niche [4, 5]. H. pylori strains can be 
divided in various populations with distinct geographical distribution which plays a major role 
in tracing ancient human migration [6]. Hence, it has been suggested that H. pylori has been 
present in humans for at least 100,000 years [7] and accompanied the migration of modern 
humans out of Africa about 58,000 years ago [8].  
 
1.2 H. pylori-induced diseases 
Infection with H. pylori increases the risk for various gastric diseases. A comprehensive 
overview of disease progression is presented in Figure 1. The initial infection phase during 
childhood has a predominantly subclinical outcome and is accompanied by an acute gastritis 
and a profound, but transient, hypochlorhydria [9]. During the course of persistent 
colonization with H. pylori, the infection elicits a gastric mucosal inflammatory response in 
virtually all infected persons [10]. This chronic gastritis is mainly asymptomatic but a major 
6 INTRODUCTION  
risk factor for sequelae, and 10% of infected persons develop peptic ulcers, 1-2% gastric 
adenocarcinoma and a few mucosa-associated lymphoid tissue (MALT)-lymphoma [11].  
 
 
Figure 1: H. pylori-induced disease progression 
See text for further information. MALT: Mucosa-associated lymphoid tissue. Modified from [11]. 
 
In the majority of infected patients, H. pylori-induced gastritis is more common in the antrum 
than in the corpus of the stomach (antral-predominant gastritis) [9]. This phenomenon is 
mostly attributed to high local acid concentrations in the corpus which favors a colonization 
of the antrum by H. pylori. In agreement, a corpus-predominant pattern of gastritis is 
observed in individuals with low gastric acid output, which is mainly attributed to a genetic 
predisposition of the host [12]. The different gastritis forms promote two types of peptic 
ulceration: duodenal and gastric ulcers. Patients with antral-predominant gastritis are 
susceptible to duodenal ulcers, as this type of gastritis causes hypergastrinemia (high gastrin 
secretion levels) and increased acid leakage from the stomach to the duodenum [13]. The 
duodenum develops gastric metaplasia in response to the high acid load, and can be 
subsequently colonized by H. pylori, which leads to subsequent inflammation and duodenal 
ulceration [13]. Gastric ulcers are associated with pan- or corpus-predominant gastritis, 
related to normal or low acid levels, and the ulceration forms at the junction of antral and 
corpus mucosa [9, 13]. Duodenal ulcers occur in middle age, while gastric ulcers affect older 
people [14].  
Infection with H. pylori significantly increases the risk for gastric MALT-lymphoma. MALT-
lymphoma originates from marginal zone B cells of mucosa-associated lymphoid tissue. As 
MALT is usually absent in an uninfected stomach, its acquisition seems to depend on 
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H. pylori infection, and the transformation into MALT-lymphoma usually arises from pan-
gastric inflammation [15, 16].  
The most serious H. pylori-induced disease is gastric cancer, and 90% of new cases 
worldwide are attributed to infection with the bacterium [17]. Gastric adenocarcinoma is 
classified into a more common intestinal and a less common diffuse type. Diffuse-type 
carcinoma derives from individually infiltrating neoplastic cells, but underlying mechanisms 
have not been studied extensively [14]. Intestinal-type gastric adenocarcinoma describes a 
malignant epithelial tumor that originates from the glandular epithelium. The development of 
this adenocarcinoma can be considered as the long-term consequence of progression from 
gastritis to gastric atrophy (loss of specialized cell types such as parietal and chief cells), 
intestinal metaplasia (replacement of gastric mucosa by intestinal-type epithelium), and 
dysplasia (neoplasia of lining epithelial cells), collectively called the Correa pathway [18, 19]. 
The decisive step in this cascade is the development of atrophy, as progression to cancer can 
only be prevented when H. pylori is eradicated prior to atrophy formation [14, 20]. Gastric 
adenocarcinoma is predisposed by pan- or corpus-predominant gastritis and a resulting 
hypochlorhydria, which might explain why persons with duodenal ulcers (associated with 
antral-predominant gastritis and increased acid production) are partially protected from this 
kind of cancer [21]. Gastric cancer is one of the leading causes of cancer-related deaths 
worldwide [22]. As infection with H. pylori increases the risk for gastric cancer 
approximately 10-fold [23, 24], H. pylori has been classified as a class 1 carcinogen by the 
World Health Organization´s (WHO) International Agency for Research into Cancer (IARC) 
[25].  
In general, antibiotic therapy can drastically decrease the risk for H. pylori-linked gastric 
malignancies and will be specified in Chapter 5.  
 
2. Colonization of the gastric mucosa: virulence factors  
The disease outcomes described above are strongly influenced by the genetic predisposition 
of the host, environmental parameters and the molecular repertoire of H. pylori [26, 27]. 
H. pylori is highly adapted to survive and colonize the human stomach. Within its small 
genome (1.67 megabases), H. pylori encodes, besides a minimal set of metabolic genes [28], 
various virulence factors that enable the bacterium not only to persist in but also to exploit the 
gastric environment. Studies in various rodent models have revealed more than 100 bacterial 
genes that are required for gastric colonization [29, 30]. An overview of some selected 
virulence factors will be given in the following section and a simplified schematic is shown in 
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Figure 2. The major virulence factor cytotoxin-associated gene product A (CagA) together 
with the Cag type IV secretion system (Cag-T4SS) will not be focused on in this chapter, but 
described in detail in Chapters 3 & 4.  
 
 
Figure 2: Strategies of H. pylori for persistent stomach colonization  
H. pylori survives the gastric acidity by production of urease, and quickly moves to the neutral mucus layer 
responding to chemotactic cues, which is assisted by its helical shape and flagella (Chapter 2.1.1). Adherence to 
the mucus and gastric epithelial cells is mediated by various outer membrane proteins (Chapter 2.1.2). H. pylori 
exhibits a high genomic variability for adaptation during long-term colonization (Chapter 2.2.1). This also 
facilitates evasion from the innate host immune response (Chapter 2.2.2). Adaptive immunity is modulated by 
secreted GGT and VacA proteins (Chapter 2.2.2). Further interference with host cell signaling is achieved by 
type IV secretion-injected CagA protein (see Chapters 3 & 4). CagA: cytotoxin-associated gene product A, Cag-
T4SS: Cag type IV secretion system, GGT: γ-glutamyl transpeptidase, VacA: vacuolating toxin A. Modified 
after [31]. 
 
2.1 Initial steps of stomach colonization 
2.1.1 From the acidic lumen to the neutral mucosa 
First of all, H. pylori has to deal with the acidity of the stomach lumen (pH 1-2). H. pylori is 
neither an acidophilic nor an acid-tolerant organism, and thus has to move as fast as possible 
from the lumen to the thick gastric mucus layer, where it is protected from the acidic milieu. 
H. pylori resists the initial luminal acid exposure through production of urease, which 
converts urea into ammonia generating a neutral environment on the bacterial surface [32]. In 
addition, the increased local pH facilitates motility through the mucus, because the gel-like 
mucin layer is pH-dependently transformed into a solution where the bacterium can freely 
swim [33]. Moreover, H. pylori possesses a unique helical shape for rotational cork-screw like 
movement through the viscous environment and indeed, modifications regarding the cell 
shape inhibit colonization in animal studies [34]. Motility is enabled by up to six unipolar 
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flagella and crucial at early stages of infection [35, 36]. However, motility is irreversibly lost 
within one minute in the acidic lumen [37]. Hence, movements are strictly regulated by 
chemotaxis, which alters flagellar activity and is pivotal for a successful infection [38]. For 
localization of the epithelium, H. pylori uses the mucus pH gradient for orientation [39]. 
Furthermore, the energy sensor TlpD is essential for initial infection and persistence of 
H. pylori in animal models of infection [40]. Responding to chemotactic cues, injured gastric 
sites are preferred which might be attributed to a higher nutrient availability [41].  
 
2.1.2 Adhesion in the gastric mucosa 
Another crucial step in gastric colonization of H. pylori is its ability to adhere to the human 
gastric epithelium and mucosa. This prevents shedding of H. pylori by peristalsis and enables 
proximity to the host cells for direct interaction and nutrient availability. Adhesion is 
mediated by outer membrane proteins (OMPs) that can bind to distinct host cell components 
and are accordingly termed adhesins. The genome of H. pylori contains about 60 genes that 
are predicted to encode OMPs [42]. The first adhesin that was discovered was BabA (blood 
group antigen-binding adhesin), which can adhere to the carbohydrate moiety of the 
fucosylated Lewis b (Leb) histo-blood group antigen on the surface of gastric epithelial cells 
[43]. Moreover, adhesins are also linked to the induction of host cell signal transduction 
pathways. For example AlpA and AlpB (Adherence associated lipoproteins A and B [44]) are 
homologous proteins that bind to the extracellular matrix protein laminin on the basolateral 
side of host epithelial cells [45]. Infection experiments in Mongolian gerbils with respective 
deletion mutants revealed a severe inflammation and suggested abrogation of anti-
inflammatory signaling mediated by the alpAB locus [46]. In addition, H. pylori infection can 
induce the expression of several receptors like sialyl-dimeric-Lewis x glycosphingolipid, 
which are bound by the SabA (Sialic acid-binding) adhesin [47]. Just recently, a novel 
bacterial adhesin, termed LabA (HopD) was identified and characterized to bind specifically 
to MUC5AC mucins [48]. The high diversity of adhesin binding partners underscores the 
capability of the bacterium to initially establish various interactions that promote its 
persistence in the gastric mucosa in close proximity to the host cells. 
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2.2 Long-term persistence 
2.2.1 Generation of genetic diversity 
For adequate adaptation to changing environmental conditions, H. pylori is highly efficient in 
generating genetic diversity by its high mutational rate [49]. Individuals are often infected 
with more than one distinct H. pylori strain. Due to the natural competence of the bacterium 
(ability for exogenous DNA uptake), conjugation systems and subsequent recombination 
events, the genetic repertoire can broadened further [50, 51]. Consequently, strains undergo a 
rapid microevolution and drastically vary their genome during long-term colonization [52]. 
One well-studied example is the gene conversion and phase variation of the earlier described 
adhesins. In particular, 5´- and 3´-end regions of the omp genes are highly conserved which 
allows gene conversion, and distinct dinucleotide repeats in the 5´ regions enable slipped-
strand mispairing, resulting in phase variation. This leads to modifications in OMP sequence 
or expression levels, which makes an adapted adherence capability as well as immune evasion 
possible [53, 54].  
 
2.2.2 Manipulation of the host immune response 
Infection with H. pylori elicits a humoral and cellular immune response, and leukocytes 
infiltrate the stomach tissue upon persistent colonization [10, 55]. Nevertheless, the host 
immune response is not effective in eradicating H. pylori, which is mainly attributed to 
manipulation of the innate and adaptive immune system. 
The modulation of the innate immunity is mainly based on target modification or subversion 
of innate recognition pathways [31]. Target modification is facilitated by the above-described 
high genomic plasticity. Moreover, H. pylori avoids detection by several pattern recognition 
receptors (PRRs) that are crucial for identification of pathogen-associated molecular patterns 
(PAMPs) in other bacterial pathogens. For example, the LPS (lipopolysaccharide) of H. pylori 
is 1000-fold less biologically active than the LPS of E. coli [56] due to a dephosphorylation of 
the lipid A domain [57]. This provides not only resistance to host antimicrobial peptides but 
also subverts activation of the PRR Toll-like receptor 4 (TLR4), and results in the inhibition 
of pro-inflammatory cascades. Besides, H. pylori flagellin is not recognized by Toll-like 
receptor 5 (TLR5) due to modifications in the N-terminal TLR5 recognition domain and 
hence protected from host clearance [58]. In contrast, H. pylori non-LPS ligands (e.g. 
lipoproteins) are identified by Toll-like receptor 2 (TLR2), and this recognition triggers the 
expression of anti-inflammatory genes [59]. In conclusion, the innate immune response is 
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mainly subverted by reduced activation of pro-inflammatory cascades or 
manipulation/activation of anti-inflammatory cascades [31]. 
Manipulation of the adaptive immunity is mainly achieved by two secreted virulence factors: 
vacuolating toxin A (VacA) and γ-glutamyl transpeptidase (GGT) [31]. VacA is a 
multifunctional toxin (reviewed in [60, 61]) and was first described for its ability to induce 
vacuoles in eukaryotic cells upon H. pylori infection [62]. To do so, VacA is secreted via an 
auto-transporter mechanism, binds to the host cell and, after internalization, forms hexameric 
anion-selective channels in the endosomal membrane [63]. Generally, most VacA-induced 
cellular alterations are attributed to its capacity to form pores in cell membranes. For example, 
VacA inserts into the inner mitochondrial membrane which triggers apoptosis [64]. Moreover, 
VacA causes functional alterations in a variety of immune cells. Upon infection of 
macrophages with H. pylori, phagosome maturation is VacA-dependently inhibited and thus 
bacterial clearance prevented [65]. Also, an inhibition of antigen presentation of B-
lymphocytes by VacA has been described [66]. The interference of VacA with T-lymphocytes 
is of major importance. VacA enters T-lymphocytes by binding to the β2 (CD18) integrin [67] 
and suppresses an immune response by blocking proliferation via suppression of IL-2 
transcription [68]. In addition, T-lymphocyte function is modified by GGT. GGT induces 
cell-cycle arrest of T-cells by glutamine deprivation at the site of infection [69, 70]. 
Moreover, T-cell-mediated clearance of H. pylori is indirectly suppressed by synergistic 
action of VacA and GGT. Both virulence factors promote a preferential differentiation of 
naive T-cells into regulatory T-cells, and thus prevent them from maturation into T-helper 1 
(Th1) and T-helper 17 (Th17) lymphocytes which could control or even eliminate H. pylori 
infection [71].  
Furthermore, regulation of the activity of distinct virulence factors facilitates gastric 
persistence. For example, the pathophysiological actions of VacA are attenuated by the 
presence of CagA and vice versa [72, 73]. In summary, H. pylori uses various strategies to 
persist in the gastric mucosa which are mainly based on a dynamic adaption to the 
environment and distinct mechanisms to evade elimination by the host immune system. 
 
3. The Cag type IV secretion system: virulence determinant 
with unique features 
The injection of the H. pylori oncoprotein CagA into host cells constitutes the key event in 
various infection-associated malignancies. CagA is delivered through a type IV secretion 
system-mediated process, and represents the only known translocated effector protein [74-76]. 
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This section describes this CagA translocation machinery, the Cag type IV secretion system 
(Cag-T4SS) (schematically depicted in Figure 2). As the architecture of the Cag-T4SS is only 
partly elucidated, a prototypical gram-negative type IV secretion system is first depicted.  
 
3.1 Prototypes of bacterial type IV secretion systems 
Type IV secretion systems (T4SS) designate multiprotein complexes that span the inner and 
outer membrane and are found in various bacteria. T4SS can be functionally divided into 
three subfamilies [77]: DNA conjugation machineries, DNA uptake/release systems and 
effector translocator systems. DNA conjugation systems constitute the largest family and 
enable transport of DNA substrates within and across bacterial species as well as into 
eukaryotic target cells. Conjugation is responsible for the spread of antibiotic resistance and 
virulence traits among bacteria, and H. pylori uses this type of T4SS for horizontal gene 
transfer as well [78]. Less common systems are substrate uptake/release T4SS that import or 
export DNA fragments or proteins independently of any cell contact. One such T4SS, the 
ComB competence system, is also produced by H. pylori and enables exogenous DNA import 
[79]. Effector translocator systems transport bacterial proteins into eukaryotic cells. This 
group incorporates, apart from the Cag-T4SS of H. pylori, other T4SS of human pathogens 
that are linked to disease including those of Brucella, Bartonella, Coxiella, Rickettsia spp., or 
Legionella pneumophila [80].  
A prototypical T4SS is the VirB/VirD4 system of the phytopathogen Agrobacterium 
tumefaciens. This system acts both as a conjugation machine and as an effector translocator 
which delivers the oncogenic T-DNA and/or several effector proteins into plant cells, eliciting 
the tumorous crown-gall disease. The VirB/VirD4 T4SS apparatus consists of 12 proteins (11 
VirB proteins and VirD4) and most other T4SS consist of a conserved VirB/VirD4 protein set 
[77]. The general architecture of a prototypic T4SS apparatus is presented in Figure 3A. The 
system is composed of four functional machine subassemblies [77, 81, 82]: a type IV 
coupling protein, an inner membrane complex (cytoplasmic membrane translocon, IMC), an 
outer membrane complex (core complex, OMC), and an external pilus. The coupling protein 
is an ATPase (VirD4) that binds substrates and initiates transfer to the cytoplasmic membrane 
translocon. This complex is composed of two further ATPases (VirB4, VirB11), two 
polytopic membrane proteins (VirB3 and VirB6) and one bitopic protein (VirB8) which 
facilitate substrate transfer across the inner membrane. VirD4 forms, together with the VirB4 
and VirB11 ATPases, a motor complex at the translocation channel entrance that is assumed 
to drive T4SS biogenesis and any ATP-dependent translocation step. Substrate passage across 
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the periplasm is enabled by the core complex, which is composed of two outer membrane-
associated proteins (VirB9 and the lipoprotein VirB7) and the cell-envelope-spanning subunit 
VirB10. The translocation channel extending through the core complex might be composed of 
the major pilin subunit VirB2 and parts of VirB8 and VirB9 [83-85]. It is suggested that the 
pilus constitutes the extended part of the transfer channel [83]. The pilus itself is an 
extracellular organelle for contact initiation with recipient cells. It is composed of VirB2, 
forming the shaft, and the pilus-associated adhesin VirB5. Moreover, a lytic transglycosylase 
(VirB1) that hydrolyzes the peptidoglycan layer is crucial for pilus biogenesis [77, 81, 82]. 
 
 
Figure 3: Models of a prototypical type IV secretion system  
A) Schematic model of a T4SS according to the nomenclature of the VirB/VirD4 T4SS of Agrobacterium 
tumefaciens. Colors refer to the components highlighted in C).  
B) Electron density map reconstruction of eight components of an E. coli T4SS (copied from [86]).  
C) Localization of known components and position of cell membranes in the map from B).  
I-: inner, IM: inner membrane, IMC: inner membrane complex, O-: outer, OM: outer membrane, OMC: outer 
membrane complex, PG: peptidoglycan, T4SS: type IV secretion system. 
 
A relevant advance in T4SS research has been achieved by the structure elucidation of the 
core unit of a T4SS apparatus from plasmid R388 of E. coli [86], which is presented in Figure 
3B. The structure revealed a 3 MDa assembly of eight VirB/VirD4 homologue subunits 
(highlighted in Figure 3C) consisting of an IMC (composed of VirB4 ATPase subunits as well 
as VirB3, VirB6 and VirB8), an OMC spanning the periplasm as well as a flexible central 
stalk linking both components. In accordance with prior studies [84, 85], the core complex 
assembles as a large barrel and is composed of 14 copies each of VirB10, VirB7 and VirB9 
homologues. These are arranged in symmetric inner and outer layers (I- and O-layers) that 
form chambers divided by a central middle platform. Importantly, the T4SS core structure 
shows no continuous central channel. Thus, apart from a one-step translocation, a two-step 
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process could be assumed as well, where substrates access the core complex secretion 
chambers from the periplasm [86]. 
 
3.2 Delivery of the oncoprotein CagA by a type IV secretion system 
The Cag type IV secretion system (Cag-T4SS) is evolutionarily related to other T4SS and 
harbors various Vir homologues. However, the Cag-T4SS markedly differs from the 
prototypical A. tumefaciens VirB/VirD4 T4SS. 
 
3.2.1 The cag pathogenicity island 
The Cag-T4SS is, together with its effector protein CagA, encoded on the cag pathogenicity 
island (cagPAI), schematically depicted in Figure 4. This chromosomal insertion element 
incorporates an approximately 37 kb locus containing 27-31 genes [87, 88]. Of importance, 
the presence of the cagPAI increases the risk of cancer development, and H. pylori strains are 
divided into highly virulent cagPAI-positive (type-1) and less virulent cagPAI-negative (type-
2) strains [89]. Apart from strains carrying a complete cagPAI, some contain an incomplete 
cagPAI lacking one or more genes, or one that was disrupted by chromosomal 
rearrangements. Nevertheless, cagPAI-encoded genes are highly conserved, thus it has been 
suggested that the pathogenicity island was acquired about 60,000 years ago and might confer 
an evolutionary advantage [90].  
 
 
Figure 4: Scheme of the cag pathogenicity island (cagPAI) 
The cagPAI is integrated at a defined chromosomal locus flanked by genes hp0519 and hp0549. Gene 
designations are indicated below, and putative Vir protein homologies above the boxes. LJ: left junction, RJ: 
right junction. Adapted from [87]. 
 
3.2.2 Assembly model of the Cag type IV secretion system 
For all prototypical VirB/D4 components, respective Cag counterparts with sequence 
similarities can be found and are listed in Figure 5A [87, 91]. However, most of these Cag 
components exhibit domain structures distinct from their Vir counterparts. For example, the 
VirB10 homologue CagY has only a small C-terminal region similar to VirB10, is 
considerably larger and contains additional domains composed of repeat regions [92]. 
Moreover, the Cag-T4SS incorporates additional components with unique structures that are 
LJ RJ
helcagACDEFGHILNMPQSTVWXYZαβγδεζ U B
hp0519 hp0549
virB1 D4 B11 B10 B9 B6 B8 B7 B3/4 B2B5
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essential for functionality (see Chapter 3.2.3). Nevertheless, according to Vir homologies and 
various protein-protein interaction studies, a model of the Cag-T4SS has been established and 
is presented in Figure 5B [87]. 
 
 
Figure 5: Model of the Cag type IV secretion apparatus of H. pylori 
A) Vir and Cag component similarities according to [87, 91]. 
B) Schematic model of the Cag type IV secretion system. Components refer to the Cag nomenclature and are 
divided into several functional classes (color schemes indicated at the right side). CM: cytoplasmic membrane, 
IM: inner membrane, OM: outer membrane, PG: peptidoglycan. Modified from [87]. 
 
The coupling protein (VirD4) homologue Cagβ is predicted to be located in the inner 
membrane [93] and its cytoplasmic part has been shown to interact with the effector protein 
CagA as well as with CagZ [94, 95]. It has been hypothesized that Cagβ and CagZ form a 
signal recognition receptor complex where CagA is additionally stabilized by its membrane-
associated chaperone CagF [87]. The energy for biogenesis and translocation processes is 
delivered by two more ATPases, Cagα (VirB11) and CagE (VirB3/4). It has been shown that 
the cytoplasmic protein Cagα assembles into dynamic hexamers and is catalytically active 
[96]. CagE exhibits sequence similarities to the VirB4 ATPase and possesses a VirB3-like 
extension at the N-terminus [93]. Hence, the cytoplasmic membrane translocon might be 
composed of CagE, and the inner membrane proteins CagW (polytopic, VirB6 [93]) and 
CagV (bitopic, VirB8 [97]) [88]. The integral membrane proteins CagU and CagH might be 
associated with the inner membrane complex as well, but functional studies are lacking [87]. 
The core complex is built up by the membrane spanning VirB10 homologue CagY, CagX 
(VirB9) and CagT (VirB7, lipoprotein). Accordingly, direct interactions between CagX and 
CagY [93], as well as between CagX and CagT [98], have been reported. In addition, CagM 
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[93] and Cagδ [99] are outer membrane-associated and co-assemble into an extended core 
complex [100]. In various studies, pilus-like surface structures associated with the Cag-T4SS 
could be identified [101-103]. Although the major pilin (VirB2) homologue CagC is supposed 
to be involved in pilus formation [104], a cagC deletion mutant was found to produce pili as 
the wild-type [105]. Staining of pili with antibodies identified the VirB5-like adhesin CagL as 
well as CagY, CagX and CagT localizing to the pilus surface or to the base of the pilus [101, 
102]. This seems to be reasonable for CagL, which has been shown to bind to host cell 
integrins (see Chapter 3.2.4), but inconsistent for the putative core complex components. 
Moreover, CagL has been shown to interact with CagI and CagH [103, 106], and such an 
assembly might also associate with pili as all subunits are involved in pilus formation (see 
Chapter 3.2.3). In addition, CagH is predicted to be an integral cytoplasmic membrane protein 
[93], and a subassembly of CagH, CagI and CagL at the periplasmic face of the inner 
membrane is speculated. As cagG is genetically organized together with cagH, I and L, a 
functional connection of CagG to this subcomplex could also be imagined [106]. 
Accordingly, CagG is supposed to be located in the periplasm (see Figure 5B) and various 
interactions with other Cag components are assumed [94]. Also for the enzymatically-active 
peptidoglycan hydrolase Cagγ (VirB1 [107]), a periplasmic location is postulated. CagN is 
probably anchored in the cytoplasmic membrane [108] and has been shown to interact with 
CagY [93]. However, specific localization of Cag-T4SS components might be speculative, 
but studies deciphering Cag-T4SS functionalities give additional insights and are described in 
the next section.  
 
3.2.3 Role of Cag components on Cag type IV secretion system function  
Mutagenesis studies with isogenic deletion mutants of cagPAI-encoded genes identified 
various Cag components essential for Cag-T4SS function. To validate the functionality of the 
Cag-T4SS, examination of various phenotypes can be considered: CagA phosphorylation and 
induction of IL-8 secretion upon in vitro infection as well as bacterial pilus formation. After 
delivery into host cells, CagA gets tyrosine-phosphorylated immediately by cellular kinases 
[74-76]. This phosphorylation event can be analyzed via immunoblotting using specific 
antibodies. Besides CagA translocation, one consequence of Cag-T4SS activity is the 
upregulation of pro-inflammatory cytokine secretion including IL-8 [109, 110]. The larger 
part of IL-8 induction is independent of CagA translocation and proves functionality of the 
T4SS apparatus. It should be mentioned that IL-8 secretion might be triggered by T4SS-
delivered peptidoglycan which is recognized by NOD1 [111], although these results are 
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controversial as another study showed peptidoglycan delivery by outer membrane vesicles 
[112]. Moreover, the presence of pili is directly linked to Cag-T4SS function as mutants that 
fail to produce pili are defective in CagA translocation and IL-8 induction [103, 105, 113, 
114]. But on the contrary, mutants that form pili do not necessarily translocate CagA or 
induce IL-8 secretion (e.g. cagα). The outcome of several studies focusing on the above-
mentioned phenotypes is summarized in Table 1. 
 
Table 1: Overview of characteristics and functions of cagPAI-encoded proteins 
Gene designations and protein sizes refer to [28]. CagA-P: CagA phosphorylation. +/- refers to phenotype 
characteristics of respective deletion mutants with -: abolished, +: weak, ++: moderate, +++: unchanged, ++++: 
increased. AF: accessory factor, IM: inner membrane, IL-8: interleukin-8, OM: outer membrane, SA: secretion 
apparatus component, SC: supportive component, TF: translocation factor. Modified from [87] and [88]. 
Gene Protein 
Size [kDa] 
   Effect of gene deletion Proposed function 
  
 CagA-P   IL-8     Pilus 
 
hp0520 Cagζ (13) +++ +++ n.d. AF 
hp0521 Cagε (10) +++ +++ n.d. AF 
hp0522 Cagδ (50) - - - OM complex, SA 
hp0523 Cagγ (18) - - n.d. VirB1, peptidoglycan hydrolase, SA 
hp0524 Cagβ (80) - +++ +++ VirD4, coupling factor, TF 
hp0525 Cagα (35) - - +++ VirB11, ATPase, SA 
hp0526 CagZ (21) ++ ++ n.d. Cagβ stabilization, SC 
hp0527 CagY (220) - - - VirB10, core complex, integrin binding, SA 
hp0528 CagX (55) - - - VirB9, core complex, SA 
hp0529 CagW (55) - - n.d. VirB6, IM translocon, SA 
hp0530 CagV (27) - - - VirB8, IM translocon, SA 
hp0531 CagU (23) - - n.d. SA 
hp0532 CagT (30) - - - VirB7, core complex, OM lipoprotein, SA 
hp0534 CagS (21) +++ +++ n.d. AF 
hp0535 CagQ (14) +++ +++ n.d. AF 
hp0536 CagP (13) +++ +++ n.d. AF 
hp0537 CagM (40) - - - OM complex, SA 
hp0538 CagN (32) + + n.d. SC 
hp0539 CagL (26) - - - VirB5, pilus biogenesis, integrin targeting, SA 
hp0540 CagI (40) - -/+++ - Pilus biogenesis, integrin targeting, SA or TF* 
hp0541 CagH (39) - - ++++ Pilus biogenesis, SA 
hp0542 CagG (16) + ++ n.d. SC 
hp0543 CagF (29) - +++ n.d. CagA chaperone, TF 
hp0544 CagE (100) - - - VirB3 / VirB4, ATPase, SA 
hp0545 CagD (22) -/+ + n.d. SC or TF** 
hp0546 CagC (13) - - +++ VirB2, pilus subunit (?), SA 
n.d. CagB (8) n.d. n.d. n.d. n.d. 
hp0547 CagA (125) - +++ +++# Effector protein 
*conflicting data with respect for requirement for IL-8 induction [89, 115, 116]. 
**conflicting data with respect for requirement for CagA translocation [115, 117]. 
#derived from [123]. 
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In general, Cag components can be discriminated into four factor classes [87]: secretion 
apparatus components (SA), translocation factors (TF), supportive components (SC) and 
accessory factors (AF). Secretion apparatus components are necessary for CagA 
phosphorylation (CagA-P) as well as IL-8 induction. In total, 14 cagPAI genes have been 
identified to be essential components [115, 116] and include all proposed Vir homologues 
(except Cagβ) as well as several Cag-T4SS-specific components. Following this, the Vir 
counterparts are likely to fulfill the same essential role in the Cag-T4SS as in the prototypical 
T4SSs. For example, core complex components such as CagT and CagX or proposed inner 
membrane complex forming CagE and CagV proteins are essential for both Cag-T4SS 
functions as well as pilus formation. Apart from the VirB homologues, essential Cag-T4SS-
specific components include the outer membrane complex-associated proteins Cagδ and 
CagM as well as the above-mentioned inner membrane translocon-related CagU. Moreover, 
CagI and CagH are indispensable for a functional Cag-T4SS which is in accordance with a 
reported involvement in pilus formation, and cagH deletion even leads to a hyperpiliated 
phenotype [103]. This again stresses the requirement of all these unique Cag components for 
full function of Cag type IV secretion. So-called translocation factors designate Cag 
components that are exclusively required for CagA phosphorylation but dispensable for 
functional IL-8 induction. These include the putative coupling protein Cagβ, the chaperone 
CagF, and CagD, albeit conflicting data exist regarding the latter protein [115, 117]. The 
exclusive requirement of Cagβ for CagA delivery seems reasonable as the integrity of the 
T4SS machinery should be independent of the coupling protein. Moreover, CagF is supposed 
to support CagA delivery to the coupling complex by protection of CagA from premature 
degradation [118-120]. Some Cag-T4SS components, like CagZ, CagN and CagG, are not 
necessary but their absence clearly reduces functional phenotypes. They are thus denominated 
supportive components. For example CagG, the absence of which reduces CagA 
phosphorylation and IL-8 induction, is proposed to be functionally associated with the 
essential secretion apparatus components CagH, CagL and CagI [106], and a lack of this 
connection upon cagG deletion is likely the reason for the weak phenotypes. The last group is 
constituted by accessory factors including Cagζ, Cagε, CagS, CagQ and CagP. These factors 
do not seem to contribute to function but transcription of respective genes has been shown 
[121]. Of these, cagP is transcribed together with a non-coding upstream RNA, CncR1. This 
small RNA has been shown to inversely modulate bacterial motility and adhesion to host cells 
attributing a major regulatory function to the cagP locus [122].  
Overall, CagA translocation underlies a complex regulation and is also influenced by cagPAI-
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independent factors. For example, a functional dependence between HopQ, an outer 
membrane protein, and the Cag-T4SS has been reported [124]. Moreover, pilus formation 
seems to be highly dependent on environmental conditions. Following this, iron limitation has 
been shown to induce T4SS pili and increase CagA phosphorylation [125], while zinc 
depletion reduced T4SS pili and CagA translocation [126]. 
 
3.2.4 A mechanistic view on CagA translocation 
The exact CagA delivery mechanism into host cells is only poorly understood. Host cell 
contact is assumed to be mediated by binding to α5β1 integrin via the pilus-located proteins 
CagL, CagY, CagI as well as CagA [113, 114]. All components have been shown to directly 
bind to β1 integrins, while CagL might act as the major tip adhesin. The VirB5 homologue 
CagL is described to bind via an RGD motif to β1 integrins, leading to an integrin activation 
that induces CagA translocation and subsequent tyrosine phosphorylation [113]. But the 
requirement of this binding event for CagA translocation is controversial [114]. However, 
blocking of integrins inhibits CagA translocation, supposing a role of α5β1 integrins as target 
receptors for the Cag-T4SS, and importantly, the CagA protein itself exhibits the strongest 
binding capability to β1 integrin compared to the other Cag components [114, 127]. As CagA 
has been localized at or near the tips of Cag-T4SS pili [113, 128], it is suggested that this 
pilus-exposed CagA protein constitutes a translocation intermediate following a multistep 
translocation process, as has already been proposed for other T4SS (see Chapter 3.1). 
Moreover, CagA has been shown to be located on the bacterial surface in a T4SS-dependent 
manner [129]. Thus, it is not clear whether CagA is delivered through the pilus shaft or if the 
pilus is just necessary to mediate direct cell contact. However, CagA protein does not enter 
cells autonomously and translocation is strictly dependent on a functional Cag-T4SS. Also, 
the uptake process of CagA into the host cell cytoplasm is not fully understood. It has been 
shown that CagA binds to phosphatidylserine at the outer leaflet of the host cell membrane 
which is speculated to be crucial for uptake [129]. In addition, treatment of cells with various 
cellular inhibitors, like actin cytoskeleton modulators, block CagA phosphorylation [114, 
129]. But a definite contribution of host cellular processes or pore formation in the host cell 
membrane is still a matter of debate. 
 
 
 
 
20 INTRODUCTION  
4. The CagA protein: insights into its carcinogenic potential 
CagA is a unique bacterial oncoprotein and considered as the major virulence determinant of 
H. pylori. How CagA has evolved its cancer-promoting properties will be described in the 
following sections. 
 
4.1 Structural and translocation-relevant domains 
Depending on the H. pylori strain, CagA has a size of ~120-145 kDa. CagA exhibits a unique 
fold without obvious similarity to other proteins and can be divided into a structured N-
terminal region (70%) and an intrinsically disordered C-terminal tail (30%). Crystallographic 
studies could thus only elucidate the structure of C-terminal truncated CagA [127, 130]. The 
structure derived from Hayashi et al. [130] is presented in Figure 6A. The N-terminal region 
can be divided in domain D1-3. The N-terminal D1 domain is, besides a small interaction 
surface area with D2, structurally isolated from the other domains and consists predominantly 
of α-helices that constitute a single folded compact domain with multiple tertiary contacts in 
between. D2 comprises anti-parallel strands forming a single layer β-sheet (SLB) region and 
two independent subdomains (D2´ and D2´´, see Figure 6B). D3 consists of a long α-helix and 
a four-helix bundle at the carboxyl-terminal part (also entitled as D4 according to [127]). 
Besides the unstructured C-terminus, also the N-terminal portion comprises short disordered 
stretches including the first 23 amino acids, an unstructured part between D1 and D2 as well 
as two internal stretches in D2 [130]. Moreover, an intramolecular interaction between the N-
terminal D3 domain and the C-terminus via an N-terminal binding sequence (NBS) and a C-
terminal binding sequence (CBS) is assumed [130] (see Figure 6B). The above-mentioned 
SLB region within D2 constitutes the binding site for β1 integrin, which was shown to be 
crucial for CagA delivery into host cells [127]. The D2 middle domain also harbors positively 
charged regions (“basic patch”) that are important for the binding to host cell 
phosphatidylserine (PS) via electrostatic interactions, which are necessary for translocation 
[129]. Many T4SS substrates carry secretion signals in the C-terminus and often charged 
amino acids play a major role [77]. Indeed, deletion of the C-terminal 20 amino acids of 
CagA rendered the protein translocation-incompetent [131]. However, site-specific mutations 
of C-terminal charged amino acids did not result in any impact on translocation, and a specific 
secretion signal of CagA has not been defined yet [131]. Additionally, an intact N-terminus 
has been revealed to be important for translocation [131]. As mentioned earlier, also the 
interaction with the secretion-assisting chaperone CagF is important for delivery [118, 119]. 
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Although at first a distinct CagF binding domain of ~100 amino acids in the C-terminal CagA 
region was assigned [119] (Figure 6B), recent data suggests that multiple copies of CagF form 
various CagA domain contacts to maintain CagA in a translocation-competent and protease-
resistant conformation [120]. Whether CagA is translocated in an unfolded or folded state is 
still unclear. Indeed, folded N-terminal CagA would fit through the estimated diameter of the 
Cag-T4SS channel [101, 130], assuming that CagA uses this transport route (see Chapter 
3.2.4). In another study, spontaneous refolding of recombinant expressed D2/3 and C-terminal 
CagA could be observed after denaturation, while the N-terminal D1 domain did not. Thus, it 
was speculated that CagA delivery is performed in an unfolded state where the C-terminus, 
crucial for substrate recognition, is transported first and assists N-terminal refolding 
afterwards [132].  
In general, the intrinsically disordered C-terminal tail as well as flexible linkers in the N-
terminal domain offer diverse surfaces for host cell interactions and will be described next. 
 
 
Figure 6: Structure of the CagA N-terminal region 
A) Cartoon diagram of the CagA N-terminal region from H. pylori 26695. The region is composed of domain 
D1-3 with D1 in blue, D2 in red tones and D3 in green tones. The N-terminus and the beginning of the 
unstructured C-terminus are indicated. The structure was copied and modified from [130]. 
B) Schematic representation of CagA. Colors refer to the domains in A) and numbers to the amino acid positions 
of CagA from H. pylori P12. CBS: C-terminal binding sequence, NBS: N-terminal binding sequence, PS: 
phosphatidylserine, SLB: single layer β-sheet. 
 
4.2 Interference with host cell signaling 
For a better overview, a schematic of the CagA structural domains and functional regions is 
given in Figure 7 (adapted from [133]). Once inside the host cell, CagA is tethered to the 
inner leaflet of the cell membrane via the above-described interactions with 
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phosphatidylserine (PS) in polarized epithelial cells [129], while the EPIYA sequence motif is 
responsible for membrane association in nonpolarized cells [134]. EPIYA (glutamate-proline-
isoleucine-tyrosine-alanine) motifs are located in the C-terminal region and are rapidly 
tyrosine-phosphorylated by the oncogenic Src family (Src family kinases (SRK)) as well as c-
Abl kinases [135, 136]. The phosphorylation of EPIYA motifs constitutes the previously 
described phosphorylation event which can be detected via immunoblotting (see Chapter 
3.2.3). Four distinct EPIYA motifs can be distinguished, EPIYA-A to D, that are classified on 
the basis of their surrounding amino acid sequence. H. pylori strains from East Asian 
countries harbor East Asian-type CagA including EPIYA-A, EPIYA-B and one EPIYA-D 
motifs, whereas strains from Western countries carry Western-type CagA containing EPIYA-
A, EPIYA-B and one or multiple EPIYA-C motifs [137]. This variation in EPIYA motifs also 
affects CagA action, and a higher number of EPIYA motifs promotes binding to intracellular 
targets enhancing the activity within host cells [138, 139], which ultimately correlates with 
the severity of H. pylori-induced disease outcome [140, 141]. In particular, phosphorylated 
EPIYA segments are able to interact with SH2-domain (Src homology 2 domain)-containing 
proteins, as for example the SHP-2 tyrosine phosphatase [142]. SHP-2 constitutes a bona fide 
oncoprotein and mutations are linked to various cancer types [143]. CagA-induced 
deregulation of SHP-2 leads to the dephosphorylation of various host cellular proteins, which 
triggers pro-oncogenic cell signaling. One phenotypically observable consequence of this is 
the induction of an elongated cell shape known as the hummingbird phenotype [144]. 
Adjacent to the EPIYA motif are one or more MKI motifs (MARK kinase inhibitor or 
multimerization motif CM). This motif participates in interaction with the activated c-Met 
receptor (hepatocyte growth factor receptor), which leads to sustained activation of NF-kB 
causing an increased pro-inflammatory signaling [145]. The MKI motif also specifically 
interacts with the PAR1b/MARK2 kinase by mimicking substrates thereby inhibiting its 
activity which leads to disruption of tight junctions and loss of cellular polarity [146, 147]. 
Moreover, binding to the Par1b/MARK2 homodimers mediates CagA dimerization via the 
MKI motif, which at the same time stabilizes the binding of CagA and SHP-2. Thus it is 
assumed that the CagA dimer simultaneously builds a complex with SHP-2 and PAR1 
sustaining CagA pathophysiological activity [146]. In addition, the intramolecular interaction 
of CagA between the C-terminus and N-terminal D3 mediated by CBS and NBS exposes the 
EPIYA / MKI region and brings the disordered C-terminus in a rigid formation, further 
stabilizing interactions [130]. Also, the N-terminal region is involved in various interactions. 
For example, D1 and the linker region between D1 and D2 interact with the gastric tumor 
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suppressor RUNX3 mediating its degradation [148], and indeed, RUNX3 is frequently 
inactivated in gastric cancer. Moreover, a CagA-mediated degradation of the p53 tumor 
suppressor, via association of domain D1 with apoptosis stimulating protein of p53 (ASPP2), 
has been described and further contributes to an anti-apoptotic effect [149].  
Overall, CagA has been shown to interact with more than 20 host cell proteins (reviewed in 
[133, 150]). Generally, CagA hijacks intracellular signaling cascades in an either 
phosphorylation-dependent (via EPIYA motifs) or phosphorylation-independent manner. In 
the course of this, various changes including the induction of uncontrolled cell growth, 
disruption of epithelial integrity as well as sustained pro-inflammatory signaling are mediated 
which promote gastric carcinogenesis.  
 
 
Figure 7: Schematic of CagA domains and host interaction sites 
CagA physically interacts with various host cell proteins which mediates the modulation of cell signaling 
promoting gastric carcinogenesis. D1, D2, D3 refer to structural N-terminal domains (compare Figure 6). CBS: 
C-terminal binding site, CM: cytoplasmic membrane, MKI: MARK kinase inhibitor motif, NBS: N-terminal 
binding site, PS: phosphatidylserine. See text for further details. Adapted from [133]. 
 
4.3 Evidence for a link between CagA and cancer  
The risk for developing disease upon infection with H. pylori is influenced by various 
parameters but with CagA being the greatest risk factor (reviewed in [26, 27]). In addition to 
the above-mentioned studies on the molecular level, various in vivo data also underscore the 
disease-promoting activity of CagA. For example, upon infection of Mongolian gerbils with 
H. pylori, the strength of inflammation increases and gastric malignancies including 
adenocarcinoma develop in a CagA-dependent manner [125, 152, 153]. Moreover, transgenic 
mice expressing CagA form malignancies [154] and in a transgenic Zebrafish model, 
intestinal carcinogenesis is enhanced upon CagA expression [155]. Also various 
epidemiological studies show a significantly higher prevalence of gastric diseases including 
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gastric cancer in individuals that are infected with cagA- or cagPAI-positive strains compared 
to persons infected with cagPAI-negative H. pylori strains [156-158]. These observations 
strikingly suggest that the CagA-mediated cellular deregulation, together with a general 
inflammatory response to the infection, marks the pathological progression towards gastric 
cancer.  
 
5. Treatment of H. pylori infection: the increasing failure  
Successful eradication of H. pylori infection results in regression of ulcers as well as MALT 
lymphoma and prevents gastric cancer development if atrophy has not evolved yet (see also 
Chapter 1.2) [159, 160]. In general, only symptomatic individuals are treated with at least two 
antibiotics in combination with a proton pump inhibitor (PPI). PPI are concomitantly 
prescribed in order to increase the gastric pH which augments the solubility and local 
concentration of the antibiotic. However, due to the increasing antibiotic resistance rates [161, 
162], treatment efficacy of H. pylori infection has decreased drastically with eradication rates 
often below 50% [163]. According to the latest therapy recommendations [163], first-line 
therapies should be either composed of a nonbismuth quadruple therapy (PPI, amoxicillin, 
metronidazole, clarithromycin) or a bismuth quadruple therapy (PPI, bismuth, metronidazole, 
tetracycline), while the classical triple therapy (PPI, clarithromycin, amoxicillin or 
metronidazole) should be restricted to areas with low clarithromycin resistance or high 
eradication rates. Although several other antibiotic combinations are available (second and 
third line), the problem of the worldwide spreading antibiotic resistances will further 
deteriorate in the future, and therapies are predicted to fail at increasing rates. Vaccine 
developments against H. pylori infection have been in progress for years, and various pre-
clinical and some clinical trials have been performed, but only with limited success [164]. So 
far, no complete sterilizing immunity was achieved which is mainly attributed to an 
insufficient induction of a humoral immune response due to the various immune evasion 
strategies of the bacterium (see Chapter 2.2.2) [165]. The most promising clearance effects 
were observed in trials where a T-helper cell response could be induced but the efficacy of 
these approaches is hampered by H. pylori persistence mechanisms that subvert adaptive 
immunity (see Chapter 2.2.2) [133, 164]. 
However, most people tolerate the presence of H. pylori without any adverse effects, and 
some epidemiological studies even documented an inverse association of H. pylori infection 
with allergic and chronic inflammatory diseases, which is suggested to rely on the H. pylori-
immunomodulatory effects [14, 166]. Thus, new therapies might be aimed at preventing 
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H. pylori-induced pathology, rather than to achieve a complete eradication. Indeed, regarding 
the increasing failure of traditional antibiotic therapy, novel approaches to combat the disease 
progression upon H. pylori infection are urgently needed.  
 
6. Aims of this work 
H. pylori becomes increasingly resistant to the current therapeutic antibiotics and the 
development of new treatment strategies is a challenging issue. Novel antibacterial 
approaches try to target bacterial virulence factors instead of bacterial viability [167, 168]. So-
called pathoblockers provide moreover the benefits of reduced resistance development due to 
a missing selective pressure, as well as a preservation of the gut microbiome [168]. In the case 
of H. pylori, novel anti-infectives that directly block type IV secretion-mediated CagA 
translocation into host cells would be most effective to prevent CagA-induced carcinogenesis 
(see Chapter 4). Hence, studying exact CagA translocation mechanisms as well as strategies 
to inhibit this process are of major interest. Once inside the host cell, CagA is rapidly 
phosphorylated by host cell kinases, a process which is routinely analyzed via 
immunoblotting. As this method is time-consuming and labor-intensive, a novel reporter 
system should be established that allows fast, sensitive and quantitative CagA translocation 
analysis. This assay should then be used to study CagA translocation dynamics as well as the 
type IV signal recognition and secretion process. Moreover, the assay system should be 
applied to high-throughput screening of different compound libraries to identify specific Cag 
type IV secretion inhibitors. Compounds discovered during these screenings should be further 
characterized for their action on H. pylori. 
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II. MATERIALS & METHODS 
1. Materials 
1.1 Cell lines 
Cell lines used in this work are listed in Table 2. 
 
Table 2: Overview of cell lines 
FCS: fetal calf serum, Gln: L-glutamine 
Cell line Description Culture conditions Source or 
reference 
AGS  Human gastric epithelial 
adenocarcinoma cell line 
RPMI / 10% FCS;  
37°C / 5% CO2 
ATCC CRL-
1739 
HEK-293 Human embryonic kidney 
epithelial cell line 
DMEM / 15% FCS / 2 mM Gln; 
37°C / 5% CO2 
ATCC CRL-
1573  
HEK-293 
CEA 
Human embryonic kidney 
epithelial cell line, expressing 
CEA 
DMEM / 15% FCS / 2 mM Gln / 
0.5 µg/mL G418; 37°C / 5% CO2 
[169] 
J774A.1 Murine macrophage cell line DMEM / 10% FCS / 2 mM Gln; 37°C / 10% CO2 
ATCC TIB-67 
Kato III Human gastric carcinoma cell line 
DMEM / 20% FCS / 2 mM Gln; 
37°C / 5% CO2 
ATCC HTB-103 
L929 Murine fibroblast cell line DMEM / 10% FCS/ 2 mM Gln; 37°C / 5% CO2 
ATCC CCL-1 
 
1.2 Bacterial strains 
1.2.1 H. pylori strains 
A list of H. pylori strains used or generated in this work is presented in Table 3. 
 
Table 3: Overview of H. pylori strains 
Expression of (tem)-cagA in various mutants is under control of the endogenous promoter within the cagA locus, 
if not otherwise specified. Plasmids are described in detail in Table 5. 
Strain Internal ID Genotype/properties Source or 
reference 
26695 WSP86/TIGR Wild-type; first H. pylori strain to be 
completely sequenced [28] 
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Strain Internal ID Genotype/properties Source or 
reference 
B8 EL5 Wild-type; adapted to Mongolian gerbils  [170] 
P12 WSP12 Wild-type; clinical isolate (888-0) of the University of Hamburg [171] 
P12 CagA-
KKKA WSP607 
P12[pWS321] transformed with pWS349; CmR; 
CagA-K1203,1208,1213A expression This work 
P12 CagA-
REEHKKKA WSP620 
P12[pWS321] transformed with pWS350; CmR; 
CagA-R1195E1196,1199H1200K1203,1208,1213A 
expression 
This work 
P12 CagAΔ5C WSP805 P12[pWS321] transformed with pWS497; Cm
R; 
CagAΔ1210-1214 expression This work 
P12 CagAΔ6C WSP661 P12[pWS321] transformed with pWS387; Cm
R; 
CagAΔ1209-1214 expression This work 
P12 CagAΔ7C WSP991/WSP343 P12[pWS321] transformed with pWS502; Cm
R; 
CagAΔ1208-1214 expression This work 
P12 CagAΔ8C WSP662 P12[pWS321] transformed with pWS388; Cm
R; 
CagAΔ1207-1214 expression This work 
P12 CagAΔ9C WSP1000 P12[pWS321] transformed with pWS580; Cm
R; 
CagAΔ1206-1214 expression This work 
P12 CagAΔ10C WSP663 P12[pWS321] transformed with pWS389; Cm
R; 
CagAΔ1205-1214 expression This work 
P12 CagAΔ10C-
GSK FSP75 
P12[pWS321] transformed with pFS12; CmR; 
CagAΔ10C-GSK expression This work 
P12 CagAΔ10C-
Myc FSP76 
P12[pWS321] transformed with pFS13; CmR; 
CagAΔ10C-Myc expression This work 
P12 CagAΔ12C WSP1001 P12[pWS321] transformed with pWS581; Cm
R; 
CagAΔ1204-1214 expression This work 
P12 CagAΔ181C WSP558 P12 transformed with pWS321; Cm
R; 
CagAΔ1034-1214 expression This work 
P12 CagAΔ17N WSP849 P12[pWS373] transformed with pWS522; Cm
R; 
CagAΔ1-17 expression This work 
P12 CagAΔD1 WSP979 P12[pWS373] transformed with  pWS571; CmR; CagAΔ18-284 expression This work 
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Strain Internal ID Genotype/properties Source or 
reference 
P12 CagAΔEPIYA WSP999 P12[pWS373] transformed with pWS579; Cm
R; 
CagAΔ868-1019 expression This work 
P12 ΔcagA WSP649 P12 transformed with pWS373; Kan
R; deletion 
of cagA This work 
P12 ΔcagI WSP556 P12 transformed with pWS320; Erm
R; deletion 
of cagI [106] 
P12 TEM-CagA FSP1 P12[pWS373] transformed with pWS486; Cm
R; 
TEM-CagA expression This work 
P12 TEM-CagA & 
CagA WSP874 
P12[pWS486] transformed with pJP104; CmR, 
KanR; TEM-CagA expression, CagA expression 
(cagA encoded in recA locus) 
This work 
P12 TEM-CagA & 
CagAΔ20C FSP74 
P12[pWS486] transformed with pWS178; CmR; 
KanR; TEM-CagA expression, CagAΔ20C 
expression (cagAΔ20C encoded in recA locus) 
This work 
P12 TEM-CagA; 
ΔcagF FSP71/WSP943 
P12[WS486] transformed with pWS474; CmR, 
ErmR; TEM-CagA expression, deletion of cagF This work 
P12 TEM-CagA; 
ΔcagG WSP925 
P12[WS486] transformed with pWS428; CmR, 
ErmR; TEM-CagA expression, deletion of cagG This work 
P12 TEM-CagA; 
ΔcagH WSP927 
P12[WS486] transformed with pWS423; CmR, 
ErmR; TEM-CagA expression, deletion of cagH This work 
P12 TEM-CagA; 
ΔcagI FSP2 
P12[pWS486] transformed with pWS320; CmR, 
ErmR; TEM-CagA expression, deletion of cagI This work 
P12 TEM-CagA; 
ΔcagP WSP926 
P12[WS486] transformed with pWS503; CmR, 
ErmR; TEM-CagA expression, deletion of cagP This work 
P12 TEM-CagA-
GSK LKP1 
P12[pWS486, pWS321] transformed with 
pWS491; CmR; TEM-CagA-GSK expression This work 
P12 TEM-CagA-
M45 WSP809 
P12[pWS486, pWS321] transformed with 
pWS500; CmR; TEM-CagA-M45 expression This work 
P12 TEM-CagA-
KKKA WSP821 
P12[pWS486, pWS321] transformed with 
pWS349; CmR; TEM-CagA-K1203,1208,1213A 
expression 
This work 
P12 TEM-CagA-
REEHKKKA WSP820 
P12[pWS486, pWS321] transformed with 
pWS350; CmR; TEM-CagA-
R1195,E1196,1199,H1200,K1203,1208,1213A expression 
This work 
P12 TEM-
CagAΔ5C WSP808/824 
P12[pWS486, pWS321] transformed with 
pWS497; CmR; TEM-CagAΔ1210-1214 
expression 
This work 
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Strain Internal ID Genotype/properties Source or 
reference 
P12 TEM-
CagAΔ6C WSP992 
P12[pWS486, pWS321] transformed with 
pWS387; CmR; TEM-CagAΔ1209-1214 
expression 
This work 
P12 TEM-
CagAΔ7C WSP857 
P12[pWS486, pWS321] transformed with 
pWS502; CmR; TEM-CagAΔ1208-1214 
expression 
This work 
P12 TEM-
CagAΔ8C WSP993 
P12[pWS486, pWS321] transformed with 
pWS388; CmR; TEM-CagAΔ1207-1214 
expression 
This work 
P12 TEM-
CagAΔ9C WSP1002 
P12[pWS486, pWS321] transformed with 
pWS580; CmR; TEM-CagAΔ1206-1214 
expression 
This work 
P12 TEM-
CagAΔ10C WSP994 
P12[pWS486, pWS321] transformed with 
pWS389; CmR; TEM-CagAΔ1205-1214 
expression 
This work 
P12 TEM-
CagAΔ10C-GSK FSP77 
P12[pWS486, pWS321] transformed with 
pFS12; CmR; TEM-CagAΔ10C-GSK 
expression 
This work 
P12 TEM-
CagAΔ10C-Myc FSP78 
P12[pWS486, pWS321] transformed with 
pFS13; CmR; TEM-CagAΔ10C-Myc expression This work 
P12 TEM-
CagAΔ12C WSP1003 
P12[pWS486, pWS321] transformed with 
pWS581; CmR; TEM-CagAΔ1204-1214 
expression 
This work 
P12 TEM-
CagAΔ181C WSP801 
P12[pWS486] transformed with pWS321; 
KanR; TEM-CagAΔ1034-1214 expression This work 
P12 TEM-
CagAΔ17N WSP955 
P12[pWS373] transformed with pWS559; CmR; 
TEM-GSGGGS-CagAΔ1-17 expression This work 
P12 TEM-
CagAΔD1 WSP996/997 
P12[pWS373] transformed with pWS575; CmR; 
TEM-CagAΔ18-284 expression This work 
P12 TEM-
CagAΔD2-D3-
EPIYA 
WSP1007 P12[pWS373] transformed with pWS586; Cm
R; 
TEM-CagAΔ260-1019 expression This work 
P12 TEM-
CagAΔEPIYA WSP806 
P12[pWS373] transformed with pWS498; CmR; 
TEM-CagAΔ868-1019 expression This work 
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1.2.2 E. coli and other strains 
E. coli and other bacterial strains used in this work are listed in Table 4. 
 
Table 4: E. coli and other bacterial strains 
Strain Genotype/description Source or 
reference 
E. coli DH5α 
F-Φ80d lacZ ΔM15 Δ(lacZYA-argF) U169 deoR recA1 
endA1 hsdR17 (rK-, mK+) phoA supE44 λ-thi-l gyr A96 
relA1 
Life Technologies 
[172] 
E. coli TOP10 
F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacO74 
recA1 araΔ139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG 
Life Technologies 
[173] 
C. jejuni C31 W. Fischer 
S. aureus Staphylococcus aureus subsp. aureus Rosenbach ATCC 29213 
 
1.3 Plasmids 
Plasmids used in this work are listed in Table 5. 
 
Table 5: Overview of plasmids 
Genomic DNA of H. pylori P12 served as template for PCRs if not otherwise stated. Numbering of CagA refers 
to codon positions. Corresponding primers are listed in Table 6. 
Name Purpose  Backbone/modification Source or 
reference 
pBluescript II 
KS Cloning vector  
Agilent 
Technologies 
pCX340 Template for tem (blaM) sequence  [174] 
pFS12 
Construction of 
(tem)-cagAΔ10C-
gsk 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & FS8 This work 
pFS13 
Construction of 
(tem)-cagAΔ10C-
myc 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & FS10 This work 
pJP104 Insertion of cagA in 
recA locus  [175] 
pUC18 Cloning vector 
 
Life 
Technologies 
32 MATERIALS & METHODS  
Name Purpose  Backbone/modification Source or 
reference 
pWS178 
Insertion of 
cagAΔ20C in recA 
locus  
[131] 
pWS320 
Deletion of cagI 
locus, ΔcagI::rpsL-
erm 
 [106] 
pWS321 
Deletion of cagA 3´ 
region, ΔcagA 
3´::aphA-3 
 
pBluescript II KS; insertion of a cagA 
downstream fragment amplified with primers 
WS390 & WS391 into BamHI/NotI site and 
an aphA-3 kanamycin resistance cassette; 
insertion of an internal cagA fragment (codons 
847-1033) amplified with primers WS423 & 
WS424 into XhoI/ClaI site 
 
This work 
pWS336 
cagA reconstitution 
plasmid for 3´ 
modifications 
pUC18; insertion of a cagA downstream 
fragment amplified with primers WS390 & 
WS391 into BamHI/NotI site and a catGC 
chloramphenicol resistance cassette; insertion 
of the cagA 3´ region (codons 847-1214) 
amplified with WS423 & WS425 into 
SalI/PstI site 
This work 
pWS349 
Construction of 
(tem)-cagA-
KKKA 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & RL5 This work 
pWS350 
Construction of 
(tem)-cagA-
REHHKKKA 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & RL6 This work 
pWS373 
Deletion of cagA 
gene, ΔcagA::aphA-
3 
pBluescript II KS; insertion of a cagA 
downstream fragment amplified with primers 
WS390 & WS391 into BamHI/NotI site and 
an aphA-3 kanamycin resistance cassette; 
insertion of a cagA upstream fragment 
amplified with primers hp546r & WS400 into 
XhoI/BamHI site 
This work 
pWS387 Construction of (tem)-cagAΔ6C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS477 
This work 
pWS388 Construction of (tem)-cagAΔ8C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS281 
This work 
pWS389 Construction of (tem)-cagAΔ10C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS479 
This work 
pWS403 cagA reconstitution plasmid 
pUC18; insertion of a cagA downstream 
fragment amplified with primers WS390 & 
WS391 into BamHI/NotI site and a catGC 
chloramphenicol resistance cassette; insertion 
of cagA amplified with WS370 & WS425 into 
NdeI/PstI site and insertion of cagA upstream 
region amplified with primers hp546r & 
WS242 into SalI/NdeI site 
This work 
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Name Purpose  Backbone/modification Source or 
reference 
pWS423 
Deletion of cagH 
gene, ΔcagH::rpsL-
erm 
 
W. Fischer 
pWS428 
Deletion of cagG 
gene, ΔcagG::rpsL-
erm 
 
W. Fischer 
pWS474 
Deletion of cagF 
gene, ΔcagF::rpsL-
erm 
 
W. Fischer 
pWS476 
Plasmid 
intermediate for 
construction of tem-
cagA (blaM-cagA) 
pWS403; insertion of tem (blaM) amplified 
with WS553 & WS428 into NdeI/BglII site 
and pCX340 as template 
This work 
pWS486 Construction of tem-
cagA (blaM-cagA) 
pWS476; insertion of full-length cagA 
amplified with WS265 & WS425 into BglII 
and KpnI site 
This work 
pWS491 Construction of tem-
cagA-gsk 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS597 
This work 
pWS497 Construction of (tem)-cagAΔ5C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS177 
This work 
pWS498 Construction of tem-
cagAΔ868-1019 
pWS476; insertion of PCR product with 
primer WS265 & WS318 into BglII This work 
pWS500 Construction of tem-
cagA-m45 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS267 
This work 
pWS502 Construction of (tem)-cagAΔ7C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS281 
This work 
pWS503 
Deletion of cagP 
gene, ΔcagP::rpsL-
erm 
 
W. Fischer 
pWS508 Construction of (tem)-cagAΔ20C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS178 
This work 
pWS522 Construction of 
cagAΔ1-17 
pWS403; replacement of NdeI/KpnI fragment 
by PCR product of primers WS611 & WS425 This work 
pWS559 
Construction of tem-
GSGGGS-cagAΔ1-
17 
pWS476; replacement of BglII/KpnI fragment 
by PCR product with primers WS652 & 
WS425  
This work 
pWS571 Construction of 
cagAΔ18-284 
pWS403; replacement of NdeI/KpnI fragment 
by overlap extension PCR product with 
primers WS370, WS613, WS612 & WS425 
This work 
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Name Purpose  Backbone/modification Source or 
reference 
pWS575 Construction of tem-
cagAΔ18-284 
pWS476; replacement of BglII/KpnI fragment 
with PCR product with WS265 & WS425 and 
pWS571 as template 
This work 
pWS579 Construction of 
cagAΔ868-1019 
pWS403; replacement of NdeI/BglII fragment 
by PCR product with primers WS370 & 
WS318 
This work 
pWS580 Construction of (tem)-cagAΔ9C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS704 
This work 
pWS581 Construction of (tem)-cagAΔ12C 
pWS336; replacement of XbaI/KpnI fragment 
by PCR product with primers WS237 & 
WS291 
This work 
pWS586 Construction of tem-
cagAΔ260-1019 
pWS476; insertion of PCR product with 
primers WS265 & WS705 into BglII site This work 
 
1.4 Oligonucleotides 
Salt-free oligonucleotides were purchased from Biomers.net or Metabion. Oligonucleotides 
were dissolved in ddH2O to a stock concentration of 100 pmol/µL and diluted to a final 
working concentration of 10 pmol/µL. Oligonucleotides were stored at -20°C. Primer design, 
specifity and amplicon length was determined with the CLC DNA workbench software. All 
primers used in this work are summarized in Table 6.  
 
Table 6: Overview of oligonucleotides 
Recognition sites of restriction enzymes are underlined. 
Name Sequence (5´  3´) Restriction 
enzyme 
   
FS8 GGGGTACCTTATGATTCTGCAAAACTTGTAGTTCGAGGTCGGCCAGACATCTCGAGATTCTTGATTCCATGCTCTGCAT KpnI 
FS10 GGGGTACCTTACAGATCCTCTTCTGAGATGAGTTTTTGTTCATTCTTGATTCCATGCTCTGCAT KpnI 
hp546r ACCGCTCGAGTGTAAAAAATTTCATGCGTT XhoI 
RL5 CCGGTACCTTAAGATGCTTGGAAACCACCTGCTGTATTAACATTCGCGATTCCATGC KpnI 
RL6 CCGGTACCTTAAGATGCTTGGAAACCACCTGCTGTATTAACATTCGCGATTCCAGCCGCTGCATTTGCCGCCGCCAAGCAG KpnI 
WS177 GGGGTACCTTAACCTTTTGTATTAACATTC KpnI 
WS178 CTGGTACCTTACGCCAAGCAGTAATATCCT KpnI 
WS237 AATCTAGAGCAAACGATAGAC XbaI 
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Name Sequence (5´  3´) Restriction 
enzyme 
WS242 ACCGCTCGAGCATATGTTCTCCTTACTAACTAGTTTC NdeI 
WS265 CAGGATCCGACTAACGAAACCATTAACC BamHI 
WS267 GGGGTACCTTATAAGATCCTGGTTTCTGTTTCAAAAGGCGGCAAACGATCCCTGCTCCTGTCGACAGATTTTTGGAAACCACCTTTTG KpnI 
WS281 CGGGTACCTTATGTATTAACATTCTTGATTC KpnI 
WS291 GCGGTACCTTAGATTCCATGCTCTGCATTTTC KpnI 
WS318 CGGGATCCGAAAAGTTTTTAGAAAG BamHI 
WS370 AGCATATGACTAACGAAACCATTAAC NdeI 
WS390 CGGGATCCTAAAGGATTAAGGAATACC BamHI 
WS391 ACCTGCGGCCGCTAAAGTGGAATTTCATGCG NotI 
WS400 GCGGATCCCATATGTTCTCCTTACTAACTAGTTTC BamHI 
WS423 ACCGCTCGAGAACCCTAGTCGGTAATGGG XhoI 
WS424 ATATCGATTTAAGCCAATTTTTGATTCCTTG ClaI 
WS425 ACCGCTGCAG GGTACCTTAAGATTTTTGGAAACCAC PstI &KpnI 
WS428 GAAGATCTCCCCAATGCTTAATCAGTGAGGCACC BglII 
WS477 CGGGTACCTTATTTTGTATTAACATTCTTGATTC KpnI 
WS478 CGGGTACCTTAATTAACATTCTTGATTCCATG KpnI 
WS479 CGGGTACCTTAATTCTTGATTCCATGCTCTGC KpnI 
WS553 ACGCGTCGACCATATGCACCCAGAAACGCTGGTGAAAG NdeI 
WS597 GGGGTACCTTATGATTCTGCAAAACTTGTAGTTCGAGGTCGGCCAGACATCTCGAGAGATTTTTGGAAACCACCTTTTG KpnI 
WS611 ACCGTACATATGGATCCGCAGCAATTTATCAATAATC NdeI 
WS612 GGCTTTTAACCCTAATTACAAGTTCAACCAATTATTGATTC 
 
WS613 GTTGAACTTGTAATTAGGGTTAAAAGCCGCTTCGGTTTG 
 
WS652 ACCGTACATATGGATCCGGGATCTGGGGGTGGGTCTGGTCCGCAGCAATTTATCAATAATC BamHI 
WS704 CGGGTACCTTAAACATTCTTGATTCCATGCTC KpnI 
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Name Sequence (5´  3´) Restriction 
enzyme 
WS705 GCGGATCCTCAAGTAAATCTCTAGCTTCAGG BamHI 
 
1.5 Chemicals and standard buffers 
Chemicals were purchased from Roth, Merck, or Sigma-Aldrich if not otherwise specified. In 
general, distilled water (dH2O) was used for the preparation of buffer or media, while 
ultrapure water (ddH2O, Roth) was used for any molecular biological reaction. Cell culture 
grade DPBS (Dulbecco’s PBS without calcium and magnesium, Life Technologies) was used 
for experiments with living bacteria or cells, and self-prepared PBS for all other purposes.  
Self-prepared PBS (phosphate-buffered saline) 
2.7 mM Potassium chloride (KCl) 
138 mM Sodium chloride (NaCl) 
1.5 mM  Monopotassium phosphate (KH2PO4) 
8 mM Disodium phosphate (Na2HPO4) 
 
1.6 Cultivation media and additives 
1.6.1 Liquid media and supplements 
Liquid media and supplements used for cultivation of bacteria and eukaryotic cells are listed 
in Table 7.  
 
Table 7: List of liquid media and supplements 
Media Supplier Comment 
Brucella broth (BB) Becton Dickinson for BB liquid media, 28 g/L 
Dulbecco´s Modified Eagle media with sodium 
pyruvate and pyridoxine (DMEM) Life Technologies  
Fetal calf serum (FCS) Life Technologies heat inactivated  (56°C, 20 min) 
G418 Sigma-Aldrich  
Lennox-L-Medium (Luria-Bertani broth, LB)  Invitrogen for LB liquid media, 20 g/L 
L-glutamine Life Technologies  
RPMI 1640 media with L-glutamine Life Technologies 
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1.6.2 Agar plates 
Lennox-L agar (32 g/L, Invitrogen) and GC agar base (36 g/L, Oxoid) were used for LB agar 
and GC agar (serum) plates, respectively. Serum plates were additionally supplemented with 
8% horse serum (PAA) and 1% vitamin mix after autoclaving and cooling down below a 
temperature of 55°C. If necessary, antibiotics (see Table 8) were added. Plates were stored at 
4°C.  
GC agar plates (serum plates) formula per 0.455 L dH2O 
18 g GC agar base 
40 mL Horse serum (8%) 
5 mL Vitamin mix (1%) consisting of 100 g/L α-D-glucose, 10 g/L L-glutamine, 26 g/L L-
cysteine, 1.1 g/L L-cystine, 0.15 g/L L-arginine, 0.1 g/L cocarboxylase, 20 mg/L 
iron(III)nitrate, 3 mg/L thiamine, 13 mg/L p-aminobenzoic acid, 0.25 g/L nicotinamide 
adenine dinucleotide, 10 mg/L vitamin B12, 1 g/L adenine, 30 mg/L guanine, 0.5 g/L uracil 
 
1.6.3 Antibiotics 
Antibiotics were dissolved in respective solvents, sterile filtrated (0.22 μm) and stored in 
aliquots at -20°C. Additional information is listed in Table 8.  
 
Table 8: List of antibiotics 
Antibiotic Supplier Solvent Final concentration in media/agar plate 
   
H. pylori E. coli 
Ampicillin Sigma-Aldrich Water - 100 mg/L 
Chloramphenicol Fluka Ethanol 6 mg/L 30 mg/L 
Erythromycin AppliChem Ethanol 10 mg/L 250 mg/L 
Kanamycin Sigma-Aldrich Water 8 mg/L 50 mg/L 
Streptomycin Sigma-Aldrich Water 250 mg/L 250 mg/L 
 
1.7 Compounds for high-throughput screenings and follow-up studies 
For high-throughput screening assays, compound libraries as well as any resupply were 
derived from the Helmholtz Center for Infection research (Braunschweig). The libraries 
comprised purified natural products from the HZI (Saarbrücken) and IMIT (Tübingen), 
chemically synthesized molecules from the SPECS company, and pharmacologically active 
substances from Sigma-Aldrich´s LOPAC library. Further substances, used as reference 
substances in follow-up studies, are listed in Table 9. 
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Table 9: Commercial compounds for follow-up studies 
Compound Solvent Supplier  
Antimycin A from Streptomyces sp. Ethanol Sigma-Aldrich 
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) DMSO Sigma-Aldrich 
Rotenone DMSO Sigma-Aldrich 
 
1.8 Antibodies  
All antibodies including the applied final concentration are listed in Table 10. 
 
Table 10: List of antibodies 
AP: alkaline phosphatase, POX: horseradish peroxidase, α: anti- 
Antibody Internal-ID Antigen (origin) Final 
concentration 
Supplier or 
reference 
Primary antibodies 
α CagA  AK257 Polyclonal antibody against C-terminal part of CagA (rabbit) 
1:5000 (AP) 
1:50000 (POX) [74] 
α CagA  AK268 Polyclonal antibody against N-terminal part of CagA (rabbit) 1:1000 (AP) [131] 
α CagF AK284 Polyclonal antibody against CagF (rabbit) 1:1000 (AP) [119] 
α CagI AK293 Polyclonal antibody against C-terminal part of CagI (rabbit) 1:2000 (AP) [106] 
α IL-8 
 
Monoclonal antibody against 
human interleukin-8 (mouse) ELISA/coating  BD Pharmingen 
α IL-8 biotin 
 
Monoclonal antibody against 
human interleukin-8, biotin 
conjugated 
ELISA/detection BD Pharmingen 
α M45 
 
Polyclonal antibody against the 
M45-epitope (mouse) 1:1000 (AP) [176] 
α Myc tag 
 
Monoclonal antibody against the 
Myc epitope tag (mouse) 1:5000 (AP) 
Cell Signaling 
Technology, 
Inc. 
α P-GSK 
 
Polyclonal antibody against 
phospho-GSK(glycogen synthase 
kinase)-3β (rabbit) 
1:1000 (POX) 
Cell Signaling 
Technology, 
Inc. 
α P-Tyr  4G10 
Monoclonal antibody against 
tyrosine-phosphorylated proteins 
(mouse) 
1:5000 (POX) Merck Millipore 
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Antibody Internal-ID Antigen (origin) Final 
concentration 
Supplier or 
reference 
Primary antibodies 
α P-Tyr PY99 
Monoclonal antibody against 
tyrosine-phosphorylated proteins 
(mouse) 
1:5000 (POX) Santa Cruz Biotechnologies 
α RecA  AK263 Polyclonal antibody against RecA (rabbit) 1:1000 (AP) [177] 
α TEM-1 
 
Monoclonal antibody against 
TEM type β-lactamases from E. 
coli (mouse) 
1:2500 (AP) Abcam 
α Tubulin 
 
Monoclonal antibody against 
tubulin (mouse) 1:50000 (POX) Abcam 
     
Secondary antibodies 
   
Protein A-AP 
 
AP coupled to protein A  
(S. aureus) 1:5000 Sigma-Aldrich 
α mouse-AP 
 
AP-coupled polyclonal antibody 
against mouse-IgG (goat) 1:1000 Sigma-Aldrich 
α mouse-POX 
 
POX-coupled polyclonal 
antibody against mouse-IgG 
(goat) 
1:10000 Sigma-Aldrich  
α rabbit-POX 
 
POX-coupled polyclonal 
antibody against rabbit-IgG 
(goat) 
1:10000 Sigma-Aldrich  
 
2. Methods 
2.1 Microbiological methods 
2.1.1 Cultivation of H. pylori  
H. pylori was streaked onto serum plates from glycerol stock cultures (2.1.3) and incubated 
for at least 48 h at 37°C under microaerobic conditions (5% O2, 10% CO2, 85% N2). Grown 
cultures were passaged onto fresh serum plates every day or at least once before experiments 
and again cultivated for about 24 h. For liquid cultures, BB supplemented with 10% FCS 
(BB/FCS) was inoculated and incubated in an anaerobic pot under microaerobic atmosphere 
(see above) while shaking (85 rpm).  
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2.1.2 Cultivation of E. coli and other bacteria 
E. coli and S. aureus were pre-cultured from glycerol stocks on LB agar plates. Plates were 
stored at 4°C for maximal 2 weeks. For overnight cultures, LB medium was inoculated with 
one single colony and incubated at 37°C while shaking (150 rpm). If necessary, LB was 
supplemented with respective antibiotics (see Table 8). C. jejuni was always freshly streaked 
out from glycerol stock culture (2.1.3) on serum plates followed by incubation for 24 h at 
37°C / 10% CO2. 
 
2.1.3 Maintenance of bacterial cultures 
For long-term storage, bacterial strains were frozen in a glycerol emulsion to prevent any cell 
damage. To do so, freshly grown bacteria were suspended in a so-called freezing media 
(70% BB containing 10% FCS and 20% glycerol) and stored at -80°C in cryogenic tubes 
(Nalgene, Thermo Fisher Scientific).  
 
2.1.4 Determination of the optical density of bacterial suspensions 
The concentration of bacterial suspensions was determined by measuring the amount of light 
scattered by the culture at a wavelength of 550 nm (OD550) with a spectrophotometer (DR 
2000, Hach). Bacteria were derived directly from liquid cultures or resuspended from agar 
plates in medium or buffer using a sterile cotton swab. An OD550 of 0.1 was estimated to 
correspond to approximately 2.5 x 107 cfu/mL. 
 
2.1.5 Growth curves 
H. pylori and C. jejuni grown on serum plates or E. coli and S. aureus derived from liquid 
cultures (2.1.1 and 2.1.2) were diluted to an OD550 of 0.075 (2.1.4) and subcultured in 96-well 
microtiter plates (clear, flat-bottom, Costar, Corning Inc.), which were then sealed with a gas-
permeable membrane (Breathe-Easy® sealing membrane, Diversified Biotech). Plates were 
incubated at 37°C (while shaking) in the Clariostar plate reader (BMG Labtech), and the 
optical density at 550 nm was automatically monitored. Thereby, for H. pylori and C. jejuni a 
microaerobic environment (5% O2 / 10% CO2 or 18% O2 / 10% CO2) was generated by an 
atmospheric control unit (ACU, BMG Labtech). Measurements were conducted until the 
stationary phase was reached. Growth curves were analyzed and processed using the MARS 
Data Analysis software 3.10 R5 (BMG Labtech). Percental growth was expressed as 
[(ΔODsample / ΔODcontrol) x 100], while ΔOD corresponded to “ODstationary phase – ODlag phase”. 
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2.1.6 Generation of genetically manipulated bacteria  
Transformation describes the direct uptake of exogenous DNA into bacterial cells, occurring 
when bacteria are in a competent state. For the introduction of plasmid DNA into E. coli, 
competence was artificially induced by a chemical pre-treatment to permeabilize the cell 
membrane. In the case of H. pylori, the natural competence of the bacterium was exploited for 
genetic manipulation. 
 
Preparation and transformation of rubidium chloride (RbCl) competent E. coli cells 
For preparation of rubidium chloride (RbCl) competent E. coli (modified after [173]), 200 mL 
of LB medium was inoculated with 20 mL of the respective E. coli overnight pre-culture 
(2.1.2). The cell suspension was incubated at 37°C and grown to an optimal OD550 of about 
0.56, which corresponds to the logarithmic growth phase. Cultures were transferred in pre-
chilled falcon tubes and harvested by centrifugation (3000 x g, 10 min, 4°C). The LB medium 
was decanted and cells were resuspended in 80 mL of ice-cold TfbI. After a rest on ice for 
5 min, cells were pelleted again (3000 x g, 10 min, 4°C) and the supernatant discarded. 
Finally, the cell pellet was resuspended in 8 mL of ice-cold TfbII solution. Aliquots of 50 µL 
were dispensed, immediately frozen in liquid nitrogen and stored at -80°C.  
TfbI buffer in dH2O 
30 mM Potassium acetate  
 
100 mM Rubidium chloride (RbCl) 
 
10 mM Calcium chloride (CaCl2)  
50 mM Manganese chloride (MnCl2)  
Glycerol was added to a final concentration of 15% (v/v), pH adjusted to 5.8 and sterile-filtrated. 
 
TfbII buffer in dH2O 
10 mM 3-(N-morpholino)propanesulfonic acid (MOPS) 
 
75 mM CaCl2  
10 mM RbCl 
 
Glycerol was added to a final concentration of 15% (v/v), pH adjusted to 6.5 and sterile-filtrated. 
 
For effective transformation (protocol adapted from [178]), 15 µL of a ligation reaction 
mixture (2.4.9) was added to frozen RbCl competent E. coli. Then, the bacterial cells were 
thawed rapidly by warming between hands, gently swirled and immediately placed on ice for 
30 min. Cells were heat shocked for 90 s at 42°C (Thermoblock, Eppendorf) and instantly 
transferred on ice again for 2 min. 1 mL of LB medium was added and bacteria were 
incubated for at least 1 h at 37°C while shaking to allow expression of antibiotic resistance. 
The culture suspension was centrifuged (2500 x g, 5 min), the supernatant decanted, the cell 
pellet resuspended in the remaining medium and gently plated on LB agar plates containing 
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respective antibiotics (Table 8). Incubation was performed at 37°C for 24 h.  
 
Natural transformation of H. pylori cells 
H. pylori was harvested from serum plates and suspended in BB/FCS (modified after [179]). 
Cells were adjusted to an OD550 of 0.2 and dispended in a 24-well plate with a total volume of 
1 mL per transformation reaction. H. pylori was incubated for 1-2 h at 37°C / 10% CO2 to 
increase motility and transformation competence. After addition of 5-10 µL plasmid DNA, 
suspensions were incubated for another 4-6 h. Bacteria were collected by centrifugation 
(1000 x g / 5 min), resuspended in the remaining medium and plated on selective serum 
plates. For detection of single colonies, H. pylori was incubated for at least 3 days at 37°C 
under microaerobic conditions (5% O2, 10% CO2, 85% N2). 
 
2.2 Cell culture 
2.2.1 Cultivation and maintenance of cell lines  
Cell lines were cultivated in 75 cm2 tissue culture flasks (BD Falcon®) under standard 
conditions (see Table 2) and subcultured every 2-3 days. In detail, adherent cells (except 
J774) were washed with Dulbecco´s buffered saline (DPBS, Life Technologies), treated with 
3 mL of 0.05% Trypsin-EDTA (TE, Life Technologies) and incubated for 5 min at 37°C to 
detach the cells. This reaction was stopped by adding culture medium supplemented with 
FCS, cells were diluted in fresh media and further cultured. J744 were washed with DPBS, 
scraped off with a cell scraper and transferred into fresh media. For cell counting, cells were 
resolved in solution, live/dead stained with trypan blue (Life Technologies) and applied to a 
Neubauer counting chamber. For experiments, cells were dispended in 6-, 12-, 24-, 48 or 384-
well plates (tissue culture-treated, Costar, Corning Inc.), and in 96-well plates (black, 
transparent bottom, tissue culture-treated, 4titude®) or 386-well plates (black, transparent 
bottom, tissue culture-treated, Corning Inc.) for fluorescence-assisted plate reader 
applications.  
 
2.2.2 Freezing and thawing of cell lines 
For long-term storage, cells were collected by centrifugation (about 106 cells) and 
resuspended in freezing medium (50% culture medium, 45% FCS, 5% DMSO). Stocks were 
stored in cryogenic tubes (Nalgene, Thermo Fisher Scientific) for at least 24 h at -70°C and 
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then transferred to liquid nitrogen tanks. For thawing of cells, frozen stocks were incubated at 
37°C, washed twice with pre-warmed culture medium (250 x g, 10 min) and cultivated under 
recommended conditions (see Table 2).  
 
2.3 In vitro infections 
To mimic the infection process of H. pylori with eukaryotic cells, in vitro infections were 
carried out. When H. pylori was cultured on plates, bacteria were first suspended in DPBS 
containing 10% FCS (DPBS/FCS), diluted to an OD550 appropriate for the later multiplicity of 
infection (MOI) (2.1.4), and then incubated for about 2 h at 37°C / 10% CO2 to increase 
fitness and motility of bacteria. Eukaryotic cells, grown to a confluency of ~80% (2.2.1), were 
infected with H. pylori with an MOI of 100, if not otherwise specified. The infection was 
incubated for 2.5 h at 37°C / 5% CO2 (only J774 cells at 37°C / 10% CO2), if not otherwise 
stated. Further analysis was carried out via tyrosine/GSK phosphorylation assay (2.5.4), 
immunoprecipitation (2.5.5), ELISA (2.5.6), or with the TEM-CagA assay (2.8). 
 
2.4 DNA methods 
2.4.1 Preparation of genomic DNA 
For isolation of genomic H. pylori DNA (gDNA), the QIAmp DNA Mini Kit (Qiagen) was 
employed. Briefly, H. pylori was collected from serum plates and suspended in 180 µL ATL 
buffer. After addition of 20 µL proteinase K, the suspension was incubated at 56°C for at least 
3 h while shaking for efficient cell lysis. Then, 200 µL of AL buffer was added and heated at 
70°C for 10 min. After the precipitation of nucleic acids, 200 µL of ethanol was added and the 
mixture was applied to a column which was followed by several washing steps according to 
the manufacturer´s instructions. Finally, gDNA bound to the column matrix was dissolved in 
ddH2O to a concentration suitable for further experimentation and stored at -20°C. 
 
2.4.2 Preparation of plasmid DNA 
Plasmids derived from E. coli were either purified with the QIAprep Spin Miniprep Kit 
(Qiagen) for highly pure plasmid preparations or by a rather impure boiling procedure 
(adapted from [180]).  
The commercial kit was performed following the spin protocol. For this purpose, liquid 
overnight cultures were harvested by centrifugation or bacteria grown on plates were directly 
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suspended in P1 buffer, then lysed, applied to the column and the DNA bound to the silica-
based membrane. Remaining contaminates were removed by washing steps and plasmid DNA 
was eluted with 40 µL ddH2O.  
For the plasmid preparation by boiling, bacteria were first resuspended in 300 µL STET 
buffer. After the addition of 15 µL lysozyme (10 mg/mL in STET buffer), the suspension was 
left on ice for at least 5 min. To break the cells further down, the suspension was cooked for 
1 min and centrifuged (20,000 x g / 10 min) for the removal of cell debris. The supernatant 
was mixed with 200 µL isopropanol and incubated at -20°C for at least 10 min to increase 
precipitation of DNA. The DNA was pelleted by centrifugation and washed with 70% 
ethanol, dried and resuspended in 50 µL ddH2O. Purified DNA was stored at -20°C. 
STET buffer in dH2O 
50 mM Tris/HCl, pH 8.0 
50 mM Ethylenediaminetetraacetic acid (EDTA) 
8% Saccharose 
5% Triton X-100 
 
2.4.3 Nucleic acid concentration determination 
Nucleic acid samples were routinely controlled for their concentration and purity by 
measuring optical densities (at 260, 280 and 230 nm) with the NanoDrop ND-1000 
spectrophotometer (PeqLab). For this purpose, 1 µL of nucleic acid in the respective solvent 
was applied on the sample column and the OD260, which is proportional to the nucleic acid 
concentration (Lambert-Beer law), was determined. OD260/OD280 as well as OD260/OD230 
ratios were recorded to assess impurities with proteins or other organic components.  
 
2.4.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a common technique for in vitro enzymatic amplification 
of a specific segment of DNA. For amplification of DNA with cloning purposes, the ExTaq 
DNA polymerase (Takara, Clontech) was applied. This polymerase exhibits a 3'5' 
exonuclease (proofreading) activity that enables the polymerase to correct nucleotide 
incorporation errors, resulting in high fidelity [181]. For conventional gene amplification (e.g. 
mutant screening) the PanScript Polymerase (pan-biotech), lacking this proofreading ability, 
was used. A 1:50 dilution of genomic (2.4.1) or plasmid DNA (2.4.2) served as template. In 
general, annealing temperatures were adjusted to primer specifity and elongation time was 
adapted to the amplicon size. Reactions were carried out in a thermal cycler (Thermo Hybaid 
Px2, Thermo Fisher Scientific; Mastercycler personel, Eppendorf). 
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PCR mix for ExTaq polymerase  
50 µL volume   
PCR mix for PanScript polymerase  
50 µL volume 
14.9 µL ddH2O   13.4 µL ddH2O 
5 µL 10x ExTaq buffer    5 µL 10x PanScript NH4-buffer  
5 µL Magnesium chloride (MgCl2, 25 mM)    2.5 µL MgCl2 (50 mM)  
10 µL 3´-Oligonucleotide (10 pmol/µL)   10 µL 3´-Oligonucleotide (10 pmol/µL) 
10 µL 5´-Oligonucleotide (10 pmol/µL)   10 µL 5´-Oligonucleotide (10 pmol/µL) 
4 µL dNTP-Mix (2.5 mM)    8 µL dNTP-Mix (1.25 mM) 
0.1 µL ExTaq polymerase    0.1 µL PanScript polymerase  
1 µL DNA template   1 µL DNA template 
 
PCR Cycling program       
 
  ExTaq PanScript 
 
Initial denaturation 94°C / 5 min 
 Denaturation 94°C / 30 s 
30 times Annealing 50 – 52°C / 30 s 
 
Elongation 68°C / 2 kb/min 72°C / 1 kb/min 
 
Final elongation 68°C / 5 min 72°C / 5 min 
 
2.4.5 Agarose gel electrophoresis 
In order to separate and purify DNA fragments derived from PCR amplification (2.4.4) or 
restriction enzyme digest (2.4.7), agarose gel electrophoresis was performed. DNA 
(negatively charged) migrates in an electric field from the cathode to the anode. Thus, DNA 
fragments of different length can be easily separated, as shorter DNA fragments move faster 
through the agarose matrix than longer fragments. Gels were prepared by heating 1-2% (w/v) 
agarose in 1x tris-acetate-EDTA (TAE) buffer, until the agarose was completely dissolved. 
This mixture was put into a filling device and pockets were formed with a comb. Prior to 
loading the gel pockets, DNA samples were premixed with GEBS buffer. A DNA ladder 
(GenerulerTM 1kb DNA Ladder, Thermo Fisher Scientific) served as reference. Gels were run 
in horizontal gel chambers (Bio-Rad) in 1x TAE buffer with a constant voltage of up to 
15 V/cm gel length for 30 to 60 min to achieve optimal separation of DNA fragments. 
Staining of analytic gels was performed in ethidium bromide (1 mg/L) for 45 min and gels 
were photographed under ultraviolet (UV) light using a gel documentation system (Molecular 
Imager Gel Dox XR System, Bio-Rad). Preparative gels were stained with a 0.1% methylene 
blue solution. After destaining with tab water, DNA bands were cutted with a scalpel and 
purified (2.4.6). 
1x tris-acetate-EDTA (TAE) buffer GEBS buffer  
 
in dH2O 20% (v/v) Glycerine 
40 mM Tris/HCl, pH 8 50 mM EDTA 
20 mM Acetic acid 0,05% (w/v) Bromphenol blue 
1 mM EDTA  0,5% (w/v) N-Laurylsarcosyl 
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2.4.6 Purification of DNA fragments 
To guarantee a high purity of DNA fragments for any downstream application, impurities in 
DNA samples (derived from enzymatic reaction or agarose gel) had to be removed. Therefore, 
the illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare) was employed 
following the manufacturer´s recommendations. 
 
2.4.7 Digestion of DNA with restriction enzymes 
DNA was digested with restriction enzymes (RE) from Thermo Fisher Scientific or Roche 
Applied Science following the manufacturer´s instructions. Briefly, Plasmid DNA or PCR 
amplicon DNA was incubated with the respective enzyme in the recommended reaction 
buffer for 2-3 h at 37°C. Therefore, 1-2 µg DNA were used for preparative and 30-100 ng 
DNA for analytic restrictions. DNA fragments were either first purified via agarose gel 
electrophoresis (2.4.5) or directly re-buffered after every digestion step (2.4.6). Purified DNA 
was eluted in ddH2O and stored at -20°C.  
Digestion mix e.g. 10 µL volume  
8 µL Plasmid/insert diluted in ddH2O 
1 µL 10x RE-specific buffer  
1 µL RE  
 
2.4.8 Dephosphorylation of DNA plasmid ends 
To prevent recirculation of vector DNA plasmids after restriction digest (2.4.7), a shrimp 
alkaline phosphatase (SAP, Roche Applied Science) treatment was conducted. Together with 
a SAP-specific buffer, the reaction mixture was incubated for 1 h at 37°C and plasmids were 
re-purified afterwards (2.4.6). 
Dephosphorylation mix 100 µL volume 
88 µL Digested plasmid 
10 µL 10x SAP buffer  
2 µL SAP  
 
2.4.9 Ligation 
For ligation of restriction enzyme-generated DNA fragments, the T4 DNA Ligase 
(Fermentas) was employed. Respective amounts of inserts and vector DNA were determined 
following a molar ratio of 3:1 for cloning PCR products in plasmid vectors and equimolar 
amounts for DNA fragments of similar length. Reaction mixtures were incubated overnight at 
RT and then used for transformations (2.1.6).  
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Ligation mix 20 µL volume 
20-100 ng Linear vector DNA 
1:1 or 1:3 Insert DNA 
(molar ratio of insert : vector) 
2 µL 10x Ligase buffer  
1 µL T4 DNA Ligase  
to 20 µL ddH2O 
 
2.4.10 In silico cloning and DNA sequence analysis 
In silico cloning was performed with the CLC DNA Workbench 6 software in order to 
determine and monitor the base pair length of various DNA fragments (generated during 
digestion and amplification steps). For analysis of DNA sequences, 10-20 ng/µL of purified 
PCR products or 50 ng/µL of plasmid DNA were subjected to sequencing by the GATC 
Biotech AG. Evaluation of sequences was performed with the CLC DNA Workbench 6 
software. 
 
2.5 Protein biochemistry methods  
2.5.1 Production of bacterial lysates 
To produce bacterial lysates, the OD550 (2.1.4) of a bacterial suspension was determined and 
the desired amount sedimented by centrifugation (1500 x g, 5 min). The supernatant was 
discarded and the cell pellet resuspended in SDS sample buffer (see 2.5.2). Samples were 
cooked for 10 min at 95°C and finally analyzed via SDS-PAGE (2.5.2) and subsequent 
Immunoblotting (2.5.3). 
 
2.5.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE (modified from [182]) enables analytical separation of proteins. Prior to SDS-
PAGE, proteins are denatured by heating in the presence of thiols and SDS. Proteins bind 
SDS in a constant weight ratio, and the negatively charged SDS-protein complexes are 
separated according to their molecular size when migrating through the gel matrix in response 
to an electrical field. To increase the resolution during separation, a discontinuous gel was 
applied [178]. This consisted of an upper stacking gel with a low polyacrylamide 
concentration (5%) and slightly acidic pH, and a resolving gel which is more basic and has a 
higher polyacrylamide content. To do so, resolving gel solutions (6-12%) were filled into slab 
mini-gel polymerization cassettes up to 1.5 cm beneath the glass plate edge and overlaid with 
water to provide a barrier to oxygen (that inhibits polymerization) as well as to form a flat 
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interface. After polymerization (about 1 h), the water layer was poured off and the stacking 
gel solution applied. A comb was inserted to form sample wells and polymerization was 
allowed for about 1 h. Gels were either directly clambed to the Mini-PROTEAN® 3 Cell 
chamber (Bio-Rad) or stored at 4°C.  
Before performing electrophoresis, samples had to be diluted in SDS sample buffer and 
heated for 10 min at 95°C to break up cells and denature secondary and tertiary protein 
structures. Then, 2-10 µL of sample volume was loaded into the gel pockets. As a size 
reference, 5 µL of Page RulerTM Prestained Protein Ladder (Fermentas) was used. 
Electrophoresis was conducted in SDS-running buffer with a voltage of 100 V until the 
tracking dye entered the resolving gel. Then, voltage was increased up to 140 V until the dye 
had reached the bottom of the separating gel. 
SDS-polyacrylamide gel composition sufficient for 1 minigel 
  Resolving gel  
Stacking 
gel 
  6% 8% 10% 12%    
dH2O 2.6 mL 2.3 mL 1.9 mL 1.6 mL  0.68 mL 
Acrylamide (Rotiphorese® Gel 30 (37.5:1)) 1.0 mL 1.3 mL 1.7 mL 2.0 mL  0.17 mL 
1.5 M Tris/HCl, pH 8.8 1.3 mL 1.3 mL 1.3 mL 1.3 mL  - 1.0 M Tris/HCl, pH 6.8 -  0.13 mL 
10% (w/v) SDS 50 µL  10 µL 
10% (w/v) Ammonium peroxide sulfate (APS) 50 µL  10 µL 
Tetramethylethylenediamine (TEMED)*) 4 µL 3 µL 2 µL 2 µL  1 µL *)
 starts polymerization of acrylamide and was added last 
 
SDS-running buffer 
250 mM Glycine 
0.1% (w/v) SDS 
25 mM Tris/HCl, pH 8.3 
 
Gels were either analyzed via immunoblotting (2.5.3) or stained with Coomassie Brilliant 
Blue solution (according to [183]) for 2 h while slightly agitating. After incubation in 
destaining solution for 24 h, gels were photographed with the ChemiDoc MP device (Bio-
Rad). 
Coomassie Brilliant Blue staining solution 
 
Destaining solution 
0.275% (w/v) Coomassie Brilliant Blue R250 
 
7.5% (v/v) Acetic acid 
7.5% (v/v) Acetic acid 
 
10% (v/v) Ethanol 
50% (v/v) Methanol 
 
10% (v/v) Methanol 
 
2.5.3 Immunoblot (Western blot) 
Immunoblotting is a common technique for the detection of proteins that are immobilized on 
a membrane and visualized with specific antibodies. Therefore, protein samples are first 
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electrophoretically separated by SDS-PAGE and then transferred onto a membrane applying 
an electric field. 
 
Blotting procedure 
A piece of PVDF (polyvinylidene fluoride) membrane (9 x 6 cm, Bio-Rad) was activated by 
wetting in 100% methanol for 15 s. Subsequently, the membrane was transferred to a 
container of anode II buffer for at least 2 min to equilibrate the membrane. Using a semi-dry 
blot system [184], two thick sheets of anode I saturated whatman filter paper and two thin 
sheets saturated with anode II buffer were placed into the blotting chamber (Biotec-Fischer). 
The SDS-PAGE gel (2.5.2) together with the membrane was put on top followed by two thin 
and two thick sheets soaked with cathode buffer. For transfer of the proteins from the gel onto 
the blot, a current of 1.25 mA/cm2 was applied for 70-80 min. Afterwards, the membrane was 
dried on a clean filter paper for at least 1 h, reactivated in 100% methanol and equilibrated in 
anode II buffer. All subsequent steps, except chemiluminescent development, were performed 
while slightly agitating on a rocking platform.  
Anode I buffer  
 
Cathode buffer 
300 mM Tris/HCl, pH 10.4 
 
25 mM Tris/HCl, pH 9.6 
10% Methanol 
 
40 mM 6-Amino caproic acid 
   
10% Methanol 
Anode II buffer 
   
25 mM Tris/HCl, pH 10.4 
   
10% Methanol 
   
 
Detection of immobilized proteins with antibodies 
At first, remaining binding sites on the membrane were blocked by incubation in blocking 
solution (consisting of 5% milk powder in TBST) overnight at 4°C. The membrane was then 
incubated for 2 h with the first antibody in TBST/1% milk powder in the respective dilution 
(see Table 10). To remove unspecifically bound antibodies, washing steps were performed 
(5x 5 min with 1x TBST). A second antibody (conjugated with POX or AP, see Table 10) in 
TBST/1% milk powder was incubated with the membrane for 1 h and extensively washed 
afterwards (at least 5x 5 min with TBST). For chromogenic development of AP activity, 
membranes were incubated with 5 mL AP detection solution until desired bands were visible, 
and the reaction was stopped with tab water. For chemiluminescent detection of POX-coupled 
antibodies, the membrane was immersed for 2 min in a substrate solution containing luminol 
(Immobilon Chemiluminescent HRP Substrate, Millipore) and luminescence was detected in 
a ChemiDoc MP device (Bio-Rad). Further analysis, including densitometric evaluation for 
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relative quantification of signal bands, was conducted with the Image Lab software (Bio-
Rad).  
10x TBS in dH2O AP detection solution  
1.5 M NaCl 100 mM Tris/HCl, pH 9.6 
200 mM Tris/HCl, pH 7.5 7 mM MgCl2 
  
50 mg/L 5-Bromo-4-chloro-3-indolyl phosphate (BCIP) 
TBS-Tween buffer (TBST)  0.1 g/L Nitro blue tetrazolium (NBT) 
100 mL 10x TBS 
1 mL Tween 20 
up to 1 L dH2O 
 
Membrane stripping 
After chemiluminescent development, membranes could be re-used by soaking in an acid 
solution (25 mM glycine/HCl, 1% SDS, pH 2) for 60 min to remove bound antibody 
complexes. Prior to re-incubation with antibodies, membranes were extensively washed with 
tab water and again saturated in TBST/1% milk powder.  
 
2.5.4 Tyrosine and GSK phosphorylation assay 
H. pylori is able to inject its CagA protein into eukaryotic host cells. As the protein itself or a 
GSK-tag, genetically fused to CagA, gets phosphorylated inside the target cell, the analysis of 
these phosphorylation events are routinely used as proof of CagA translocation. For this, AGS 
cells were infected with H. pylori following the standard protocol (2.3) and then chilled on 
ice. To remove dead cell debris and unbound bacteria, cells were washed two times with pre-
chilled PBS and AGS cells were scraped off on ice in PBS, which was supplemented with a 
protease and phosphatase inhibitors mixture (PBS*). Cells were sedimented by centrifugation 
and either directly resuspended in SDS sample buffer for SDS-PAGE (2.5.2) or first in RIPA 
buffer for an upstream pull-down assay (2.5.5). After immunoblotting (2.5.3), bacterial CagA 
protein or CagA fused to a phosphorylatable GSK-tag was visualized with specific antibodies 
(see Table 10). 
Inhibitor mixture for PBS* 
1 mM Phenylmethylsulfonyl fluoride (PMSF) 
1 mM Sodium vanadate 
1 μM Leupeptin 
1 μM Pepstatin 
1 per 10 mL PhosSTOP tablet (only for GSK assay, Roche Applied Science) 
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2.5.5 Immunoprecipitation (Pull-down assay) 
Pull-down experiments were conducted to concentrate and purify specific proteins, including 
corresponding interacting proteins, from a bacteria or bacteria-cell lysate. First, bacteria 
grown on agar plates (2.1.1) or infected AGS cells (2.3) were washed twice with PBS. In the 
latter case, cells were scraped off as described in the previous chapter (2.5.4). Bacteria, or 
cells with adherent bacteria, were resuspended in radioimmunoprecipitation (RIPA) buffer 
and lysed by sonication (50% duty cycle, output control 3, three 10 s intervals followed by 
10 s rest; Sonifier 250, Branson). Cell debris was removed by centrifugation 
(10 min / 15,000 x g) and a 1:500 dilution of a respective antiserum was added to the 
supernatant. After an overnight incubation at 4°C while slightly agitating, 50 µL of pre-
washed protein G-agarose (Roche Applied Science) was added to the samples, and incubation 
was continued for at least another 2 h to achieve maximal absorption of antibody-bound 
proteins to the agarose beads. To remove unspecific bound proteins, the beads were washed 
three times with RIPA buffer and proteins were eluted by boiling for 10 min in SDS-PAGE 
sample buffer. Samples were analyzed via SDS-PAGE (2.5.2) and subsequent 
immunoblotting (2.5.3). 
RIPA buffer 
50 mM Tris/HCl, pH 8.0 
150 mM NaCl 
1 mM  EDTA 
1% (v/v) Nonidet P-40 
0.25% (w/v) Sodium deoxycholate 
+ Inhibitor mixture (see 2.5.4) 
 
2.5.6 ELISA for interleukin-8 (IL-8) quantification  
AGS cells release IL-8 in response to infection with H. pylori. To quantify this, supernatants 
of in vitro infections (see 2.3) were analyzed by ELISA (Enzyme Linked Immunosorbent 
Assay). For this purpose, the wells of an immunoabsorbent 96-well plate (Nunc) were coated 
with 100 µL IL-8 antibody (see Table 10) diluted in coating buffer (3 µg/mL in 100 mM 
Na2HPO4, pH 9.0), and incubated overnight at 4°C. Wells were washed three times with 
washing buffer (PBS with 0.05% Tween-20) and saturated in 200 µL blocking buffer 
(washing buffer with 10% FCS) for 2-4 h at RT. Wells were again washed three times and 
100 µL of diluted supernatant samples (in RPMI / 10% FCS) were added. To enable 
quantitative analysis, a dilution series of human IL-8 (BD Pharmingen) in RPMI / 10% FCS 
was established, ranging from concentrations of 0 to 800 µg/mL, and added to the wells. After 
an overnight incubation at 4°C, wells were four times washed to remove unbound antigens, 
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and 100 µL of biotinylated anti-IL-8 antibody (0.5 µg/mL in blocking buffer, see Table 10) 
was added. After incubating at RT for 2 h and washing four times, 100 µL of a Streptavidin-
Biotin-POX solution (Peroxidase Standard, Biozol) was added and incubated for another 
hour. The wells were extensively washed in six washing cycles, 100 µL of TMB substrate 
solution (BD OptElaTM, BD Biosciences) was added to each well and incubated for 30 min in 
the dark at RT. The chromogenic development was stopped with 50 µL 1 M sulfuric acid 
(H2SO4) per well. Subsequently, the optical density at 450 nm was determined (Clariostar, 
BMG Labtech) and a standard calibration curve was computed using OD450 values of the IL-8 
standard dilutions. IL-8 concentrations were determined with the standard curve function and 
multiplied by the dilution factor. 
Streptavidin-Biotin-POX solution per 96-well microtiter plate 
1.5 µL Solution A 
1.5 µL Solution B 
mixed in 200 µL  50 mM Tris/HCl, pH 7.6 
After incubation for 30 min at RT, the mixture was filled up to 10 mL with 50 mM Tris/HCl, pH 7.6 
 
2.6 Brightfield and phase-contrast microscopy 
Bacteria, cells or cells infected with H. pylori were routinely checked via brightfield or phase-
contrast microscopy using a WILOVERT S (Hund Wetzlar) or a LEICA DM IRB (Leica) 
microscope. Pictures were taken using the latter one with the SPOT Insight 2Mp 
Monochrome FireWire digital camera system (Diagnostic instruments). 
 
2.7 Flow cytometry (FACS) 
In flow cytometry, bacterial or eukaryotic cell suspensions are hydrodynamically focused 
before entering a laser beam, and the emitted light signals are detected by photomultiplier 
tubes (PMT) (including a forward angle light scatter detector (FSC), a side-scatter detector 
(SSC), and multiple fluorescence emissions detectors). Signals are then digitized for computer 
analysis. FACS measurements were applied for examination of TEM-1 activity (2.8.1), 
bacterial membrane potential (2.10), and permeability (2.11). Briefly, cell populations were 
first defined by means of the FSC (as a measure for volume) and SSC (as a measure for 
granularity) detector signals, and the fluorescence emission of at least 10,000 cell counts was 
recorded. All measurements were conducted with the FACS CantoII instrument (BD 
Biosciences, Heidelberg), and data was evaluated using the FACSDiva software or the 
FlowJo software (Tree Star). 
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2.8 TEM-CagA translocation assay 
The TEM-CagA translocation assay is a novel method to analyze H. pylori CagA 
translocation into eukaryotic cells. The test principle is in detail described in the results 
section (1.1). Briefly, eukaryotic cells were infected with H. pylori P12 harboring a TEM-
CagA fusion (2.3). After infection, cells were loaded with the fluorescent substrate CCF4-AM 
in the corresponding loading solution (Live-BLAzer-FRET B/G loading kit, Invitrogen) 
which was supplemented with 1 mM probenecid (Sigma-Aldrich).  
1x CCF4-AM loading solution for 1 mL volume 
1 µL Solution A (= 1 mM CCF4-AM) 
10 µL Solution B 
156 µL Solution C 
5 µL Probenecid (200 mM) 
828 µL DPBS 
 
2.8.1 Analysis by flow cytometry  
For flow cytometry applications (see 2.7), cells were incubated in the staining solution for 
90 min in the dark at RT. Stained cells were washed three times with DPBS, finally 
suspended in 200 µL DPBS and subjected to FACS analysis. CagA translocation was 
expressed as the ratio of the Pacific Blue to the AmCyan emission channels (Blue-to-Green). 
Percental CagA translocation rates were determined following [(Blue-to-Green(sample-
negative control) / Blue-to-Green(positive control-negative control)) x 100] with P12[TEM-CagA] as positive, 
and P12[TEM-CagA]ΔcagI as negative control. 
 
2.8.2 Analysis by fluorescence-assisted plate reading 
For fluorescence quantification by plate reading, infected cells were incubated with the 
loading solution at RT in the dark for at least 120 min and directly measured with a Clariostar 
reader (BMG Labtech) using an excitation wavelength of 405 nm (10 nm bandwidth). 
Emission was detected with 460 nm (20 nm bandwidth, blue fluorescence) and 530 nm (15 
nm bandwidth, green fluorescence) filters. CagA translocation was defined as the emission 
ratio at 460 nm(sample-blank) divided by that at 530 nm(sample-blank) (Blue-to-Green), where the 
blank wells contained only CCF4-AM loading solution, but no cells or bacteria. Relative 
CagA translocation levels were calculated using the formula described in 2.8.1. 
 
2.8.3 Analysis by fluorescence microscopy 
For the detection of TEM-1 activity by fluorescence microscopy, infected AGS cells were 
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covered with CCF4-AM in the respective loading solution, and examined with a Leica TCS 
SP5 confocal microscope. Routine image processing was performed with ImageJ v1.45h (US 
National Institutes of Health). 
 
2.9 High-throughput screening of compound libraries  
Compound libraries were derived from the Helmholtz Center for Infection Research 
(Braunschweig). For screening analysis with the TEM-CagA assay (2.8.2), compounds were 
pre-pipetted in 384-well plates (low volume, sterile, Corning Inc.), and each well content was 
sufficient for a 20 µL test volume. In detail, 20 µl of bacterial cells (OD550 of 0.075 in 
DPBS/FCS) were added into each well and incubated for 30 min at 37°C / 10% CO2. Then, 
17 µL of the bacteria-compound mixture was gently pipetted up and down, and transferred 
onto AGS cells which were seeded in 384-well plates (low volume, sterile, Corning Inc.; see 
also 2.2.1). Infection proceeded following standard conditions (2.3), and TEM-1 activity was 
determined via plate reading (2.8.2). For screening analysis via growth curves, compounds 
were derived in 96-well plates (half-volume, sterile, Corning Inc.). Per well, 50 µL of 
bacterial suspension was dispended and the OD550 automatically monitored (see 2.1.5). 
 
2.10 Measurement of bacterial membrane potential 
To evaluate the effect of various compounds on H. pylori membrane potential, the 
BacLight™ Bacterial Membrane Potential Kit (Molecular Probes), which contains the 
carbocyanine dye DiOC2(3) (3,3′-diethyloxacarbocyanine iodide), was used. DiOC2(3) 
exhibits green fluorescence in the bacterial cytosol, but larger membrane potential causes self-
association of the dye, leading to a fluorescence shift towards red emission. First, 75 µL of a 
H. pylori suspension (OD550 of 0.075 in BB/FCS) was incubated in the presence of the 
respective compound for 3 h at 37°C / 10% CO2. Thereby, 10 µM of the protonophore CCCP 
(carbonyl cyanide 3-chlorophenylhydrazone) was applied as a membrane potential destroying 
control. 12.5 µL of the suspension was then transferred into 200 µL DPBS (supplemented 
with 1 mM EDTA and 15 µM DiOC2(3)), and incubated for another 30 min at 
37°C / 10% CO2. Bacterial cells were analyzed by flow cytometry with the FITC- and PE-
fluorescence emission detectors (see 2.7), and the red to green fluorescence ratio was 
determined.  
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2.11 Measurement of bacterial membrane permeability 
Increased membrane permeability leads to the destruction of the membrane potential. To 
assess the influence of several compounds on membrane permeability, which would explain 
the effect on membrane potential, the fluorescent dye propidium iodide (PI, Miltenyi Biotec) 
was applied. PI is membrane impermeant and can only enter permeabilized cells. Once PI is 
in the cell, it intercalates into the DNA which leads to an increase in red fluorescence. For this 
analysis, a H. pylori suspension was incubated with respective compounds as described in the 
previous section (2.10). Then, 12.5 µL of the suspension was added to 200 µL DPBS 
(containing 1 mM EDTA and 4 µL PI), and incubated at RT for 1 h in the dark. The red 
fluorescence shift was analyzed via flow cytometry in the PE emission channel (see 2.7) and 
expressed as median fluorescence intensity (MFI). 
 
2.12 Quantification of bacterial ATP content 
The influence of several compounds on cellular ATP content of H. pylori was determined 
using the ATP bioluminescence assay Kit CLS II (Roche Applied Science). Thereby, even 
low concentrations of ATP can be detected due to the ATP dependency of the light emitting 
oxidation of luciferin. To do so, 450 µL of bacterial cell suspension (OD550 of 0.15 in 
BB/FCS) was first exposed to the compounds of interest for 5 min at 37°C / 10% CO2. 
Bacteria were collected by centrifugation (10,000 x g / 5 min), the supernatant discarded, and 
the pellet was resuspended in 75 µL 100 mM Tris/HCl (containing 4 mM EDTA, pH 7.75). 
This suspension was cooked for 2 min at 95°C, the cell debris removed by centrifugation 
(10,000 x g / 1 min) and 50 µL of the supernatant was added into a 96-well plate (black, 
transparent bottom, tissue culture-treated, 4titude®). In addition, the ATP calibration stock 
(provided by the kit) was solved in 100 mM Tris/HCl (containing 4 mM EDTA, pH 7.75), 
serially diluted in the range of 10-5 to 10-10 M, and added to the wells. The plate was left on 
ice until measurement. After the addition of 50 µL of the luciferase reagent to the 
samples/standards by automated injection, bioluminescence development was recorded with a 
1 s delay plus signal integration time of 10 s in the Clariostar plate reader (BMG Labtech). 
The blank control (standard without ATP) was subtracted and the ATP concentrations were 
calculated from a log-log plot of the standard curve data. Percental concentrations relate to 
[1-((ATPcontentuntreated control - sample / ATPcontentuntreated control) x 100)].  
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2.13 Determination of bacterial oxygen consumption 
To test the influence of specific substances on H. pylori oxygen consumption, OxoPlates® 
(96-well microtiter plates, round bottom, PreSens), which have an integrated chemical optical 
oxygen sensor, were applied. For this, 140 µL of H. pylori suspensions (OD550 of 1.0 in 
DPBS) together with the test substances, were added into the wells. Besides, freshly-prepared 
oxygen-free water (cal0, 300 µL per well, sealed with a strip of adhesive foil) and air-
saturated water (cal100, 200 µL per well) were used as calibration standards.  
Oxygen-free water = cal0   Air-saturated water = cal100 
0.15 g Sodium sulfite (Na2SO3)  
 
20 mL dH2O 
in 15 mL dH2O 
 
                  in a 50 mL falcon tube 
A 15 mL falcon vessel with a tightly fitting 
screw top was used for preparation.   
The water was vigorously shaken for at least 
2 min.  
 
Organic acids in DPBS, pH 7.4 
 
  Injected volume 
500 mM Pyruvate 2 µL 
500 mM D,L-Lactate 2 µL 
500 mM α-Ketoglutarate 4 µL 
250 mM Succinate 4 µL 
 
Before starting the measurement, the plate was incubated for at least 10 min at 37°C in the 
pre-warmed plate reader (FluoStar Optima, BMG Labtech) in order to equilibrate the samples 
and standards. Fluorescence was recorded every 2 min using a 550 nm excitation filter, and 
emission was detected with a 660 nm (indicator fluorescence, Iindicator) and 590 nm filter 
(reference fluorescence, Ireference). With it, the time-resolved mode was applied with an 
integration start at 0 µs and integration time of 500 µs. After the third measurement cycle, an 
organic acid solution was automatically injected to the samples and the fluorescence detection 
proceeded for at least 10 more cycles. For each well the reference signal “IR = Iindicator / 
Ireference” was calculated. The oxygen partial pressure pO2 (in % air saturation) was calculated 
for each measurement point following pO2[% air sat.] = [100 x ((k0/IR – 1) / (k0/k100 – 1))], 
where k0 is the IR of cal0 and k100 the IR of cal100, respectively. 
 
2.14 Evaluation of cellular cytotoxicity 
The effect of several compounds on eukaryotic cell proliferation and viability was assessed 
with the Cell Proliferation Reagent WST-1 (Roche Applied Science). This assay is based on 
the cleavage of the tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases. 
Thus, the color change correlates with the number of metabolically active cells in culture. At 
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first, 30 µL of cell suspensions were seeded into 384-well plates (black, clear bottom, Corning 
Inc.) and cultivated at respective conditions (see Table 2) but using a phenol red-free culture 
medium (for reduction of background in the later measurement). On the following day, test 
substances were added in corresponding dilutions and incubation was continued for three 
days. Then, 2.5 µL of WST-1 solution was added to each well and further incubated for at 
least 60 min. The absorbance of the formazan product at OD450 and a reference wavelength at 
690 nm (OD690nm) were recorded in the Clariostar plate reader (BMG Labtech). For 
evaluation, the difference of OD450nm and OD690nm was determined, and the blank control 
(only medium and WST-1) was subtracted, resulting in ODnorm. Percental cytotoxicity was 
expressed as the ODnorm of the sample divided by ODnorm of the corresponding DMSO 
control, and IC50 values were determined by non-linear regression analysis. 
 
2.15 Statistical analysis 
Statistical analysis was performed with the GraphPad prism 5 software. Experimental data 
sets shown are generally average values resulting from at least three independent 
measurements including the standard error of the mean. The significance of differences was 
determined using either Student´s t-test, one-way ANOVA with Tukey post hoc test, or two-
way ANOVA with Bonferroni post hoc test. 
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III. RESULTS 
1. Development of a novel Cag type IV secretion reporter 
H. pylori translocates its oncogenic protein CagA via type IV secretion into eukaryotic cells. 
Once inside, CagA gets phosphorylated immediately at several tyrosine residues (EPIYA 
motifs) via host cell kinases [74-76]. For years, CagA translocation has been routinely 
checked by detection of this phosphorylation event via immunoblotting. However, this 
method gives only insights into the rate of CagA phosphorylation, but not the translocation 
process itself. Moreover, it is stringently dependent on the presence of the EPIYA region and 
hence, also limits CagA translocation evaluation of specific mutants. To overcome these 
restrictions, a phosphorylatable GSK-tag was fused to CagA [131], which allowed an 
extended evaluation of CagA translocation via phospho-GSK specific antibodies. But still, 
immunoblotting constitutes a labor-intensive and time-consuming procedure with limited 
sensitivity and quantifiability. Thus, a phosphorylation-independent reporter that enables not 
only fast but also quantitative analysis should be developed. 
 
1.1 Principle of a β-lactamase (TEM-1)-dependent translocation assay 
In other bacterial pathogens such as Escherichia coli, Yersinia pestis or Legionella 
pneumophila, the translocation of various effector proteins has been studied via fusion of a 
29 kDa TEM-1 β-lactamase [174, 185, 186]. This compact enzyme, which is originally the 
product of an E. coli plasmid-encoded ampicillin resistance gene, can efficiently cleave β-
lactam antibiotics including penicillins and (first generation) cephalosporins. Thus, a modified 
version of TEM-1 (lacking the endogenous secretion signal) has been found to be an excellent 
reporter tag. A general schematic how this should work as a type IV secretion reporter in 
H. pylori is depicted in Figure 8. Briefly, H. pylori translocates the TEM-1 (β-lactamase)-
CagA fusion protein into the host cell cytosol, where the enzymatic activity of the reporter tag 
is detected via conversion of the cell-permeable fluorescence substrate CCF4 (Figure 8A). 
The structure of CCF4 is shown in Figure 8B. This FRET (Fluorescence Resonance Energy 
Transfer)-based fluorescent substrate consists of a cephalosporin core linking a 7-
hydroxycoumarin to a fluorescein. The esterified form of CCF4 (CCF4-AM) is non-
fluorescent but when entering the cell, esters get cleaved off by endogenous esterases and the 
intact molecule produces a green fluorescence signal due to the FRET-excited fluorescein 
molecule. Upon cleavage of the β-lactam ring of the cephalosporin core, the two fluorophores 
get spatially separated, the FRET disrupted, and only the blue fluorescence of the coumarin 
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can be detected. This permits a ratiometric read-out of the Blue-to-Green fluorescence by any 
fluorescence-assisted device allowing quantitative analysis of translocated CagA protein.  
In the following sections, the transfer of this method into H. pylori for quantitative Cag type 
IV secretion analysis will be described.  
 
 
Figure 8: Principle of a β-lactamase (TEM-1)-dependent CagA translocation reporter 
A) H. pylori translocates the TEM-1 (β-lactamase)-CagA fusion protein (TEM-CagA) into the eukaryotic host 
cell. Enzymatic activity of the TEM-1 reporter tag can be monitored by conversion of the β-lactam derivative 
CCF4. The intact molecule emits green fluorescence, while after enzymatic cleavage of CCF4, blue fluorescence 
is emitted. The ratio of Blue-to-Green fluorescence serves as a measure of CagA translocation (adapted from 
[174]). 
B) The lipophilic, esterified form of CCF4 (CCF4-AM) enters the cell and ester moieties get cleaved off by 
endogenous cytoplasmic esterases converting the molecule into a negatively charged substrate, which is retained 
in the cytosol. CCF4 consists of a cephalosporin core linking a 7-hydroxycoumarin to a fluorescein. In the 
absence of TEM-1 activity, excitation of the coumarin (at 409 nm) in the intact CCF4 results in FRET to the 
fluorescein, emitting a green fluorescence signal (at 520 nm). In the presence of TEM-1, enzymatic cleavage of 
CCF4 spatially separates the two fluorophores and disrupts FRET, with the result that excitation of the coumarin 
(at 409 nm) leads to a blue fluorescence signal (450 nm). CCF4-AM structure is derived from [187]. 
FRET: Fluorescence Resonance Energy Transfer, T4SS: type IV secretion system. 
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1.2 Construction and evaluation of TEM-CagA-expressing reporter 
strains 
For construction of TEM-CagA-expressing reporter strains, a chromosomal cagA 
reconstitution system was established that only introduced minimal changes into the wild-
type. Hence, expression of variant cagA genes should be enabled in the cagA locus itself 
under control of the endogenous cagA promoter. For this purpose (see Figure 9A), the wild-
type cagA gene in H. pylori P12 was exchanged by transformation using pWS373 with an 
aphA-3 kanamycin resistance cassette (P12[pWS373]). Subsequently, the TEM-1 β-lactamase 
gene (tem-1 or blaM), lacking its N-terminal secretion signal, was fused in-frame to the 5´ end 
of P12 wild-type cagA (tem-1-cagA), and the corresponding construct (pWS486) was 
introduced into P12[pWS373] via homologous recombination (P12[pWS486] or P12[TEM-
CagA]).  
 
 
Figure 9: Construction of TEM-CagA-expressing reporter strains 
A) Chromosomal reconstitution strategy for generation of H. pylori P12 strains expressing the TEM-CagA 
fusion protein. The cagA gene was deleted via insertion of an aphA-3 cassette by transformation with pWS373. 
The tem-1-cagA-encoding plasmid pWS486 including a cat resistance cassette as selection marker was 
subsequently introduced via homologous recombination. Arrows depict primer binding sites used for 
construction of deletion and reconstitution plasmids (see Materials & Methods section for details). 
B) Immunoblot (WB) of a bacterial lysate showing the stable expression of the TEM-CagA fusion protein using 
a TEM-1 antibody. Generation of an isogenic cagI deletion mutant of the TEM-CagA producing strain served as 
a type IV secretion-defective control.  
 
Bacterial lysates of P12[TEM-CagA] were analyzed via immunoblotting using a TEM-1 
antibody (see Figure 9B) and stable expression of the TEM-CagA fusion protein was 
detected. In addition, a negative control reporter strain was engineered by deletion of the cagI 
gene locus (with plasmid pWS320) in P12[TEM-CagA]. Although cagI deletion mutants are 
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defective in type IV secretion [106], a stable TEM-CagA expression is still guaranteed (see 
Figure 9B). 
 
To determine whether the TEM-CagA-producing reporter strain is able to translocate the 
fusion protein into host cells, AGS cells (~2 x 107) were infected, lysed and TEM-CagA was 
immunoprecipitated using CagA antiserum as well as TEM-1 antibody. Fractions were 
analyzed via immunoblot using CagA and phosphotyrosine-specific antibodies (shown in 
Figure 10A) and a clear phosphorylation of the TEM-CagA protein was observed, indicating 
translocation of the reporter-tagged protein into the host cells. In contrast, the isogenic cagI 
deletion mutant yielded no tyrosine-phosphorylated TEM-CagA upon infection, further 
confirming that phosphorylation depends on functionality of the type IV secretion machinery. 
However, phosphorylation of the native CagA protein was much higher as compared to TEM-
CagA. This might be either due to the lower expression level of TEM-CagA, or to a less 
effective phosphorylation by host cell kinases.  
To independently prove translocation of the TEM-CagA protein, a phosphorylatable GSK-tag 
was genetically fused to the C-terminus of TEM-CagA (P12[TEM-CagA-GSK]). This 
reporter tag gets phosphorylated independently of EPIYA motifs and was also applied in 
previous studies to monitor CagA translocation [131]. AGS cells (~106) were infected with 
P12[TEM-CagA-GSK] or P12[TEM-CagA] and analyzed by Western blotting with a TEM-1 
and a phospho-GSK-specific antibody (Figure 10B). Phosphorylation of the GSK-tag could 
be detected for the TEM-CagA-GSK fusion protein but not for TEM-CagA or uninfected 
cells. Because of the known unspecific background binding of the phospho-GSK antibody to 
the unphosphorylated GSK tag, lysates of TEM-CagA-(GSK)-producing bacteria were 
applied as controls. Although a weak cross-reaction could be detected for TEM-CagA-GSK, 
the signal was much lower than upon AGS cell infection, thus verifying the translocation of 
TEM-CagA-GSK.  
For evaluation of TEM-CagA-induced cytokine secretion, supernatants derived from infected 
AGS cells were analyzed by ELISA for IL-8 concentration (Figure 10C). The IL-8 level 
induced by translocated TEM-CagA protein was the same as for the native CagA protein, 
while infections with type IV secretion-deficient strains (ΔcagI) yielded similar IL-8 baseline 
values. Hence, it was concluded that TEM-CagA induces IL-8 secretion upon infection to the 
same rate as the native protein. In addition, an induction of the hummingbird phenotype in 
AGS cells was examined (see Figure 10D). As expected, after 4 h infection with P12 wild-
type, a strong hummingbird phenotype was induced (left picture, Figure 10D). In contrast, 
infection with P12[TEM-CagA] produced no morphological differences of AGS cells in 
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comparison to uninfected cells. Hence, the TEM-CagA fusion was not able to stimulate a 
hummingbird phenotype, which could be either due to relatively low levels of TEM-CagA or 
to an incapability of the fusion protein to interact with host cell components that are 
responsible for the morphological changes.  
Taken together, although some pathophysiological properties of CagA were impaired by 
fusion to TEM-1, translocation of TEM-CagA into the cells via type IV secretion could be 
clearly demonstrated.  
 
 
Figure 10: Evaluation of TEM-CagA-producing reporter strains 
A) Analysis of immunoprecipitation fractions with CagA and phosphotyrosine immunoblots (WB). AGS cells 
were infected with the reporter strains P12[TEM-CagA], its isogenic cagI deletion mutant and the P12 wild-type 
strain. Infected cells were lysed and subjected to immunoprecipitation using the polyclonal CagA antiserum 
AK257 and a monoclonal TEM-1 antibody. 
B) Immunoblot analysis (WB) of AGS cells infected with P12[TEM-CagA-GSK] and P12[TEM-CagA] reporter 
strains as well as corresponding bacterial lysates using TEM-1 and phospho-GSK specific antibodies. 
C) Quantitative IL-8 determination in supernatants of AGS cells infected with P12[TEM-CagA], the P12 wild-
type and corresponding cagI deletion mutants. All values were normalized to the IL-8 values found in the 
supernatants of P12 wild-type-infected cells, and are indicated as mean values with standard errors of the mean 
from four independent infections. ANOVA (one-way, Tukey post hoc test), ***: p<0.001, ns: non-significant. 
D) Phase-contrast microscopy to detect the hummingbird phenotype of AGS cells after infection with P12 wild-
type and P12[TEM-CagA]. 
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1.3 Determination of TEM-CagA-mediated hydrolysis of CCF4  
Having proven that TEM-CagA is translocated into cells, the next step of assay establishment 
incorporated the monitoring of TEM-CagA-mediated hydrolysis of the CCF4 substrate via 
fluorescence-assisted devices (summarized in Figure 11). For visualization with fluorescence 
microscopy, AGS cells were infected with P12[TEM-CagA] or its isogenic cagI deletion 
mutant as a negative control, fixed and covered with the CCF4-AM substrate solution. Blue 
and green fluorescence signals were recorded and are shown in Figure 11A. For translocated 
TEM-CagA protein (left panel), a clear blue fluorescence signal was detected due to CCF4 
hydrolysis, while the weak green fluorescence signal derived from uncleaved CCF4. In 
contrast, cells infected with the negative control (right panel) exhibited solely a strong green 
fluorescence signal, which demonstrates that CCF4 does not hydrolyze spontaneousely.  
For flow cytometry analysis, AGS cells were incubated with CCF4-AM substrate after 
infection, washed and fluorescence emission was recorded with the Pacific Blue (blue) and 
AmCyan (green) channels, and blue-to-green fluorescence ratios were calculated for each 
individual cell (see Figure 11B). As expected, cells left uninfected or infected with the P12 
wild-type did not exhibit any shift in the blue fluorescence channel (upper panel, Figure 11B), 
but only green fluorescence showing that CCF4-AM entered the cells. Accordingly, only a 
very low blue-to-green fluorescence ratio (lower panel, Figure 11B) was detectable. In 
contrast, infection with P12[TEM-CagA] yielded a strong shift of cells in the Pacific Blue 
channel and a considerable increase of the blue-to-green fluorescence ratio. Of importance, no 
signal was detected for cells infected with the translocation-deficient reporter strain in the 
Pacific Blue detector and the corresponding blue-to-green fluorescence ratio was at a 
background level. To exclude unspecific lysis of CCF4 at the cell surface, AGS cells were 
also incubated with ultrasonicated P12[TEM-CagA] lysates. No blue fluorescence increase 
and thus no blue-to-green fluorescence ratio above background level could be observed, 
further proving that CCF4 gets exclusively hydrolyzed by type IV secretion-translocated 
TEM-CagA. Moreover, CCF4 seems to only enter and get cleaved in eukaryotic cells but not 
in the H. pylori cytoplasm, as the background signal of translocation-deficient, but TEM-
CagA-expressing strains, did not differ in blue or green fluorescence signals compared to 
infection with P12 wild-type or cells left uninfected.  
To show that analysis can also be conducted via fluorescence-assisted plate reading, infected 
cells were incubated with CCF4 loading solution for 120 min and subsequently measured 
(Figure 11C). In accordance with the previous analysis, a strong blue-to-green signal could be 
observed after infection with P12[TEM-CagA] while only a low background signal was 
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detectable upon infection with the ΔcagI mutant. To test whether the CagA translocation 
process is stopped after addition of CCF4 substrate, cells were directly infected with 
P12[TEM-CagA] in CCF4-AM substrate solution (CCF4 infection, Figure 11C). In this case, 
only a blue-to-green background signal was observed, indicating that type IV secretion-
mediated CagA translocation is interrupted upon addition of CCF4 and respective incubation 
conditions. This offers the possibility to stop CagA delivery at defined time points and hence 
control the infection duration.  
 
 
Figure 11: Determination of CCF4 hydrolysis by type IV secretion-translocated TEM-CagA 
A) Fluorescence microscopy of infected AGS cells. Cells were infected with P12[TEM-CagA] or its isogenic 
cagI deletion mutant, fixed and incubated with the CCF4-AM substrate solution. Blue and green fluorescence 
signals were recorded. 
B) Flow cytometry analysis of infected AGS cells. Cells were either left uninfected or infected with wild-type 
P12, P12[TEM-CagA] or its isogenic cagI deletion mutant. As a control, cells were treated with a lysate of 
ultrasonicated P12[TEM-CagA]. After incubation with CCF4-AM, turn-over of CCF4 by translocated TEM-
CagA was monitored in the AmCyan (green) or Pacific Blue (blue) fluorescence channels (upper panels). Ratios 
of blue-to-green fluorescence calculated for each individual cell are plotted in the lower panels. 
C) Plate reader analysis of infected AGS cells. Cells were infected with P12[TEM-CagA] or its isogenic cagI 
deletion mutant for 2.5 h and subsequently incubated with CCF4-AM. As a control, P12[TEM-CagA] was added 
to cells together with the CCF4-AM substrate solution (CCF4 infection). Values shown are mean blue-to-green 
ratios with standard errors of the mean of three independent measurements. ANOVA (one-way, Tukey post hoc 
test), ***: p<0.001, ns: no significant difference. 
D) Flow cytometry analysis of different cell lines. Cells were infected with P12[TEM-CagA] or its isogenic cagI 
deletion mutant and loaded with CCF4-AM. Depicted values correspond to blue-to-green fluorescence ratios. 
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To test the applicability of the assay with other cell lines besides gastric epithelial AGS cells, 
gastric carcinoma cells (Kato III), murine macrophage cells (J774A.1), and embryonic kidney 
epithelial cells either expressing CEACAM 5 receptors (HEK-293 CEA) or not (HEK-293) 
were infected with P12[TEM-CagA] or its isogenic ΔcagI mutant. Flow cytometry analysis 
(see Figure 11D) revealed high blue-to-green fluorescence ratios for Kato III and J774A.1 
upon infection with P12[TEM-CagA] as well as low background signals for the negative 
controls, and signals were comparable to those of infected AGS cells. HEK-293 CEA cells 
infected with the TEM-CagA-expressing reporter strain produced a lower blue-to-green 
fluorescence ratio, but nevertheless yielded a clear difference to cells infected with the ΔcagI 
mutant. Only weak background signals were detected for HEK-293 cells after infection with 
the translocation-competent and -deficient strains, as it has been shown that CagA can only be 
translocated into these cells when they express CEACAM receptors (R. Haas, personal 
communication).  
In summary, turn-over of CCF4 by translocated TEM-CagA is a highly specific event and can 
be detected in various cell types where CagA translocation is possible. 
 
To determine the dynamics of CCF4 turnover and hence the optimal incubation time with the 
CCF4-AM substrate solution, AGS cells infected with P12[TEM-CagA] and the isogenic cagI 
deletion mutant were loaded with the substrate solution and fluorescence development was 
immediately recorded in a plate reader every 5 min for about 16 h. Respective curves of blue 
and green fluorescence as well as blue-to-green signals are presented in Figure 12. The blue 
fluorescence emission (=CCF4 hydrolysis by translocated TEM-CagA; Figure 12A) of cells 
infected with P12[TEM-CagA] increased the first 6 h in a linear fashion before the signal 
started to saturate. Importantly, the fluorescence values at MOI 100 and 7 differed 
significantly, indicating that the bacterial load correlates with amounts of translocated TEM-
CagA, which would allow quantitative analysis of CagA translocation. In addition, no blue 
fluorescence signal was detected for cells infected with translocation-deficient controls, 
further highlighting that even after a long incubation time (at least 16 h), CCF4 was 
specifically hydrolyzed by translocated TEM-CagA. The increase of green fluorescence 
(=intact CCF4 that entered the cell; Figure 12B) was strongest in the first 2 h and only slightly 
augmented afterwards, indicating substrate saturation. As expected, the level of green 
fluorescence was higher for infection with the negative control, because under this condition 
intact CCF4 accumulates inside the cell. According to the blue fluorescence development 
(Figure 12C), the blue-to-green ratio increased over time, and reliable signals were observed 
after 60 min. Again, the signal of cells infected at MOI 100 was remarkably higher than at 
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MOI 7, further supporting the possibility of quantitative analysis. As expected, only 
background signals of blue-to-green fluorescence were observed for corresponding cagI 
deletion mutants. Taken together, a minimal incubation time of 60 min with CCF4-AM 
solution should be chosen and determination of the blue-to-green ratio seems to be possible 
for up to 14 h. Moreover, calculation of the blue-to-green fluorescence ratio (Figure 12C) 
constitutes a ratiometric analysis, because the CCF4 uptake rate of every single cell is taken 
into account, as free CCF4 in the substrate solution is esterified (CCF4-AM) and non-
fluorescent (also see Figure 8). 
In summary, detection of valid blue-to-green fluorescence ratios is possible by any 
fluorescence-assisted device. All experimental set-ups confirmed the feasibility of the assay to 
monitor CagA translocation in a specific, sensitive and even quantitative way. The latter 
applicability was examined in more detail and is presented in the following chapter.  
 
 
Figure 12: Kinetic analysis of CCF4 turnover by translocated TEM-CagA protein 
AGS cells were infected with P12[TEM-CagA] or its isogenic cagI deletion mutant for 2.5 h at an MOI of 100 
and 7. Cells were loaded with CCF4-AM and fluorescence development was recorded in a plate reader every 
5 min at room temperature. MOI: multiplicity of infection, RLU: relative light unit. 
A) Blue fluorescence development over time expressed as RLU. 
B) Green fluorescence development over time expressed as RLU. 
C) Blue-to-green fluorescence ratios over time after subtraction of corresponding blank control values. 
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1.4 Quantification of TEM-CagA translocation  
For validation of the novel established TEM-CagA translocation reporter to quantify relative 
amounts of translocated CagA protein, several experimental set-ups were tested.  
First, AGS cells were infected at various MOIs (up to 400) with the P12[TEM-CagA] reporter 
strain for 2.5 h and the turnover of CCF4 was monitored by flow cytometry in the green 
(AmCyan) and blue (Pacific Blue) emission channels (Figure 13A). With increasing MOI, the 
cell population was subject to augmented shifting in the blue channel, while first signals were 
detectable at MOI 6 and seemed to stagnate at MOIs higher than 100. In accordance with the 
data of the previous chapter (1.3, Figure 12), higher MOIs resulted in increased blue-to-green 
fluorescence ratios which highly suggests a correlation between translocated CagA amounts 
and fluorescence signals. 
 
 
Figure 13: Flow cytometry analysis of cells infected at increasing MOIs and infection duration 
A) Scatter plots of infected cells in the blue (Pacific Blue) and green (AmCyan) channels. AGS cells were 
infected with P12[TEM-CagA] at increasing MOIs for 2.5 h. 
B) Timescale for a time-course infection set-up. AGS cells were infected with P12[TEM-CagA] at defined time 
points. Infection was stopped by CCF4-AM addition and after loading, cells were analyzed. 
C) Scatter plots of infected cells in the blue (Pacific Blue) and green (AmCyan) channels during time-course 
infection at MOI 100.  
MOI: multiplicity of infection. 
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To further prove this relationship, AGS cells were infected for various time spans with the 
P12[TEM-CagA] reporter strain. An overview of the infection set-up is given in Figure 13B. 
Briefly, the H. pylori reporter strain was added at defined time points to the cells at an MOI of 
100, and the infection was stopped by CCF4-AM addition (see also 1.3, Figure 11C). After 
loading with the substrate for 90 min, cells were analyzed by flow cytometry in the blue and 
green fluorescence detectors. Corresponding scatter plots (Figure 13C) showed a drastic shift 
of cells already after 15 min of infection. This shifting further increased and finally stagnated 
after approximately 120 min. Again, the signal increment can be associated to enhanced 
amounts of translocated CagA that accumulate during longer infection time spans. These 
observations further strengthen the applicability of the assay as a quantitative tool. In 
addition, signals are detectable at very low MOIs as well as after very short infection 
durations, emphasizing the high sensitivity of this method. 
 
As time-course analysis of AGS cell infections showed consistent shifts of cell populations, 
quantitative analysis of CagA translocation (expressed as blue-to-green ratio) as well as 
percental amounts of injected cells were quantified from independent measurements via flow 
cytometry (summarized in Figure 14). For this purpose, AGS cells were infected with 
P12[TEM-CagA] at various time points with an MOI of 100, 50 or 25, and blue-to-green 
ratios were recorded. As presented in Figure 14A, overall blue-to-green ratios increased with 
longer infection duration and with higher MOI. Surprisingly, the signal stagnated after 2.5 h 
infection independent of the MOI, suggesting that H. pylori stops translocation of CagA into 
the cells under these infection conditions. In a next step, a gate was defined within the Pacific 
Blue and AmCyan scatter plots (Figure 14B, shown in red) to define only the cell population 
that had received a TEM-CagA injection. Subsequently, the percentage of cells that shifted 
into this gate over time is depicted in Figure 14C. For MOI 50 and 100, 50% of the cell 
population got already injected with TEM-CagA after 15 min, and virtually the whole 
population shifted into the red gate after 60 min. For cells infected with MOI 25, the 
proportion in the red gate also incremented with longer infection duration but stagnated at 
about 60%. Hence, it appears that in an in vitro cell culture experiment every cell gets injected 
with CagA as long as the applied MOI is high enough. Additionally, blue-to-green ratios of 
the cells in the red gate were determined (Figure 14D). The calculated ratios were similar to 
the values for the ungated population (Figure 14A), although a more sensitive blue-to-green 
signal increase was detectable in the first minutes of infection which is attributed to the pre-
definition of the CagA-injected cell population. 
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Figure 14: Quantitative analysis of TEM-CagA translocation by flow cytometry 
AGS cells were infected with P12[TEM-CagA] with an MOI of 100, 50 or 25 at distinct time points. All 
depicted values represent mean values of three independent measurements with standard errors of the mean. 
MOI: multiplicity of infection.  
A) Quantification of translocated TEM-CagA during time-course experiments expressed as blue-to-green ratios. 
B) Gating of cells. Cells from the data shown in A) were gated in the AmCyan-Pacific Blue scatter plot as 
indicated (red gate). 
C) Percentage of cells that shifted into the red gate.  
D) Quantification of translocated TEM-CagA during time-course experiments expressed as blue-to-green ratios 
of cells that shifted into the red gate. 
 
In addition to flow cytometry, TEM-CagA translocation was evaluated by fluorescence-
assisted plate reading (Figure 15), for which AGS cells were infected with increasing amounts 
of P12[TEM-CagA] for 2.5 h similar to the experiment shown in Figure 13A. In accordance 
with these previous results, blue-to-green ratio signals were detectable at very low MOIs (~6), 
increased with rising MOIs and stagnated at an MOI of 100 (Figure 15A). Indeed, 
fluorescence signals even dropped at MOIs higher than 100, which might be attributable to 
the high bacterial load that damaged the cells or actually distorted fluorescence measurement. 
Moreover, time-course experiments with AGS cells that were infected with P12[TEM-CagA] 
at an MOI of 100, 50 or 7 at defined time points (Figure 15B), revealed similar results as 
those obtained with flow cytometry (Figure 14). Briefly, ratios increased after longer infection 
durations as well as with higher MOIs, and the signal stagnated again after approximately 
2.5 h, indicating a stoppage of CagA translocation. Overall, blue-to-green fluorescence 
signals were lower in the dataset of Figure 15A compared to B. While the MOI titration 
(Figure 15A) was conducted in 384-well plates, the time-course experiments (Figure 15B) 
were performed in 96-well plates. This is in accordance with other datasets where the signal 
ratio in 384-well plates was usually lower compared to values derived in 96-well plates (data 
 RESULTS 71 
not shown). In general, although gating of cells is not possible for plate reading analysis, 
results were comparable to flow cytometry.  
In summary, the newly established TEM-CagA translocation reporter assay allows 
quantitative analysis of CagA translocation with reproducible results and only little variation. 
Furthermore, an MOI of 100 and infection duration of 2.5 h assure a high blue-to-green signal 
ratio and were used as infection parameters for subsequent studies throughout this work. 
 
 
Figure 15: Quantitative analysis of TEM-CagA translocation by fluorescence-assisted plate reading 
Blue-to-green fluorescence ratios indicated represent mean values of three independent measurements with 
standard errors of the mean. MOI: multiplicity of infection 
A) Quantification of translocated TEM-CagA after infection with increasing MOIs. AGS cells were infected 
with P12[TEM-CagA] at increasing MOIs for 2.5 h in 384-well plates.  
B) Quantification of translocated TEM-CagA after time-course experiments. AGS cells were infected with 
P12[TEM-CagA] at an MOI of 100, 50 or 7 for defined time spans in 96-well plates.  
 
2. Characterization of CagA translocation and substrate 
recognition parameters 
Validation of the TEM-1-dependent Cag type IV secretion reporter demonstrated that this 
method allows a fast, sensitive and quantitative analysis of CagA translocation. Thus, the 
TEM-CagA assay was utilized to characterize various parameters of CagA translocation and 
substrate recognition. 
 
2.1 Influence of cagPAI-encoded proteins on translocation efficiency 
The cagPAI of H. pylori encodes various proteins that are structural components or accessory 
proteins of the type IV secretion system as well as the translocated effector protein CagA. 
Although this system has been intensively studied in the last decades, not all functions of 
particular components are known. In a prior study [115], the influence of various cagPAI-
encoded proteins on CagA phosphorylation was demonstrated by systematic mutagenesis. In 
this work, using the novel phosphorylation-independent TEM-CagA assay, it was investigated 
which influence specific Cag components have on the CagA translocation rate and whether 
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there are differences between phosphorylation and translocation rates, with the aim to finally 
obtain quantitative rates of CagA translocation. Besides the well-described CagA chaperone 
CagF [118, 119] and the CagH protein, important for pilus biogenesis [103], also the partially 
undescribed accessory proteins CagG and CagP were taken into focus; the respective 
encoding genes are highlighted in red in Figure 16A. Previous data showed an essential 
function of CagF and CagH for CagA phosphorylation, while the cagG deletion mutant had 
reduced CagA phosphorylation upon infection and no influence for CagP was observed [115]. 
To evaluate the influence on TEM-CagA translocation, P12[TEM-CagA] was transformed 
with plasmids to generate isogenic deletion mutants, namely ΔcagF (with pWS474), ΔcagG 
(with pWS428), ΔcagH (with pWS423) and ΔcagP (with pWS503). 
 
 
 
Figure 16: Influence of cagPAI-encoded proteins on TEM-CagA translocation 
A) Schematic overview of the cagPAI; cag genes of interest are highlighted in red.  
B) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA protein expression using a TEM-1 and a CagA 
(AK268) antibody, respectively.  
C) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] and its isogenic cagF, cagG, cagH, cagP and cagI deletion mutants. The average blue-to-green ratios of 
each infection were normalized to the mean ratio of P12[TEM-CagA]-infected cells, and are shown as mean 
percentages of five independent experiments with standard errors of the mean. t-test (one-tailed, unpaired) 
comparing to wild-type, **: p<0.005, ***: p<0.0005. 
 
Analysis by Western blotting using TEM-1 and CagA-specific antibodies (see Figure 16B), 
confirmed expression of TEM-CagA for all generated mutants, although the expression rate 
of the ΔcagF deletion mutant was relatively low. A reduced CagA expression has already 
been observed for other ΔcagF deletion mutants and might be attributed to the chaperone-like 
stabilizing effect of CagF on CagA expression [119]. Quantification of CagA translocation 
using the TEM-CagA assay (translocation efficiency defined as wild-type = 100% and ΔcagI 
mutant = 0%; Figure 16C) revealed no translocation for P12[TEM-CagA]ΔcagF as well as 
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the ΔcagH deletion mutant. This is in accordance with the corresponding CagA 
phosphorylation data where both cagPAI components were indispensable for a functional 
phosphorylation [115, 119]. The CagA translocation rate of the ΔcagG deletion mutant 
exhibited a translocation rate of 12%, which is in agreement with previous data, where only a 
very weak CagA phosphorylation was detectable [115], albeit not quantified. In contrast, the 
translocation rate of P12[TEM-CagA]ΔcagP reached about 8%, contrary to the reported 
phosphorylation capability of 100% for the cagP mutant [115]. In that previous study, 
experiments were carried out with the H. pylori strain 26695 and not the P12 strain used here, 
which could be the reason for this discrepancy.  
In conclusion, it could be shown that specific cagPAI-encoded proteins drastically influence 
CagA translocation or even completely abolish the process. Moreover, applying the novel 
TEM-CagA assay, even low translocation rates are quantifiable in a reproducible manner. 
 
2.2 Investigations on the C-terminal CagA secretion signal 
Apart from the influence of various type IV secretion-associated proteins on CagA 
translocation efficiency, CagA sequences themselves also play a remarkable role in the 
translocation process. Type IV-secreted substrates are generally recognized via C-terminal 
signal sequences [188] and indeed, previous studies indicated that CagA translocation is 
dependent on its C-terminus, as C-terminal amino acid deletions rendered the protein 
translocation-incompetent [131]. In this study, distinct mutants with variations and deletions 
in the C-terminus were constructed to further decipher and define this CagA secretion signal. 
Therefore, plasmid pWS321 was used for deletion of the cagA 3´ region in P12 or P12[TEM-
CagA], and modified versions of the pWS336 plasmid were used as reconstitution plasmids 
that recombined in the cagA 3´ region only (see Materials & Methods section for further 
details).  
 
2.2.1 Influence of C-terminal amino acid sequence extensions 
At first, it was analyzed whether extensions of the CagA C-terminus had any influence on 
translocation. Therefore, TEM-CagA variants with additional C-terminal GSK or M45 tags 
were constructed (TEM-CagA-GSK, TEM-CagA-M45; see Figure 17A). Immunoblot 
analysis of the corresponding bacterial lysates (Figure 17B) showed protein expression levels 
comparable to P12[TEM-CagA], indicating that C-terminal tags in combination with an N-
terminal TEM-1 tag are well tolerated. GSK-tag phosphorylation of TEM-CagA-GSK upon 
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AGS cell infection has already been shown in Figure 10B. In addition, translocation rates of 
P12[TEM-CagA-GSK] and P12[TEM-CagA-M45] were quantitatively determined using the 
TEM-CagA assay (translocation efficiency defined as P12[TEM-CagA] = 100% and ΔcagI 
mutant = 0%; Figure 17C). Both mutants exhibited a reduced CagA translocation to the same 
extent (about 70%), although the amino acid composition differed immensely between the 
two tags. Hence, the Cag type IV secretion system seems to tolerate C-terminal amino acid 
extensions, and these elongations do not seem to interfere with substrate recognition. 
 
 
 
Figure 17: Influence of C-terminal tag fusions on CagA translocation 
A) Schematic overview of the C-terminal amino acid composition of CagA and variants with GSK or M45 tag 
extensions. The CagA amino acid sequence is highlighted in purple and additional amino acids in orange while 
underlined sequences are corresponding to the tag sequence. 
B) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA or TEM-CagA variant expression using a  
TEM-1 antibody. 
C) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or the indicated mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages of four independent experiments 
with standard errors of the mean. ANOVA (one-way, Tukey post hoc test), ***: p<0.001, ns: no significant 
difference. 
 
2.2.2 Influence of sequential C-terminal amino acid truncations 
Prior studies showed that C-terminal truncations of 20 amino acids rendered the CagA protein 
translocation-deficient, while shorter truncations of up to 5 amino acids did not display a 
significant reduction of CagA phosphorylation [131]. To further specify this, CagA and TEM-
CagA variants were generated lacking 5-12 amino acids from the C-terminus (see Figure 
18A). At first, AGS cells were infected with P12 wild-type and the corresponding variants 
and analyzed by phosphotyrosine and CagA immunoblots (Figure 18B). As previously 
shown, truncations of 5 amino acids did not influence CagA phosphorylation. In addition, 
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truncations of 6 amino acids also did not result in any decrease in phosphorylation. 
Interestingly, these two CagA variants even appeared to exhibit increased phosphorylation 
signals, which might be attributed to higher CagA expression levels. For CagA variants with 7 
or 8 C-terminal amino acid deletions, only a very weak phosphorylation band was detectable 
(highlighted by arrowheads, Figure 18B), and longer truncations completely abolished 
phosphorylation (10, 12 or 20 amino acids; Figure 18B or data not shown).  
To control the functionality of the type IV secretion apparatus, which is able to trigger IL-8 
secretion independently of CagA translocation, supernatants of co-cultured AGS cells were 
analyzed via ELISA for IL-8 concentration (Figure 18C). Interestingly, IL-8 induction upon 
infection with an isogenic ΔcagA deletion mutant was reduced to about 60% in comparison to 
P12 wild-type-infected cells. This observation has also been reported previously [119], and 
might be due to a strain-specific NF-κB activation by translocated CagA leading to higher IL-
8 secretion [189]. IL-8 levels induced by CagAΔ5C and CagAΔ6C were as high as the wild-
type control, which was in accordance with the unaffected CagA phosphorylation. For CagA 
variants with deletions of 7 or more amino acids, IL-8 induction was at the same level as for 
the ΔcagA deletion mutant. Although slightly higher levels for CagAΔ7C and CagAΔ8C 
mutants were expected because of the weak CagA phosphorylation, the sensitivity of the IL-8 
ELISA might be limited. Nevertheless, it clearly demonstrated functionality of the Cag type 
IV secretion system in all variants.  
Moreover, corresponding P12[TEM-CagA] variants were generated and the TEM-CagA 
expression levels analyzed, depicted in Figure 18D. Expression levels were equivalent to the 
unmodified TEM-CagA control. AGS cells were infected with these variants and percental 
CagA translocation rates were determined using the TEM-CagA assay (translocation 
efficiency defined as P12[TEM-CagA] = 100% and ΔcagI mutant = 0%; Figure 18E). With 
this assay, TEM-CagA variants lacking 5 or 6 amino acids exhibited translocation rates 
comparable to the full-length protein, TEM-CagAΔ7C about 40%, and variants lacking 8 or 9 
amino acids displayed 20% translocation. Variants with longer truncations (10, 12 or 20 
amino acids) were not detectably translocated (Figure 18E or data not shown). In general, 
these results were consistent with the data for the tyrosine phosphorylation but allowed a 
more precise, sensitive and quantitative translocation analysis. Furthermore, these 
observations demonstrate that the C-terminal type IV secretion signal does not require the 
final 6 amino acids and tolerates C-terminal deletions of up to nine amino acids. 
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Figure 18: Influence of C-terminal truncations on CagA translocation  
A) Schematic overview of the C-terminal amino acid composition of CagA and variants with sequential 
truncations.  
B) Immunoblot analysis of infected AGS cells with phosphotyrosine (4G10) and CagA (AK257) antibodies. 
Cells were infected with P12 wild-type or the indicated mutants and analyzed via Western blotting (WB). The 
arrowheads highlight weak phosphorylation bands for CagAΔ7C and CagAΔ8C. 
C) Analysis of co-culture supernatants derived from B) for IL-8 secretion via sandwich ELISA. All values were 
normalized to the IL-8 values found in the supernatants of P12 wild-type-infected cells, and are indicated as 
mean values with standard errors of the mean from at least three independent infections. t-test (one-tailed, 
unpaired) comparing to ΔcagA, **: p<0.01, ns: no significant difference. 
D) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA or TEM-CagA variant expression using a  
TEM-1 antibody. 
E) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or the indicated mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages of four independent experiments 
with standard errors of the mean. t-test (one-tailed, unpaired) comparing to TEM-CagA, ***: p<0.0001, ns: no 
significant difference. 
 
2.2.3 Influence of charged amino acids located in the C-terminus 
In addition to examinations focusing on the length of the C-terminus, the role of charged 
amino acids located in the C-terminal tail was investigated. For other type IV secretion 
systems, charged amino acids play a major role in the substrate recognition process [190, 
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191]. However, it has been reported that the two lysine residues close to the CagA C-terminus 
are not essential for translocation [131]. In addition, alanine scanning mutagenesis of the 
CagA C-terminus exchanging various acidic or basic residues with alanine as well as charge 
reversal of single amino acids did not impair CagA phosphorylation [192]. To finally rule out 
any influence of charges on CagA translocation, two variants were constructed where either 
exclusively lysine residues or all charged amino acids were mutated to alanines within the last 
20 amino acids of CagA (CagA-KKKA and CagA-REEHKKKA, respectively; see 
Figure 19A).  
 
 
Figure 19: Influence of C-terminal charged amino acids on CagA translocation 
A) Schematic overview of the C-terminal amino acid composition of CagA and variants with alanine 
mutagenesis. Charged amino acids or respective alanine substitutions are highlighted in red. 
B) Immunoblot analysis of infected AGS cells with phosphotyrosine (4G10) and CagA (AK257) antibodies. 
Cells were infected with P12 wild-type or the indicated mutants and analyzed via Western blotting (WB).  
C) Analysis of co-culture supernatants derived from B) for IL-8 secretion via sandwich ELISA. All values were 
normalized to the IL-8 values found in the supernatants of P12 wild-type-infected cells, and are indicated as 
mean values with standard errors of the mean from at least three independent infections. t-test (one-tailed, 
unpaired) comparing to ΔcagA, *: p<0.05, **: p<0.01. 
D) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA or TEM-CagA variant expression using a  
TEM-1 antibody. 
E) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or the indicated mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages of six independent experiments with 
standard errors of the mean. t-test (one-tailed, unpaired) comparing to TEM-CagA, ***: p<0.001, ns: no 
significant difference. 
 
Tyrosine phosphorylation immunoblots of mutant-infected AGS cells did not show any 
difference in comparison to the wild-type (Figure 19B). Consistently, analysis of IL-8 
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secretion exhibited no impairment for these variants (Figure 19C). Nevertheless, 
corresponding TEM-CagA variants were constructed to evaluate weak changes in CagA 
translocation rates. Although TEM-CagA protein was expressed slightly less than the full-
length equivalent (Figure 19D), AGS cells were infected with TEM-CagA-expressing variants 
and percental CagA translocation rates were determined using the TEM-CagA assay 
(translocation efficiency defined as P12[TEM-CagA] = 100% and ΔcagI mutant = 0%; Figure 
19E). P12[TEM-CagA-KKKA] exhibited the same amounts of translocated CagA as the 
positive control, albeit being lower expressed. This implies that only a minor proportion of the 
usually high CagA protein levels gets translocated into the cells, which was also recently 
reported [193]. For the variant with a complete exchange of all charged amino acids to alanine 
(TEM-CagA-REEHKKKA), a slight reduction of CagA translocation (~77%) could be 
observed. This further suggested that charged amino acids are not essential for the substrate 
recognition process.  
In summary, it could be demonstrated that the C-terminal secretion signal is defined by a 
minimal length rather than the presence of charged amino acids. Moreover, applying the 
novel TEM-CagA assay, subtle changes can be easily quantified. 
 
2.2.4 Exchange of the C-terminus with arbitrary tags 
Hitherto, it was convincingly demonstrated that the C-terminus should comprise a minimal 
length of amino acids for efficient CagA translocation. Precisely, CagA translocation tolerates 
a removal of up to nine amino acids, whereas no translocation is observed for CagAΔ10C 
variants. In addition, removal of charges in the C-terminal region does not influence 
translocation rates, implying that a defined signal sequence is lacking. To further specify this 
hypothesis, CagA variants were genetically engineered where the last ten natural amino acids 
were replaced by two tags, the GSK- and Myc-tag (CagAΔ10C-GSK, CagAΔ10C-Myc; 
shown in Figure 20A). AGS cells were infected with these mutants and the tyrosine 
phosphorylation as well as CagA expression levels were analyzed via immunoblotting (Figure 
20B). Interestingly, a very weak signal could be detected for the CagAΔ10C-GSK variant, 
while CagA expression levels were slightly reduced. In contrast, no CagA phosphorylation 
was detectable for CagAΔ10C-Myc, although it was expressed at levels comparable to the 
wild-type. To evaluate the functionality of the type IV secretion system, supernatants of 
respective co-cultures were analyzed for IL-8 content (Figure 20C). P12[CagAΔ10C-GSK] 
and P12[CagAΔ10C-Myc]-infected cells secreted IL-8 to a similar level as cells infected with 
an isogenic ΔcagA mutant, which is in accordance with the weak or abolished CagA 
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phosphorylation of the variants. To quantify CagA translocation rates, corresponding TEM-
CagA fusion variants were constructed. Analysis of TEM-CagA expression revealed similar 
levels compared to the wild-type control (Figure 20D). Quantification by TEM-CagA assay 
(translocation efficiency defined as P12[TEM-CagA] = 100% and ΔcagI mutant = 0%; Figure 
20E) showed only a slight reduction of the TEM-CagAΔ10C-GSK variant (~87%) compared 
to the native fusion protein. Surprisingly, a weak translocation was observed upon infection 
with P12[TEM-CagAΔ10C-Myc] (~6%), which could not be detected applying the tyrosine 
phosphorylation assay, further stressing the sensitivity of the novel TEM-CagA assay. 
 
 
Figure 20: Reconstitution of CagA translocation by arbitrary C-terminal tags 
A) Schematic overview of the C-terminal amino acid composition of CagA and CagAΔ10C variants with GSK 
or Myc tag extension. CagA amino acid sequence is highlighted in purple and additional amino acids in orange 
while underlined sequences are corresponding to the tag sequence. 
B) Immunoblot analysis of infected AGS cells with phosphotyrosine (4G10) and CagA (AK257) antibodies. 
Cells were infected with P12 wild-type or the indicated mutants, and analyzed via Western blot (WB). The 
arrowhead highlights a weak phosphorylation band for CagAΔ10C-GSK. 
C) Analysis of co-culture supernatants derived from B) for IL-8 secretion via sandwich ELISA. All values were 
normalized to the IL-8 values found in the supernatants of P12 wild-type-infected cells, and are indicated as 
mean values with standard errors of the mean from at least three independent infections. t-test (one-tailed, 
unpaired) comparing to ΔcagA, ns: no significant difference. 
D) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA or TEM-CagA variant expression using a  
TEM-1 antibody. 
E) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or the indicated mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages of five independent experiments 
with standard errors of the mean. ANOVA (one-way, Tukey post hoc test), ***: p<0.001. 
 
Taken together, it is possible to reconstitute CagA translocation by substitution of the last ten 
amino acids with unrelated amino acid sequences. This observation strengthens the 
80 RESULTS  
hypothesis, that the type IV secretion machinery just requires any arbitrary C-terminal amino 
acid sequence for substrate recognition. However, the remarkable differences in translocation 
rates delivered by P12[TEM-CagAΔ10C-GSK] and P12[TEM-CagAΔ10C-Myc] indicate that 
the C-terminal amino acid composition can determine efficiency of translocation, although a 
specific signal cannot be defined.  
 
2.3 Influence of N-terminal and internal domains on CagA 
translocation 
In addition to C-terminal signal sequences, other regions of individual type IV-secreted 
effector proteins can be involved in the recognition and translocation process as well [77]. For 
the CagA protein, preliminary studies demonstrated that minor N-terminal deletions render 
the protein translocation-incompetent [131]. However, the respective plasmid-encoded CagA 
variants were only weakly expressed within these studies, hampering translocation analysis 
via tyrosine phosphorylation due to the low sensitivity of this technique. Hence, CagA 
variants with N-terminal and also internal domain deletions under control of the endogenous 
cagA promoter were constructed. Briefly, as for the generation of P12[TEM-CagA] (see also 
Figure 9), plasmid pWS373 was used for deletion of the cagA region in H. pylori P12, and 
subsequently, diverse plasmids, carrying modified cagA versions, were employed as 
reconstitution plasmids that recombined in the cagA region (see Materials & Methods section 
for further details).  
According to the crystal structure of CagA, the protein can be divided into a structured N-
terminal region consisting of 3-4 domains and a rather unstructured C-terminal tail [130]. 
Within the N-terminal region, domain D1 has very little interaction surface with the other 
domains, and it seemed possible to delete this domain without any structural influence on 
other CagA regions. In addition, the first 17 amino acids were unstructured in the crystal 
[130]. Thus, variants lacking the first 17 amino acids of CagA (CagAΔ17N) as well as a 
mutant lacking domain D1 (amino acids 18-284, CagAΔD1) were constructed (Figure 21A). 
Moreover, a variant lacking the whole EPIYA region was engineered (CagAΔEPIYA) to 
investigate the role of this tyrosine phosphorylatable domain onto translocation (Figure 21A). 
After infection of AGS cells with these mutants, a very weak phosphorylation band of 
CagAΔ17N could be detected via immunoblotting (Figure 21B, highlighted by an arrowhead), 
while the signal for CagAΔD1 could not be evaluated due to high background signals. As 
expected, no signal for the EPIYA deletion variant was detectable as the read-out of this assay 
is based on detection of the tyrosine phosphorylation within this region. Analysis of 
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respective co-culture supernatants revealed a significant increase of IL-8 secretion (~80%) 
upon infection with P12[CagAΔ17N] compared to the ΔcagA deletion mutant (Figure 21C), 
that correlated with the detectable CagA phosphorylation. No increase in IL-8 concentration 
was observed in the supernatants of cells infected with the P12[CagAΔD1] or 
P12[CagAΔEPIYA] variants.  
 
 
Figure 21: Influence of N-terminal and internal domain deletions on CagA translocation 
A) Schematic overview of N-terminal and internal CagA deletion variants.  
B) Immunoblot analysis of infected AGS cells with phosphotyrosine (4G10) and CagA (AK257) antibodies. 
Cells were infected with P12 wild-type or the indicated mutants and subjected to Western blotting (WB). The 
arrowhead highlights a weak phosphorylation band of CagAΔD1. 
C) Analysis of co-culture supernatants derived from B) for IL-8 secretion via sandwich ELISA. All values were 
normalized to the IL-8 values found in the supernatants of P12 wild-type-infected cells, and are indicated as 
mean values with standard errors of the mean from at least three independent infections; t-test (one-tailed, 
unpaired) comparing to ΔcagA, ***, p<0.0005, ns: no significant difference. 
D) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA or TEM-CagA variant expression using a 
TEM-1 antibody. 
E) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or the indicated mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages from at least four independent 
experiments with standard errors of the mean. t-test (one-tailed, unpaired) comparing to TEM-CagA, ***, 
p<0.0001, ns: no significant difference. 
F) Analysis of co-immunoprecipitation (IP) fractions with CagA and CagF immunoblots (WB). AGS cells were 
infected with P12 wild-type or the indicated mutants, then lysed and subjected to immunoprecipitation using the 
polyclonal CagA antiserum AK257. The arrowhead highlights a weak CagF band for CagAΔD1.  
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To quantify CagA translocation rates, corresponding TEM-fusion variants were constructed 
and exhibited protein expression levels comparable to the wild-type (Figure 21D). Evaluation 
using the TEM-CagA assay (translocation efficiency defined as P12[TEM-CagA] = 100% and 
ΔcagI mutant = 0%; Figure 21E) surprisingly showed translocation rates of TEM-CagAΔ17N 
of about 100% which could not be concluded from immunoblot analysis (Figure 21B) and 
clearly proves that the N-terminus is not involved in substrate recognition. Moreover, a slight 
translocation of TEM-CagAΔD1 could be detected (~6%), indicating a role of the D1 domain 
for efficient translocation. Regarding TEM-CagAΔEPIYA, the translocation rate was as high 
as for the wild-type, suggesting no contribution of this region to substrate recognition of the 
type IV secretion system. Nevertheless, no difference in IL-8 induction was observed upon 
infection for this variant in comparison to the ΔcagA deletion mutant (Figure 21C). This was 
consistent with previously published data, where a necessity of the EPIYA region for CagA-
dependent IL-8 induction was reported [189]. 
To investigate the drastically reduced CagA translocation of the D1 deletion variant in more 
detail, immunoprecipitation experiments were performed to evaluate the binding efficiency of 
the modified CagA protein to its secretion chaperone CagF (Figure 21F). CagF was co-
precipitated from cell extracts of the wild-type, but not the ΔcagA mutant, proving the 
specificity of this immunoprecipitation. CagF was also detectable in cell extracts of 
CagAΔ17N, CagAΔD1 and the CagAΔEPIYA variant, but the precipitation efficiency of 
CagAΔD1 was clearly reduced compared to the other mutants (highlighted with an 
arrowhead, Figure 21F). This is consistent with prior studies [120], where an interaction of 
CagF with various CagA domains (including D1) could be shown. Moreover, the data 
presented here might extend this finding, as the CagF and D1 interaction appears to be crucial 
for efficient delivery of CagA. Nevertheless, a role of the N-terminal D1 domain for direct 
CagA substrate recognition by the type IV secretion apparatus cannot be excluded.  
 
According to the data presented in this and prior chapters, CagA translocation seems to be 
highly dependent on the presence of its C-terminus and strongly influenced by the N-terminal 
D1 domain, while the first 17 N-terminal amino acids as well as the EPIYA region do not 
have a function for this process. For further experiments, a TEM-CagA fusion variant was 
constructed that incorporated translocation-promoting regions like the N-terminal D1 domain 
or C-terminus, but completely lacked the N-terminal D2 and D3 domain as well as the EPIYA 
region (amino acids 260-1019, TEM-CagAΔD2-D3-EPIYA; Figure 22A). As an additional 
negative control, a variant lacking the last 181 amino acids (TEM-CagAΔ181C) was used. 
CagA expression profiles of the mutants revealed a relatively low expression level of TEM-
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CagAΔD2-D3-EPIYA (Figure 22B). Therefore, it is obvious that the removal of large 
sequence parts might influence stability and structure of CagA. Nevertheless, the TEM-CagA 
translocation assay was conducted, depicted in Figure 22C (translocation efficiency defined as 
P12[TEM-CagA] = 100% and ΔcagI mutant = 0%). As expected, no signal was observed for 
TEM-CagAΔ181C and moreover, no translocation was detectable for TEM-CagAΔD2-D3-
EPIYA. This observation could be due to the rather low TEM-CagA expression of the mutant, 
although prior data demonstrated full translocation rates even for less well-expressed fusions 
(compare Figure 19E). In fact, it seems more likely that deletion of the N-terminal D2 domain 
renders the protein translocation-incompetent as this region directly interacts with the host 
cell integrins that are crucial for delivery into the cell [127]. 
 
 
Figure 22: Influence of an internal domain deletion on CagA translocation 
A) Schematic overview of investigated CagA deletion variants.  
B) Immunoblot (WB) of bacterial lysates analyzing TEM-CagA or TEM-CagA variant expression using a  
TEM-1 antibody. 
C) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or the indicated mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages from four independent experiments 
with standard errors of the mean. 
 
2.4 Impact of protein expression on CagA translocation 
As another translocation parameter, the influence of protein expression on CagA translocation 
was characterized. For this purpose, firstly it was examined how the co-expression of two 
CagA variants influences the total translocation rate and secondly, whether the CagA 
translocation process requires freshly synthesized proteins.  
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2.4.1 Analysis of CagA and TEM-CagA co-expressing strains 
The consistent results regarding tyrosine phosphorylation of CagA and translocation of TEM-
CagA suggested that both proteins are recognized by the same machinery. To obtain further 
data on the efficiency of this process, mutants were constructed that expressed wild-type or 
variant CagA together with TEM-CagA protein. For this purpose, P12[TEM-CagA] was 
transformed with cagA reconstitution plasmids that integrated into the recA locus [175].  
 
 
Figure 23: Analysis of CagA and TEM-CagA co-expressing strains 
A) Immunoblots (WB) analyzing CagA and TEM-CagA expression in co-producing strains using a CagA 
antibody (AK268).  
B) Immunoblot analysis of infected AGS cells with phosphotyrosine (PY99) and CagA (AK268) antibodies. 
Cells were infected with P12 wild-type or the indicated mutants and analyzed via Western blotting (WB).  
C) Tyrosine phosphorylation levels of CagA (exemplarily shown in B) were estimated by quantitative 
immunoblot analysis and are indicated as mean densitometric ratios of phosphotyrosine to CagA protein bands 
normalized to P12 wild-type from three independent experiments, with standard errors of the mean. 
D) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] or co-producing mutants. The average blue-to-green ratios of each infection were normalized to the mean 
ratio of P12[TEM-CagA]-infected cells, and are shown as mean percentages of four independent experiments 
with standard errors of the mean; ANOVA (one-way, Tukey post hoc test), ***: p<0.001. 
 
The immunoblot presented in Figure 23A depicts expression of TEM-CagA and wild-type 
CagA or a CagA variant lacking the last 20 amino acids (TEM-CagA + CagA and TEM-
CagA + CagAΔ20C). Although the TEM-CagA fusion protein was expressed less than wild-
type CagA, phosphotyrosine analysis (see Figure 23B) showed a decrease of CagA 
phosphorylation for the TEM-CagA + CagA co-producing mutant. This was additionally 
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verified by quantification of phosphorylated CagA in relation to total CagA protein amounts 
following a densitometric determination from independent experiments (see Figure 23C). In 
detail, a reduction of phosphorylated CagA to about 46% was observed for P12[TEM-
CagA + CagA] compared to the wild-type. Conversely, the percental CagA translocation 
(translocation efficiency defined as P12[TEM-CagA] = 100% and ΔcagI mutant = 0%; see 
Figure 23D), determined via CCF4 cleavage by translocated TEM-CagA, was equally 
reduced to about 46%, indicating that both proteins are competitively recognized and 
translocated to the same amounts by the type IV secretion apparatus. As expected, no tyrosine 
phosphorylation was observed for CagAΔ20C lacking the C-terminal secretion signal (see 
Figure 23B). Surprisingly, TEM-CagA translocation from a strain co-producing CagAΔ20C 
did not reach 100%, although it was significantly increased in comparison to the wild-type 
CagA co-producing variant (Figure 23D). This observation might be based on the fact that 
competition for recruitment to the secretion apparatus depends on, but is not restricted to, the 
C-terminal secretion signal.  
Taken together, the data proves that CagA and TEM-CagA are translocated with the same 
efficiency, although expressed to different amounts. Again, the data implicates that not all 
CagA molecules present in the cell are translocated and that even high amounts of wild-type 
CagA are not able to completely block delivery of TEM-CagA. This raises further 
speculations that exclusively newly synthesized CagA protein is recruited by the translocation 
machinery irrespective of the amounts already present, which will be investigated in the next 
section.  
 
2.4.2 Direct and secondary inhibition of protein synthesis 
To examine whether only freshly synthesized CagA protein is translocated into host cells, an 
antibiotic directly inhibiting protein synthesis was used and as control one with bacteriolytic 
activity. For this purpose, three different protocol layouts were designed, which are 
summarized in Figure 24A. Within these layouts, H. pylori was either pre-incubated with the 
antibiotic and washed before infection, or the washing step was skipped and AGS cells were 
directly infected with the H. pylori-antibiotic mixture after a short pre-incubation. As a 
control, solely the AGS cells were exposed to the antibiotic prior to infection to exclude any 
cell-specific effects. Following these protocols, various concentrations of erythromycin were 
employed in order to evaluate the effect of direct protein biosynthesis inhibition on CagA 
translocation, and percental rates were determined using the TEM-CagA assay (Figure 24B). 
Translocation was completely abolished using 10 mg/L erythromycin and also strongly 
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influenced at lower concentrations. In addition, growth curves of bacteria were performed in 
the presence of erythromycin, and the expected bacteriostatic effect correlated with the 
translocation inhibition (Figure 24C). In contrast, treatment of H. pylori with ampicillin did 
not influence CagA translocation as strongly as erythromycin (Figure 24D), although growth 
analysis in the presence of ampicillin revealed curves typical for this bactericidal antibiotic 
(Figure 24E). Ampicillin blocks protein synthesis only as a secondary effect, hence, the 
stronger effects of erythromycin on CagA translocation might be based on a direct deprivation 
of freshly synthesized proteins from the type IV secretion machinery. No influence on CagA 
translocation was observed for conditions where only cells were exposed to the antibiotics 
and thus, unspecific cytotoxic effects could be excluded (Figure 24B/D). 
 
 
Figure 24: Influence of direct and secondary protein synthesis inhibition on CagA translocation 
A) Layout protocols for infections with inhibiting compounds. 
B) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] in the presence of erythromycin according to the protocols described in A). The average blue-to-green 
ratios of each infection were normalized to the mean ratio of P12[TEM-CagA]-infected cells, and are shown as 
mean percentages of at least four independent experiments with standard errors of the mean. ANOVA (one-way, 
Turkey post hoc test) referring to untreated controls, ***: p<0.001, ns: no significant difference. 
C) Growth analysis of H. pylori in the presence of erythromycin. OD550 was recorded every 5 min for at least 
16 h and experiments were independently repeated at least 3 times. The figure depicts a representative growth 
curve. 
D) Quantification of TEM-CagA translocation rates by plate reading in the presence of ampicillin. Experiments 
were performed as described in B).  
E) Growth analysis of H. pylori in the presence of ampicillin. Experiments were performed as described in C). 
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Together with the time-course experiments (Chapter 1.4), the data generated from co-
producing mutants in the previous section (Chapter 2.4.1) as well as the clear inhibitory 
competence of erythromycin on CagA translocation, a dynamic model is conceivable in 
which only freshly synthesized CagA is introduced into the type IV secretion machinery. 
 
2.5 Influence of metal ions on CagA translocation competence 
It has been published that sequestration of specific metal ions has a high impact on CagA 
translocation competence [125, 126]. Indeed, this might be crucial for host colonization and 
the interplay of H. pylori with the immune system. In this work, data concerning the influence 
of metal ions should be confirmed and extended, applying the novel TEM-CagA translocation 
assay.  
 
 
Figure 25: Influence of metal ion sequestration on CagA translocation 
A) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] with various concentrations of TPEN according to the protocols described in Figure 24A). The average 
blue-to-green ratios of each infection were normalized to the mean ratio of P12[TEM-CagA]-infected cells, and 
are shown as mean percentages of at least four independent experiments with standard errors of the mean. 
ANOVA (one-way, Tukey post hoc test) referring to untreated controls, *: p<0.05, **: p<0.01, ***: p<0.001, ns: 
no significant difference. 
B) Growth analysis of H. pylori in the presence of TPEN. OD550 was recorded every 5 min for at least 16 h and 
experiments were independently repeated at least 3 times. The figure depicts a representative growth curve. 
C) Quantification of TEM-CagA translocation rates by plate reading in the presence of various concentrations of 
bipyridyl. Experiments were performed as described in A). 
 
At first, the proposed inhibitory effect of zinc sequestration on Cag type IV secretion activity 
[126] was investigated. For this purpose, TPEN (N,N,N',N'-tetrakis(2-pyridylmethyl) 
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ethylenediamine), a high-affinity zinc chelator, was applied and experiments were performed 
as depicted in Figure 24A. Following this, P12[TEM-CagA], AGS cells or the co-culture were 
exposed to various concentrations of TPEN and percental translocation rates were examined 
via the TEM-CagA assay (Figure 25A). Translocation was dose-dependently inhibited when 
H. pylori was either pre-incubated with TPEN or TPEN was present during infection. 
Nonetheless, growth analysis of H. pylori revealed a high antimicrobial activity of TPEN 
(Figure 25B). In addition, translocation rates were also reduced when only cells were in 
contact with TPEN (pre-incubation of cells, Figure 25A). This indicated a toxic effect on the 
cells and in fact, zinc sequestration induces apoptosis in eukaryotic cells [194]. For this 
reason, the effects of TPEN on translocation might be ascribed to an antimicrobial effect 
against H. pylori and a cytotoxic effect on the cells rather than to a specific decrease in Cag 
type IV secretion activity as recently reported [126].  
Moreover, it has been reported that low iron conditions can induce hypervirulent H. pylori 
strains in vivo by means of increased CagA injection into the host cell [125, 195]. To confirm 
this hypothesis with the novel TEM-CagA assay, bipyridyl, a high-affinity chelator for iron, 
was applied according to the three different protocol layouts described in Figure 17A. 
Contrary to the published results, no increase of CagA translocation could be observed 
(Figure 18C). However, translocation rates were decreased (~80%) for the condition were 
only cells got in contact with bipyridyl, indicating a cytotoxic effect on the cells. Like for 
zinc, the proposed hypothesis could not be supported.  
 
2.6 Inhibition of CagA translocation by modulation of cellular 
structures 
Hitherto, experiments focused on possibilities to influence CagA translocation by directly 
acting on H. pylori. Delivery of CagA is not only dependent on a functional type IV secretion 
system, but also on host cell machineries. To characterize several host cell contributions in 
more detail, cells as well as H. pylori as control were treated with specific inhibitors 
following the experimental set-ups depicted in Figure 24A. In general, corresponding data on 
tyrosine phosphorylation of CagA was prior reported and should be extended employing the 
phosphorylation-independent TEM-CagA reporter assay.  
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2.6.1 Modulation of the cytoskeleton and lipid rafts 
At first, the influence of the actin cytoskeleton on CagA translocation was investigated using 
various concentrations of cytochalasin D, a potent inhibitor of actin polymerization. Infection 
of cells with P12[TEM-CagA] exhibited an impairment of translocation (~50%) as long as 
AGS cells were in contact with the inhibitor (Figure 26A). No dose-dependency was 
observed, indicating a saturated inhibition by cytochalasin D. In contrast, only a slight effect 
was detected for pre-incubation with H. pylori (~80% translocation at 2 µM), suggesting a 
specific action on the actin cytoskeleton (Figure 26A). In addition, similar results were 
obtained for another actin polymerization inhibitor (latrunculin B, data not shown) and in 
accordance with previous reports investigating CagA phosphorylation [129].  
 
 
Figure 26: Impact of structural cell modifications on CagA translocation 
A) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] with various concentrations of cytochalasin D according to the protocols described in Figure 24A). The 
average blue-to-green ratios of each infection were normalized to the mean ratio of P12[TEM-CagA]-infected 
cells, and are shown as mean percentages of at least four independent experiments with standard errors of the 
mean. ANOVA (one-way, Tukey post hoc test) referring to untreated controls, *: p<0.05, **: p<0.01, ***: 
p<0.001, ns: no significant difference. 
B) Quantification of TEM-CagA translocation rates by plate reading in the presence of various concentrations of 
nocodazole. Experiments were performed as described in A). 
C) Quantification of TEM-CagA translocation rates by plate reading in the presence of various concentrations of 
heptakis-β-cyclodextrin. Experiments were performed as described in A). 
 
Also, the impact of the microtubule (filament) system on CagA translocation was examined. 
Nocodazole was applied to disrupt microtubule filaments, and effects on translocation are 
summarized in Figure 26B. No influence was observed when bacteria were pre-incubated 
with nocodazole prior to infection and a slight but significant inhibitory effect was observed 
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when cells were in contact with the substance for the highest concentrations applied (~80% 
translocation at 5 or 1.6 µM). Thus far, no effect on CagA phosphorylation was described in 
response to the inhibition of tubulin polymerization, which might be owed to the low 
sensitivity for detecting weak changes via tyrosine phosphorylation analysis.  
In order to study the influence of host cell membrane composition on CagA translocation, 
heptakis(2,6-di-O-methyl)-β-cyclodextrin was used. This substance exhibits a high affinity for 
cholesterol and is able to deplete cholesterol from the membrane, leading to the disruption of 
lipid raft microdomains [196]. Measurement of CagA translocation in the presence of 
heptakis-β-cyclodextrin showed the strongest effects when applied during infection or for pre-
incubation of AGS cells (Figure 26C). Effects were most severe in the latter set-up suggesting 
that constant cholesterol depletion is necessary for preventing CagA translocation. These 
results are consistent with prior data, where an inhibiting effect of heptakis-β-cyclodextrin on 
CagA phosphorylation was observed [114, 129, 197]. 
Taken together, experiments presented in this chapter not only confirm but further extend 
previously described data by using three different experimental set-ups together with 
quantification of CagA translocation in a phosphorylation-independent manner.  
 
2.6.2 Inhibition of eukaryotic kinases 
As a last parameter, the influence of cellular kinases on CagA translocation was analyzed. 
Once inside the host cell, CagA rapidly gets tyrosine-phosphorylated by kinases, which 
constitutes a crucial step for CagA interaction with host proteins and its interference with 
corresponding signal transduction pathways. Inhibition of this phosphorylation step was 
examined in various studies using either PP2, a specific inhibitor of Src-family kinases, or 
genistein, a general tyrosine kinase inhibitor [74, 198]. However, kinase inhibition is not 
compatible with measurement of CagA phosphorylation, and thus no information is available 
whether CagA can enter the cells upon inhibitor treatment. Hence, the newly developed 
phosphorylation-independent TEM-CagA translocation reporter was applied using various 
concentrations of PP2 or genistein (see Figure 27A&B) in combination with the different 
experimental set-ups described in Figure 24A. Pre-treatment of cells with inhibitors affected 
CagA translocation only weakly for PP2 (~80% translocation at 10 µM) and not at all for 
genistein, which confirms that CagA was still delivered into the cells. In contrast, when 
bacteria were exposed to the substances (either pre-incubated or during infection, Figure 
27A&B), a translocation inhibition by PP2 and an even stronger reduction by genistein was 
observed. Growth analysis in the presence of PP2 and genistein (Figure 27C&D) revealed an 
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antimicrobial activity against H. pylori, and growth suppression correlated with translocation 
inhibition. In fact, an anti-H. pylori activity of genistein has been described before [199]. 
Hence, the potential susceptibility of H. pylori towards supposedly exclusive eukaryotic 
inhibitors should not be neglected in future experimental set-ups.  
 
 
 
Figure 27: Influence of the inhibition of eukaryotic kinases on CagA translocation 
A) Quantification of TEM-CagA translocation rates by plate reading. AGS cells were infected with P12[TEM-
CagA] with various concentrations of PP2 according to the protocols described in Figure 24A). The average 
blue-to-green ratios of each infection were normalized to the mean ratio of P12[TEM-CagA]-infected cells, and 
are shown as mean percentages of at least four independent experiments with standard errors of the mean. 
ANOVA (one-way, Tukey post hoc test) referring to untreated controls, ***: p<0.001, ns: no significant 
difference. 
B) Quantification of TEM-CagA translocation rates by plate reading in the presence of various concentrations of 
genistein. Experiments were performed as described in A). 
C) Growth analysis of H. pylori in the presence of PP2. OD550 was recorded every 5 min for at least 16 h and 
experiments were independently repeated at least 3 times. The figure depicts a representative growth curves. 
D) Growth analysis of H. pylori in the presence of genistein. Experiments were performed as described in C). 
 
3. High-throughput screening for CagA translocation inhibitors 
Infection with H. pylori leads to various malignancies including gastric or duodenal ulcer 
disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma 
[11, 13, 18, 19, 23, 24]. Antibiotic treatment of H. pylori infection increasingly fails due to 
resistance development [161, 162] and thus, alternative strategies are urgently needed. As the 
delivery of CagA into the host cell constitutes a key event in the induction of the above-
mentioned diseases [137, 156-158], one promising approach could be to directly inhibit the 
CagA translocation process. Thereby, the cancerogenic effects of the CagA protein could be 
dampened and at the same time the risk for resistance development diminished. The search 
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for such specific inhibitors was a main part of this work and will be described in the following 
sections.  
3.1 Experimental set-up for a high-throughput screening platform 
To increase the probability for the identification of specific CagA translocation inhibitors, a 
high-throughput screening platform had to be established. For quick identification of 
substances blocking the translocation process, the newly established TEM-CagA assay was 
applied and miniaturized to the 384-well format. A chart of the final screening workflow 
including follow-up studies is presented in Figure 28.  
 
 
Figure 28: Workflow of the high-throughput screening platform 
See text for further details to individual steps.  
 
For the initial TEM-CagA assay screening step, small-molecule libraries were derived in 384-
well plates. Briefly, the reporter strain H. pylori P12[TEM-CagA] was pre-incubated with 
small-molecule compounds, the bacteria-compound mixture transferred onto AGS cells and 
after 2.5 h infection, percental CagA translocation rates were determined. To subsequently 
identify compounds with an anti-H. pylori effect, a counter-screening for growth inhibition 
was conducted in 96-well plates. The influence on growth was analyzed via growth curve 
analysis and expressed as the percental OD550 increase compared to an untreated control. This 
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step was optional and not executed for every library. Promising hit compounds that displayed 
high translocation inhibition were confirmed employing the TEM-CagA assay in the 96-well 
format. For this purpose, three different experimental set-ups were applied to quickly identify 
whether the compounds exhibited an effect on H. pylori, the cells or even both. To do so, 
either H. pylori (BACapproach) or AGS cells (CELLapproach) were pre-treated with 
compounds prior to infection. In addition, a set-up equal to the initial screening conditions 
(SCREENapproach) was applied. Antimicrobial activity of selected compounds was 
examined, if no counter-screen for growth inhibition had been performed before. To 
independently verify CagA translocation inhibition, tyrosine phosphorylation assays were 
performed following the above-mentioned protocols. Depending on the compounds favorized, 
individual follow-up studies were conducted that will be specified in detail in the respective 
sections. 
 
3.2 Evaluation of the TEM-CagA assay for high-throughput screenings 
Before describing the single library screenings in detail, a summary of all screenings is 
depicted in Figure 29A.  
 
 
Figure 29: Summary of screened libraries and corresponding statistical parameters 
A) Table summarizing all libraries screened including the number of compounds, source, properties and statistics 
of the TEM-CagA assay screening procedure. Values printed in bold either denote the total amount of screened 
compounds or mean values of statistical parameters. S/N = signal to noise, S/B = signal to background. 
B) Formulas of statistical parameters shown in A) according to [200]. µ: mean value, σ: standard deviation, 
positive control: blue-to-green fluorescence signal of untreated P12[TEM-CagA], negative control: blue-to-green 
fluorescence signal of P12[TEM-CagA]ΔcagI. 
C) Overview of Z´-factors determined for individual 384-well plates screened with the TEM-CagA assay. 
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Library-specific properties ranged from purified natural products to chemically synthesized 
compounds. Of importance, statistical parameters of TEM-CagA reporter screenings in 384-
well plates are listed, and corresponding formulas are shown in Figure 29B (according to 
[200]). The most important parameter is the Z´-factor, which is a widespread measure for the 
quality of high-throughput screening assays. In this context, values above 0.5 comply with an 
excellent screening performance [200]. Following this, an average Z´-factor of 0.66 was 
calculated for all TEM-CagA reporter screenings, which validates the experimental 
procedure. However, when analyzing Z´-factors of every single 384-well plate screened 
(n = 33, Figure 29C), 4 plates exhibited values below 0.5. In addition, the parameters “signal 
to noise” (S/N) and “signal to background” (S/B) are listed. Values of these parameters 
cannot be classified in certain ranges and are considered as the higher the value the higher the 
screening validity. Especially the S/B-ratio is less important because no signal variation is 
included. Values of S/N-ratios varied strongly (46-219) and further confirm the 
trustworthiness of the more constant Z´-factor. Considering the average Z´-factor above 0.5, 
the TEM-CagA reporter assay was successfully evaluated as a valid high-throughput 
screening method. 
 
3.3 Screening of the ExNCL library 
At first, the extended natural compound library (ExNCL) was screened. This library was 
derived from the Interfaculty Institute of Microbiology and Infection Medicine (IMIT, 
Tübingen) and comprised 340 purified natural compounds with unique structures and mainly 
antibacterial bioactivities. For screening of TEM-CagA translocation inhibition a compound 
concentration of 5 µM was employed. A total number of 39 compounds were detected that 
revealed a translocation rate lower than 50% (see Figure 30A). A subsequent counter-
screening for growth inhibition identified 157 compounds that reduced H. pylori growth by 
more than 50% (see Figure 30B). This higher hit rate was expected, as for growth screening 
double concentrations (10 µM) were applied and the library consisted mainly of antibiotics. 
To filter compounds that demonstrated CagA translocation inhibition without major anti-H. 
pylori effects, translocation rates were plotted against the respective growth rates (see Figure 
30C). In total, 181 compounds displayed no or weak effects on translocation and growth (both 
parameters >50%). A group of 37 compounds blocked translocation (<50%) and also 
influenced growth (<50%), suggesting that translocation inhibition was due to an antibacterial 
effect. Accordingly, many of these substance groups were already described to exhibit anti-H. 
pylori activities, such as several angucyclinone derivates (rabelomycin, tetrangomycin, 
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frigocyclinone) [201, 202]. Also various macrolide antibiotics (e.g. different mycinamicin 
derivates or picromycin), a substance class that can be used for H. pylori treatment, inhibited 
translocation and growth [203]. Surprisingly, also some antibiotics that were originally 
thought to be active exclusively against gram-positive bacteria, such as naphtocyclinons [204] 
or avilamycins [205], showed strong effects against H. pylori.  
 
 
Figure 30: Summary of ExNCL library screening 
A) Screening for CagA translocation inhibition using the TEM-CagA reporter assay. Each dot represents the 
effect of a compound on translocation at 5 µM. 
B) Screening for H. pylori growth inhibition via growth curve analysis. Each dot represents the effect of a 
compound on growth at 10 µM. 
C) Plot summarizing CagA translocation versus growth inhibition for every compound, represented by a red dot. 
D) Overview of compounds exhibiting a translocation rate lower than 50% and a growth rate higher than 50%. 
CCF4 loading refers to green fluorescence signals recorded in the TEM-CagA assay, and low values indicate 
eukaryotic cytotoxicity. 
E) Confirmation of the effect of cinnachinon-hydroxymethyl on CagA translocation. Translocation was 
quantified using the TEM-CagA assay according to the protocol layouts described in Figure 28. Values are 
derived from two independent measurements.  
F) Immunoblot analysis of infected AGS cells with phosphotyrosine (4G10) and CagA (AK257) antibodies. 
Cells were infected with P12 wild-type in the presence of cinnachinon-hydroxymethyl following the protocol 
layout described in E), and analyzed via Western blot (WB). 
 
However, only two compounds, namely aurantimycin-A and cinnachinon-hydroxymethyl, 
displayed CagA translocation rates below 50% and growth rates above 50% (summarized in 
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Figure 30D). Of these, aurantimycin-A exhibited the best inhibitory profile (CagA 
translocation: 15%, growth: 88%). Unfortunately, raw data of the TEM-CagA translocation 
assay revealed only weak loading of AGS cells with the CCF4 substrate (expressed as green 
fluorescence value, data not shown), which indicates a strong cytotoxic effect on the cells. In 
fact, aurantimycin-A was described to be cytotoxic [206], and was thus excluded as a 
promising hit candidate for specific translocation inhibition. Cinnachinon-hydroxymethyl did 
not show an abnormal CCF4 loading, but its inhibitory capability on translocation was weak 
(48% translocation), and the compound was also slightly active against H. pylori (74% 
growth). However, the compound was investigated in follow-up studies and the TEM-CagA 
assay was repeated following the protocol layouts described in Figure 28. Corresponding 
percental CagA translocation rates are presented in Figure 30E. An inhibition of translocation 
could be reproduced when cinnachinon-hydroxymethyl was present during infection (27% 
translocation in SCREENapproach), but not applying the BAC- or CELLapproach, excluding 
an antibacterial or cytotoxic effect of the substance. The observed effect in the 
SCREENapproach was confirmed with the orthogonal CagA tyrosine phosphorylation assay, 
and the corresponding immunoblot is depicted in Figure 30F. Unfortunately, no decrease of 
phosphorylation in the presence of cinnachinon-hydroxymethyl could be detected, which 
suggested that the compound exhibits an inhibitory effect on the TEM-CagA assay. Hence, 
the substance was excluded as a specific translocation inhibitor candidate. 
 
3.4 Screening of the LOPAC library 
Next, the LOPAC library (Sigma-Aldrich) was screened. This library comprised 1267 
pharmacologically active compounds including various drug-like molecules from the fields of 
neuroscience and cell signaling, as summarized in Figure 31A.  
Screening for TEM-CagA translocation inhibition at 50 µM compound concentration revealed 
151 substances that were able to block translocation by more than 50% (see Figure 31B). 
Within a subsequent growth counter-screen, even more compounds (n = 422) were identified 
to lower H. pylori growth below 50% (see Figure 31C), which might be due to the higher 
compound concentration of 100 µM. Remarkably, 290 of these substances completely 
blocked H. pylori growth. However, neither for translocation nor for growth inhibitors, a clear 
action spectrum of the different drug classes could be deduced. For a better overview, the 
influence of every compound on translocation was compared to its impact on growth (see 
Figure 31D). More than 65% of all compounds (n = 835, >50% for both parameters) did not 
exhibit an influence on translocation or growth. 141 compounds were able to reduce 
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translocation (<50%), but inhibited bacterial growth at the same time (Figure 31D). Thus, for 
these substances an unspecific effect on translocation due to antibacterial activity was 
concluded. In total, ten substances yielded translocation rates below 50% and percental 
growth above 50%; they are listed together with their mode of action and indication in Figure 
31E. Among these hits, related compounds were identified, such as LLH-1 and LLH-2, as 
well as cantharadin and its corresponding acid.  
 
 
Figure 31: Summary of LOPAC library screening 
A) Drug targets of compounds in the LOPAC library. Classification according to Sigma-Aldrich LOPAC®1280 
database. 
B) Screening for CagA translocation inhibition using the TEM-CagA reporter assay. Each dot represents the 
effect of a compound on translocation at 50 µM. 
C) Screening for H. pylori growth inhibition via growth curve analysis. Each dot represents the effect of a 
compound on growth at 100 µM. 
D) Plot summarizing CagA translocation versus growth inhibition for every compound, represented by a red 
dot. 
E) Overview of compounds exhibiting a translocation rate lower than 50% and a growth rate higher than 50%. 
CCF4 loading refers to the green fluorescence signals recorded in the TEM-CagA assay, and low values 
indicate eukaryotic cytotoxicity. Mode of actions and indications are also summarized.  
 
A) B)
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E)
Compound CagA translocation (%) Growth (%) CCF4 loading Mode of action Indication
LLH-1 13.7 84.9 ok
LLH-2 3.4 88.8 ok
Cantharidic acid 40.1 84.7 slightly reduced phosphatase inhibitor
Cantharidin 32.7 74.6 slightly reduced phosphatase inhibitor skin lesions;  aphrodisiac (but highly toxic)
Dihydroergocristine
methanesulfonate 39.7 72.5 ok
agonist at dopaminergic and adrenergic receptors; 
antagonist at serotonergic receptors dementia
Iodoacetamide 47.3 (inconsistent) 74.7 ok alkylating agent
Methysergide maleate 5.7 83.3 ok serotonin receptor antagonist migraine  (strong side effects)
NF449 octasodium salt 42.9 102.7 ok G protein antagonist
Propantheline bromide 38.7 65.6 ok blocking of acetylcholine hyperhidrosis; cramps or spasms 
of the intestinal tract
Wortmannin 35.1 94 ok phosphatidylinositol 3-kinase inhibitor none, high liver toxicity
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To confirm and extend the results of the screenings, the TEM-CagA assay was repeated with 
these ten substances following the protocol layouts described in Figure 28. Corresponding 
percental CagA translocation rates are summarized in Figure 32A. Unfortunately, the 
inhibitory activities of dihydroergocristine methanesulfonate, methysergide maleate, NF449 
octasodium salt and propantheline bromide could not be reproduced with the same 
suppressive potential that was observed in the initial screening; so these compounds were 
excluded from further experimentations. In addition, cantharidin and cantharidic acid revealed 
a high cytotoxic effect in the CELL- and SCREENapproaches (Figure 32A), as assessed by 
deficient CCF4 loading. This was also observed in the screening (see Figure 31E), and might 
be the reason for the discovered inhibition. Also wortmannin caused a reduced CCF4 loading 
when added to cells, and was thus omitted from future studies. A complete translocation 
blockage was discovered for iodoacetamide employing the BACapproach and an inhibition of 
approximately 50% when present during infection (SCREENapproach), which is in 
accordance with the screening results. In addition, a strong translocation inhibition was 
reproduced for the related compounds LLH-1 and LLH-2, but only when present during 
infection (33% and 8% translocation at 35 µM, SCREENapproach), indicating neither an 
antibacterial nor a cytotoxic effect of the substances.  
To independently prove the results of the TEM-CagA assay for iodoacetamide, LLH-1 and 
LLH-2, the alternative CagA tyrosine phosphorylation assay was performed; corresponding 
immunoblots are shown in Figure 32B. For iodoacetamide, the strong effect observed in the 
BACapproach could not be shown by CagA phosphorylation analysis (left blots, Figure 32B), 
suggesting that the compound might interfere with the TEM-CagA assay. Anyway, 
iodoacetamide would not have any potential for therapeutic application due to its rather 
unspecific alkylating activity. In contrast, LLH-1 reduced CagA phosphorylation drastically, 
and LLH-2 even completely abolished phosphorylation applying the SCREENapproach (right 
blots, Figure 32B), which confirmed the results of the TEM-CagA assay. Analysis of 
respective co-culture supernatants revealed a substantial decrease of IL-8 secretion upon 
LLH-1 and LLH-2 treatment (80% and 50% IL-8 induction, respectively; see Figure 32C), 
and corresponded to the strength of the translocation decline. Even so, the induction of a basal 
IL-8 secretion verified a functional Cag-T4SS despite the impaired CagA translocation 
ability. To further exclude an antibacterial effect on H. pylori, growth curves were performed 
in the presence of LLH-1 and LLH-2 (see Figure 32D). As in the primary growth screening, 
no adverse effects on H. pylori growth could be observed.  
Taken together, the related LLH-1 and LLH-2 compounds seem to specifically inhibit CagA 
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translocation, which was proven by the TEM-CagA as well as the tyrosine phosphorylation 
assay. Of importance, the substances do not exhibit an anti-H. pylori effect, as was 
demonstrated via BACapproach testing and growth analysis. Thus, LLH-1 and LLH-2 
constitute promising lead substances for specific CagA translocation inhibition and should be 
investigated in future studies. 
 
 
Figure 32: Confirmation of LOPAC screening results 
A) Confirmation of LOPAC hits. Translocation was quantified using the TEM-CagA assay according to the 
protocol layouts described in Figure 28. Compound concentrations are indicated, and values are derived from 
maximally two measurements. CCF4 loading refers to the green fluorescence signals recorded in the TEM-CagA 
assay, and low values indicate eukaryotic cytotoxicity. 
B) Immunoblot analysis of infected AGS cells with phosphotyrosine (4G10) and CagA (AK257) antibodies. 
Cells were infected with P12 wild-type in the presence of the indicated compounds following protocol layouts 
like in A), and analyzed via Western blot (WB). 
C) Analysis of co-culture supernatants derived from B) for IL-8 secretion via sandwich ELISA. All values were 
normalized to the IL-8 values found in the supernatants of infected but untreated cells, and are indicated as mean 
values with standard error of the mean from two independent infections. 
D) Growth analysis of H. pylori in the presence of LLH-1 and LLH-2. OD550 was recorded every 5 min for at 
least 16 h and experiments were independently repeated two times. The figure depicts a representative growth 
curve. 
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3.5 Screening of the NCL library 
3.5.1 Screening with the TEM-CagA translocation assay  
Next, another natural compound library (NCL; from Helmholtz Centre for Infection Research, 
Braunschweig) was screened for CagA translocation inhibition. This library comprised 259 
purified myxobacterial compounds, that are known for their unique structures as well as 
numerous described bioactivities in the nanomolar range [207]. Hence, only a low 
concentration of 4 µM was employed in the screening. Figure 33A gives an overview of the 
influence of every single compound on translocation.  
 
 
Figure 33: Summary of NCL library screening 
A) Screening for CagA translocation inhibition using the TEM-CagA assay. Each dot represents the effect of a 
compound on translocation at 4 µM. 
B) Overview of compound hits exhibiting a translocation rate lower than 80% as well as chondramide A. In 
addition, a summary of activity spectra and modes of action is indicated. See text for further information. 
 
In total, 9 compounds were able to inhibit translocation by more than 50%. All compounds 
with translocation rates below 80% are listed in Figure 33B. Of importance, most of the 
substances that influenced translocation belonged to the same compound class. Thereby, the 
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NCL-1a 13.7
antifungal, cytotoxic Eukaryotic respiratory chain inhibitor
NCL-1b 20.7
Aurachin A 18.3
antibacterial, antifungal, cytotoxic Known antibacterial & respiratory chain inhibitor
Aurachin B 78.9
Aurachin C 25.8
Aurachin variant 14.0
Chondramide A 83.8
antifungal, cytotoxic Eukaryotic cell modulator (inhibits actin polymerisation)Chondramide B 67.0
Chondramide D 51.1
Chondramide F 68.6
Cruentaren A 2.9 cytotoxic Eukaryotic respiratory chain inhibitor (inhibits F-ATPase)
Elansolid A2 72.6 antibacterial Known antibacterial
Icumazole A 20.4 antifungal Eukaryotic respiratory chain inhibitor
Myxalamid PI 79.9 antibacterial, antifungal, cytotoxic Known antibacterial & respiratory chain inhibitor
Myxovalargin A 69.1
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detected natural compounds could be classified into three groups: eukaryotic cellular 
modulators, known antibacterials, and exclusively eukaryotic respiratory chain inhibitors. The 
compounds targeting cellular structures comprised four variants of chondramides, known for 
their ability to inhibit the actin cytoskeleton [208] as well as for a cytostatic and antifungal 
activity [209], and three representatives of tubulysins, named after their property to inhibit 
tubulin polymerization [210]. Among the known antibacterials, there were three 
myxovalargins that exhibit a general antibiotic effect against gram-positive bacteria and at 
high concentrations also against gram-negatives [211] due to inhibition of protein synthesis 
and membrane disruption [212]. In addition, a derivative of the antibacterial elansolid was 
detected, although this compound has so far only been described to be active against gram-
positive bacteria [213]. Moreover, four variants of aurachins and myxalamid PI were 
discovered. Both classes have been reported to be active against gram-positive bacteria, yeast 
and molds [214, 215], as well as to inhibit the eukaryotic respiratory chain [216], whereas 
aurachins were also shown to inhibit the E. coli respiratory chain. The last group comprised 
described antifungal and/or cytotoxic substances, namely NCL-1a/b, cruentaren A [217, 218], 
icumazole A [219], two thiangazoles [220] and pellasoren A [221]. Except for the unknown 
bioactivity of the latter, all of these compounds were reported to inhibit eukaryotic 
respiration. Above all, these compounds exhibited higher inhibitory potential on translocation 
than the other two groups. Follow-up studies investigated the interaction of H. pylori with 
representative compounds of all three groups and are described in the following chapter. 
 
3.5.2 Follow-up studies 
To determine whether the substances interact with H. pylori, the cells or both components, 
TEM-CagA translocation analysis was performed using the protocol layouts described in 
Figure 28 (BAC-, CELL- and SCREENapproach). As representatives for eukaryotic cellular 
modulators, the substances with the highest inhibitory capabilities, chondramide D and 
tubulysin A, were analyzed (see Figure 34A&B). Effects on translocation in the 
SCREENapproach (equal to screening conditions) could reproduce the results of the 
screening, albeit relatively weak for tubulysin A. No inhibition was observed using the 
BACapproach, but strong effects (only ~30% translocation) were detectable applying the 
CELLapproach, suggesting that translocation reduction relied on modification of the AGS cell 
cytoskeleton. Moreover, these results were confirmed via tyrosine phosphorylation assays 
(data not shown). As the actin polymerization inhibitory activity of chondramides has been 
described to be comparable to cytochalasin D [208], and tubulysins target the same structure 
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as nocodazole [210], the observed effects are in accordance with the results already described 
in Chapter 2.6.1. Nevertheless, to validate the BACapproach, growth analysis in the presence 
of chondramide D and tubulysin A was conducted (see Figure 34C&D) and no anti-H. pylori 
effect was observed, as expected.  
 
 
Figure 34: Follow-up studies of cell modulatory and antibacterial NCL hit compounds 
A) Quantification of TEM-CagA translocation by plate reading in the presence of chondramide D. AGS cells 
were infected with P12[TEM-CagA] according to the protocol layouts described in Figure 28. The average blue-
to-green ratios were normalized to the mean ratio of untreated P12[TEM-CagA]-infected cells. 
B) Quantification of TEM-CagA translocation by plate reading in the presence of tubulysin A. Experiments were 
performed as described in A). 
C) Growth analysis of H. pylori in the presence of chondramide D. OD550 was recorded every 5 min for at least 
16 h and experiments were independently repeated at least 3 times. The figure depicts a representative growth 
curve. 
D) Growth analysis of H. pylori in the presence of tubulysin A. Experiments were performed as described in C). 
E) Quantification of TEM-CagA translocation rates by plate reading in the presence of myxovalargin A. 
Experiments were performed as described in A). 
F) Growth analysis of H. pylori in the presence of myxovalargin A. Experiments were performed as described in 
C). 
 
As a representative for the known antibacterials detected within the screening, 
myxovalargin A was further examined (see Figure 34E&F). TEM-CagA translocation 
analysis revealed a complete inhibition in the BACapproach at 4 µM and a very strong 
O
D 5
50
A)
C)
Time [min]
O
D
55
0
B)
D)
E)
Ca
gA
tr
a
n
sl
o
ca
tio
n
(%
)
Ca
gA
tr
a
n
sl
o
ca
tio
n
(%
)
Ca
gA
tr
an
s
lo
ca
tio
n
(%
)
40 nM Myxovalargin A 
4000 nM Myxovalargin A 
400 nM Myxovalargin A 
Control
40 nM Myxovalargin A
4000 nM Myxovalargin A 
400 nM Myxovalargin A 
4000 nM Chondramide D
400 nM Chondramide D 
4000 nM Tubulysin A
F)
Control
4000 nM Chondramide D
Control
4000 nM Tubulysin A
Time [min]
O
D 5
50
Time [min]
100
80
60
40
20
0
20
0
40
0
60
0
80
00
100
80
60
40
20
0
0.8
0.6
0.4
0.2
0
0.8
0.6
0.4
0.2
0
20
0
40
0
60
0
80
00
100
80
60
40
20
0
20
0
40
0
60
0
80
00
0.5
0.4
0.3
0.2
0
0.1
 RESULTS 103 
influence (~10% translocation) in the SCREENapproach. No effect was observed for the 
CELLapproach (Figure 34E), indicating an antibacterial effect of the compound against 
H. pylori. To verify this, H. pylori growth was monitored in the presence of myxovalargin A 
and similar to the CagA inhibition, a growth deficiency was detected at 4 µM (Figure 34F). In 
line with this, myxovalargins were reported to act at high concentrations against gram-
negative bacteria [211]. Similar observations were made for myxalamid PI and also 
concluded for elansolid A2, so that these substances were excluded to be useful as specific 
type IV secretion inhibitors. 
 
As the antibacterial aurachins showed a very strong influence on translocation and were 
reported to inhibit the bacterial as well as the eukaryotic respiratory chain, these substances 
were tested together with the other respiration inhibitors detected in the screening. Results are 
summarized in Figure 35A. Following the protocol layouts explained in Figure 28, 
concentrations needed for 50% translocation inhibition (IC50) were determined by non-linear 
regression analysis, and the titration of icumazole A is depicted in Figure 35B as example. 
For the BAC- and SCREENapproaches, IC50 values were constantly lower than IC50 values of 
the CELLapproach, indicating strong effects on H. pylori, although effects on cells could not 
be excluded due to the known cytotoxic properties of the compounds. Importantly, IC50 
values were in the nanomolar range, revealing a very high potential of the substances. 
Nevertheless, growth analysis of H. pylori P12 in the presence of these compounds exhibited 
remarkable anti-H. pylori effects. These observations lead to the conclusion that effects on 
CagA translocation were possibly caused by an antibacterial action on H. pylori instead of a 
specific type IV secretion system inhibition. However, the compounds seemed to be very 
interesting for further studies because of their rather undescribed antibacterial activities 
(except very weak ones against gram-positive bacteria reported for NCL-1a, aurachins [215] 
and cruentaren A [218]). Thus, MICs (minimal inhibitory concentrations) and IC50 values 
regarding H. pylori growth inhibition were determined (see Figure 35A), and again yielded 
very low effective concentrations in the nanomolar range. To rule out any strain-specific 
effects, H. pylori B8 and TIGR were additionally tested, and similar inhibitory potentials were 
detected (see Figure 35C with pellasoren A as example). For examination of a general 
antibacterial effect, three further bacterial species were cultured in the presence of the natural 
compounds: C. jejuni as the closest relative of H. pylori, E. coli as a further representative for 
gram-negative bacteria, and S. aureus as a representative for gram-positive bacteria (see 
Figure 35A&C with aurachin A as example). No antibacterial effect was observed for NCL-
1a, pellasoren A as well as thiangazoles, and small effects were detected for C. jejuni and 
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S. aureus in the presence of aurachins, cruentaren A and icumazole A. However, these effects 
were only obtained applying 4 µM compound concentration and solely delayed growth. In 
contrast, 4 µM substances were by far sufficient to completely suppress growth of H. pylori. 
 
 
Figure 35: Follow-up studies of respiration-inhibitory NCL hit compounds 
A) Table summarizing the influence of the indicated compounds on CagA translocation and bacterial growth. 
Translocation was quantified using the TEM-CagA assay according to the protocol layouts described in Figure 
28. Values depict mean IC50 values (concentration for 50% inhibition) of CagA translocation (nM) from at least 
four independent experiments, calculated by non-linear regression analysis. MIC (minimal inhibitory 
concentrations) and IC50 of growth (nM) were determined analyzing growth curves of H. pylori P12, and 
calculations were based on at least five independent experiments. Effects on C. jejuni, E. coli and S. aureus were 
monitored via growth curves in the presence of 4000 nM. Observations were based on at least three independent 
experiments. 
B) IC50 CagA translocation titration curves of icumazole A as example.  
C) Growth curves of H. pylori strains P12, B8 and TIGR in the presence of pellasoren A as example. 
D) Growth curves of C. jejuni, E. coli and S. aureus in the presence of aurachin A as example. 
 
Compound IC50 CagA translocation
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Growth inhibiton of H. pylori P12
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(at 4000 nM)
BACapproach CELLapproach SCREENapproach MIC IC50 C. jejuni E. coli S. aureus
NCL-1a 46 >4000 86 3.9 1.5 no no no
Aurachin A 72 1469 94 125 25.7 yes no weak
Aurachin B 512 >4000 893 1000 160.2 no no yes
Aurachin C 169 >4000 91 62.5 14.15 no no yes
Cruentaren A 27 >4000 144 31.25 5.0 yes no weak
Icumazole A 23 175 22 62.5 10.4 yes no weak
Pellasoren A 16 1874 76 125 40.33 no no no
Thiangazole A 37 183 8 15.6 4.2 no no no
Thiangazole B 6 247 6 7.8 2.4 no no no
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Taken together, the screening of the NCL library did not reveal promising candidates for 
specific type IV secretion system inhibition. However, interesting compounds were 
discovered that seem to be highly effective against H. pylori, but not against other bacteria. 
As these small molecules have been reported to mainly inhibit respiration, an effect on the 
H. pylori respiratory chain was assumed as well, as will be investigated in more detail in 
Chapter 4. 
 
3.6 Screening of SPECS libraries  
3.6.1 Screening with the TEM-CagA translocation assay  
Hitherto, natural compounds and commercially available pharmaceuticals were examined. In 
addition, also a library from the company SPECS, comprising 2240 uncharacterized 
chemically synthesized small molecules, was screened for CagA translocation inhibition. The 
library is split into two sub-libraries: SPECS-selected (n = 1120) and SPECS-random 
(n = 1120) (see Figure 36A). The SPECS-selected library contained exclusively substances 
with chemical structures (e.g. regarding hydrophobicity) considered to be more prone to enter 
gram-negative bacteria. Thus, the probability to detect biological activities in H. pylori should 
be enhanced. In contrast, SPECS-random comprised randomly selected substances from the 
company library. Both libraries were screened at a concentration of 35 µM using the TEM-
CagA translocation assay. Screening results of the SPECS-selected library are summarized in 
Figure 36B and those of the SPECS-random library in Figure 36C. Surprisingly, the SPECS-
selected library revealed two compounds that were able to suppress CagA translocation below 
50%, whereas the SPECS-random library comprised ten substances with a translocation 
inhibition of more than 50%. The single hits are listed in Figure 36D and were numbered 
successively SLH1 to SLH12, where SLH1 and SLH2 were derived from the SPECS-selected 
and SLH3-12 from the random library. Of these, SLH2 turned out to be a false-positive hit in 
follow-up studies (data not shown), and SLH5 exhibited virtually no loading with CCF4, 
indicating a cytotoxic activity of this small molecule against AGS cells which might be the 
reason for the reduced CagA translocation. In conclusion, the design of the SPECS-selected 
library failed with regard to its hit rate, as the control library with randomly selected 
compounds clearly revealed a higher rate (1 versus 9 compounds).  
It should be noted that the compounds of the first two plates of the SPECS-random library 
displayed a wide scattering of translocation efficiencies (see Figure 36C). These barely 
convincing results are derived from the plates already mentioned in Chapter 3.2 (Figure 29C), 
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that exhibited low Z´-factors (~0.2). Considering this, some potential hit compounds might 
not have been detected during the screening of these two plates. 
As a next step, SPECS hit compounds (except SLH2 and SLH5) were investigated in follow-
up studies, and are described in the following chapter. 
 
 
Figure 36: Summary of SPECS library screenings 
A) Overview of the SPECS-selected and the SPECS-random library. 
B) Screening of the SPECS-selected library for CagA translocation inhibition using the TEM-CagA assay. Each 
dot represents the effect of a compound on translocation at 35 µM.  
C) Screening of the SPECS-random library for CagA translocation inhibition using the TEM-CagA reporter 
assay. Each dot represents the effect of a compound on translocation at 35 µM.  
D) Overview of compound hits exhibiting a translocation rate below 50%. SLH1 and SLH2 were derived from 
SPECS-selected and SLH3 – 12 from SPECS-random. 
 
3.6.2 Follow-up studies  
A summary of SPECS follow-up studies is presented in Figure 37. All values presented with 
an approximately sign (~) refer to estimations from three independent measurements due to 
limitations in compound availability, while all other values were determined following 
statistical standards. At first, to evaluate the impact of the SPECS compounds on bacteria, 
cells or both, the TEM-CagA translocation assay was applied following different protocol 
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layouts described in Figure 28, and IC50 values were determined by non-linear regression 
analysis (summarized in Figure 37). All substances showed lower IC50 values for the 
BACapproach than for the SCREENapproach, while no effect in the CELLapproach was 
observed at 35 µM (except for SLH4), suggesting that the substances specifically target the 
bacteria. Growth analysis of H. pylori in the presence of SPECS substances showed clear anti-
H. pylori effects (presented as MIC and IC50 values, Figure 37) that correlated with the 
observed translocation inhibition. In conclusion, no specific CagA translocation inhibition 
could be inferred. But encouraged by the specific anti-H. pylori effects of the NCL hit 
compounds (Chapter 3.5.2), the effect of SPECS substances on C. jejuni, E. coli and S. aureus 
was examined at 35 µM. Only SLH12 showed an activity against all three bacteria. Indeed, 
SLH4, 6, 8, 10 and 11 did not exhibit general antibacterial activities, and only weak effects 
were observed for SLH1, 3, 7 and 8, suggesting a specific action of some SPECS compounds 
against H. pylori.  
In summary, no specific type IV translocation inhibitor was identified, as all compounds 
displayed clear anti-H. pylori effects. Nevertheless, as for the NCL library, most of the 
substances seemed to have a higher effectivity against H. pylori than against other bacteria. 
For various NCL library hits, a bioactivity as respiratory chain inhibitor was reported 
(described in Chapter 3.5). Following this, it was hypothesized that the rather undescribed 
SPECS substances might also target the H. pylori respiratory chain. Hence, the SPECS hits 
together with promising NCL respiratory chain inhibitors were investigated in individual 
follow-up studies presented in the following section. 
 
 
Figure 37: Follow-up studies of SPECS library hits 
Summary of the influence of the indicated compounds on CagA translocation and bacterial growth. 
Translocation was quantified using the TEM-CagA assay according to the protocol layouts described in Figure 
28. Values indicate mean IC50 values (concentration for 50% inhibition) of CagA translocation (nM) from at 
least four independent experiments, calculated by non-linear regression analysis. MIC (minimal inhibitory 
concentrations) and IC50 of growth (nM) were determined analyzing growth curves of H. pylori P12, and 
calculations were based on at least five independent experiments. Values presented with an approximately sign 
(~) are estimations from three independent experiments. Effects on C. jejuni, E. coli and S. aureus were 
monitored via growth curves in the presence of 35 µM of the respective compound. Observations were based on 
at least three independent experiments. 
Compound IC50 CagA translocation
(µM)
Growth inhibiton of H. pylori P12
(µM)
Effect on growth
(at 35 µM)
BACapproach CELLapproach SCREENapproach MIC IC50 C. jejuni E. coli S. aureus
SLH1 ~ 0.98 >35 ~ 1.4 0.35 – 3.5 n.d. very weak no no
SLH3 ~ 2.9 >35 ~ 8.2 3.5 - 35 n.d. very weak no no
SLH4 0.069 ~35 0.46 0.5 0.15 no no no
SLH6 0.43 >35 5.6 16 3.7 no no no
SLH7 ~ 1.7 >35 ~ 6.6 0.35 – 3.5 n.d. no no weak
SLH8 0.21 >35 1.2 1 0.25 no no no
SLH9 ~ 0.69 >35 ~ 0.97 3.5 - 35 n.d. no no yes
SLH10 ~ 4.7 >35 ~ 30 3.5 - 35 n.d. no no no
SLH11 ~ 35 >35 >35 ~35 n.d. no no no
SLH12 ~ 0.43 >35 ~ 1.3 3.5 - 35 n.d. yes weak yes
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4. Characterization of novel respiratory chain inhibitors in 
H. pylori 
Screenings of the NCL (Chapter 3.5) and SPECS libraries (Chapter 3.6) for specific type IV 
secretion system inhibitors revealed a set of small molecules that exhibited strong 
antibacterial effects against H. pylori, but not against other bacteria. Concerning the NCL hits, 
these observations are also confirmed by previous studies, where the compounds were not 
recognized as antibacterials, but as highly effective eukaryotic respiratory chain inhibitors, 
especially NCL-1a, cruentaren A [217, 218], icumazole A [219] and thiangazoles [220]. None 
of these studies tested effects on H. pylori. Hence, it was suspected that these substances 
might also target respiration of H. pylori. This hypothesis was also extended to the rather 
uncharacterized chemically synthesized SPECS substances. Following this, several efforts 
were made to demonstrate the action of the NCL and SPECS compounds on H. pylori 
respiration, which are described in the following chapters.  
 
4.1 Comparison of NCL and SPECS hits with known inhibitors 
Despite recent efforts [222], the respiratory chain of H. pylori has not been fully 
characterized, which hampers investigations to identify individual proteins as antibacterial 
targets. As a first step, more familiar respiratory chain inhibitors, namely antimycin A and 
rotenone, were examined. Both compounds were reported to inhibit H. pylori respiration 
[223-225], but as the NCL hits, antimycin A as well as rotenone are more prominent as 
eukaryotic respiratory chain inhibitors, targeting complex III (cytochrome bc1 complex) and 
complex I (NADH-ubiquinone oxidoreductase), respectively. Thus, as for the NCL and 
SPECS hits, IC50 of CagA translocation, H. pylori growth inhibition (MIC and IC50) as well as 
the effect on other bacterial species was determined for antimycin A and rotenone 
(summarized in Figure 38). As for the NCL and SPECS hits, effects on CagA translocation 
were highest in the BAC- and SCREENapproach, and H. pylori growth was completely 
inhibited at relatively low concentrations (8 µM and 0.5 µM, respectively). In contrast, no 
effects were observed for other bacteria even at concentrations as high as 50 µM (see Figure 
38). Overall, the magnitude of antimycin A effects was similar to that of SLH6, while 
rotenone was more potent and comparable to effects of SLH4 (see Figure 37).  
The main purpose of the respiratory chain is the generation of a proton motive force (PMF) 
that drives the production of ATP (oxidative phosphorylation). Thereby, the PMF can be 
independently destroyed by ionophores. To take also into account that NCL and SPECS hits 
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might act as ionophores and not as specific respiratory chain inhibitors, effects of the known 
ionophore CCCP on CagA translocation and bacterial growth were analyzed for comparison. 
Indeed, treatment of H. pylori with CCCP resulted in similar patterns regarding CagA 
translocation and growth inhibition as for the known respiratory chain inhibitors or NCL and 
SPECS hits (e.g. MIC of 2 µM, Figure 38). In contrast to these substances, however, also 
growth of C. jejuni, S. aureus and E. coli was completely inhibited or strongly affected at 
CCCP concentrations that were effective against H. pylori. Since the known respiratory 
inhibitors as well as NCL and SPECS hits displayed a high specificity towards H. pylori, an 
action as ionophores seemed very unlikely for these compounds.  
Taken together, inhibitory profiles of known H. pylori respiration inhibitors exhibited similar 
profiles to NCL and SPECS hits by means of translocation inhibition and antibacterial effects, 
while this was not the case for the rather unspecifically acting ionophore CCCP.  
 
 
Figure 38: Effects of known respiratory chain inhibitors and CCCP on H. pylori 
Summary of the influence of antimycin A, rotenone (both known H. pylori respiratory chain inhibitors) and 
CCCP (carbonyl cyanide m-chlorophenyl hydrazone, ionophore) on CagA translocation and bacterial growth. 
Translocation was quantified using the TEM-CagA assay according to the protocol layouts described in Figure 
28. Values depict mean IC50 values (concentration for 50% inhibition) of CagA translocation (µM) from at least 
four independent experiments, calculated by non-linear regression analysis. MIC (minimal inhibitory 
concentrations) and IC50 of growth (µM) were determined analyzing growth curves of H. pylori P12, and 
calculations were based on at least five independent experiments. Effects on C. jejuni, E. coli and S. aureus were 
monitored via growth curves in the presence of the indicated concentrations. Observations were based on at least 
three independent experiments. 
 
4.2 Impact of NCL and SPECS hits on membrane potential and 
permeability 
Because the comparison with known respiration inhibitors regarding translocation and growth 
inhibition properties provides only indirect parameters of respiration blockage, several 
parameters that are directly affected by respiratory inhibition were elucidated.  
At first, the influence of the compounds on membrane potential was investigated. The 
membrane potential is a component of the PMF, and thus collapses in response to respiratory 
chain inhibition. H. pylori was incubated for 3 h with NCL and SPECS hits as well as 
controls, and effects were evaluated using DiOC2(3) (3,3′-diethyloxacarbocyanine iodide), 
that exhibits a shift from red to green fluorescence in response to membrane potential 
destruction. Corresponding outcomes of the highest concentrations applied are summarized in 
Compound IC50 CagA translocation(µM)
Growth inhibiton of H. pylori P12
(µM)
Effects on growth
(50 µM antimycin A/rotenone; 10 µM CCCP)
BACapproach CELLapproach SCREENapproach MIC IC50 C. jejuni E. coli S. aureus
Antimycin A 0.55 >100 6.1 8 2.9 no no no
Rotenone 0.15 27.4 0.45 0.5 0.083 no no no
CCCP 1.9 181.4 3.8 2 0.67 inhibition yes inhibition
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Figure 39A, and flow cytometry analysis of pellasoren A, SLH8 and rotenone are exemplarily 
depicted in Figure 39B.  
 
 
Figure 39: Effect of NCL and SPECS hits on membrane potential and permeability 
A) Table summarizing the effects of the indicated substances on membrane potential and permeability at the 
highest concentrations applied. H. pylori was incubated for 3 h with the respective substances, and membrane 
potential and permeability was evaluated with DiOC2(3) (3,3′-diethyloxacarbocyanine iodide) or PI (propidium 
iodide), respectively. Experiments were repeated at least three times. 
B) Influence on membrane potential in the presence of pellasoren A, SLH8 and rotenone expressed as red-to-
green fluorescence ratio. 
C) Influence on membrane permeability in the presence of selected substances or rotenone. Ampicillin was 
applied as a positive control for membrane disintegration. Values presented are mean values of MFI (median 
fluorescence intensity) of four independent experiments with standard errors of the mean. ANOVA (one-way, 
Tukeys post hoc test) referring to untreated control, *: p<0.05. 
 
A clear membrane depolarization was observed for all substances, except for SLH11. This 
substance also showed comparatively weak effects on CagA translocation and H. pylori 
growth (see Figure 37) and thus, the used concentration might have been too low to induce a 
 RESULTS 111 
potential collapse. But more plausibly, SLH11 might have another target in H. pylori and 
might not interfere with the membrane potential. 
The membrane potential can also be destroyed when membrane integrity is disturbed by, for 
example, pore-forming agents or antibiotics like ampicillin. To exclude such rather unspecific 
effects, the influence of the compounds on membrane permeability was additionally 
determined. For this purpose, propidium iodide was applied, that only enters permeabilized 
H. pylori cells and can be detected in the red fluorescence channel by flow cytometry. 
Ampicillin was used as a positive control as it leads to disintegration of the bacterial 
membrane (shown in Figure 39C). Unfortunately, the effect of SLH1 could not be evaluated 
as its red color interfered with the measurement. Apart from that, no significant influence on 
permeability could be observed for any of the other substances (Figure 39A). Only a slight 
increase of red fluorescence could be observed for aurachin C and SLH12 (see also examples 
in Figure 39C). Concerning SLH12, the previously determined inhibitory parameters (see 
Figure 37) also showed effects on other bacteria and indicated, together with a slight 
influence on permeability, an unspecific antibacterial effect rather than specific H. pylori 
respiratory chain inhibition. 
In conclusion, all NCL hits caused a specific membrane potential inhibition, while from the 
SPECS hits, SLH11 and SLH12 were excluded as potential H. pylori respiratory chain 
inhibitors. In the following experiments, only SLH4, SLH6 and SLH8 were investigated as 
these compounds exhibited the most promising and specific anti-H. pylori inhibitory profile 
(compare also Figure 37). As the membrane potential is a component of the PMF, it is 
intimately involved in oxidative phosphorylation which was focused on next. 
 
4.3 Influence of NCL and SPECS hits on cellular ATP content 
A functional respiration is necessary for energy conservation in form of ATP production 
(oxidative phosphorylation). Hence, cellular ATP levels after incubation with NCL and 
selected SPECS hits were examined. For this purpose, H. pylori was shortly exposed to the 
respective substances (only 5 min), and ATP concentrations were determined via a luciferase-
dependent reaction in the plate reader. Corresponding percental ATP concentrations are 
summarized in Figure 40.  
Overall, bacterial ATP contents rapidly decreased in a concentration-dependent manner for all 
NCL hits (Figure 40A), SPECS hits (Figure 40B) as well as for antimycin A and rotenone as 
controls (Figure 40C). Of importance, concentrations causing a 50% decrease were close to 
the MICs for H. pylori growth (compare Figure 35 and Figure 37), except for SLH4 where 
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only a 50% reduction in ATP content was detected at 35 µM. To rule out any general 
antibacterial effects, experiments were also repeated with several antibiotics (Figure 40D). 
Although lethal concentrations were applied, no effect on bacterial ATP concentration could 
be observed under these assay conditions. In conclusion, the reduced ATP levels evoked by 
NCL and SPECS hit compounds were supposed to arise from direct respiration inhibition. 
 
 
Figure 40: Influence of NCL and SPECS hits on cellular ATP concentration 
H. pylori was incubated for 5 min with the indicated substances, and ATP content was quantified following a 
luciferase-catalyzed reaction. Values were normalized to an untreated control, and are indicated as mean values 
with standard errors of the mean from at least three independent measurements. ANOVA (one-way, Tukey post 
hoc test) referring to untreated controls, *: p<0.05, **: p<0.01, ***: p<0.001, ns: no significant difference. 
A) Effects of NCL hits on bacterial ATP concentration.  
B) Effects of SPECS hits on bacterial ATP concentration.  
C) Effects of known respiration inhibitors on bacterial ATP concentration.  
D) Effects of antibiotics on bacterial ATP concentration. 
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4.4 Impact of NCL and SPECS hits on oxygen consumption 
Oxygen consumption is stringently coupled to respiration in an obligate aerobic bacterium. 
Hence, this parameter was directly measured when H. pylori was exposed to NCL and SPECS 
hit compounds in Oxoplates, which contain an integrated fluorescence-sensitive oxygen 
detector. As H. pylori mainly oxidizes organic acids as an energy source [226], pyruvate and 
lactate were added to H. pylori suspensions, which were exposed to respective compounds in 
nutrient-free buffer, and the resulting oxygen consumption was monitored. Results for 
pyruvate as an energy source are summarized in Figure 41 and for lactate in Figure 42, and 
the arrows designate the injection of the respective organic acid.  
As expected, in the presence of rotenone and antimycin A, oxygen consumption was blocked 
with pyruvate (Figure 41A) or lactate (Figure 42A) as an energy source, with rotenone 
inhibiting respiration more efficiently than antimycin A. Consistently, the inhibitory potential 
of rotenone against H. pylori growth was also higher (compare Figure 38). Besides these 
controls, oxygen levels were also examined in the presence of various antibiotics to exclude 
any unspecific read-out (Figure 41B & Figure 42B). Although these compounds usually 
exhibit antibacterial effects against H. pylori, no influence on oxygen consumption was 
observed, strengthening the validity of this measurement. Next, NCL-1a, cruentaren A and 
icumazole A were examined (Figure 41C & Figure 42C). NCL-1a and icumazole A both 
inhibited respiration to the same level as rotenone. In addition, NCL-1a still blocked oxygen 
consumption at a lower concentration which is in accordance with its overall high impact on 
H. pylori (compare Figure 37). In contrast, no respiration inhibition was monitored for 
cruentaren A, although a drastic reduction in bacterial ATP content was shown in the previous 
chapter (4.3). One possible explanation would be that cruentaren A specifically inhibits the 
bacterial F0F1-ATPase, which leads to strongly reduced ATP levels but does not influence 
electron transport within the respiratory chain. Accordingly, cruentaren A has been shown to 
have an inhibitory effect on mitochondrial ATPase activity in eukaryotic cells [217, 218]. 
Examination of respiration in the presence of aurachins (Figure 41D & Figure 42D) showed 
an inhibitory potential of aurachin A and C on the level of rotenone and less effects of 
aurachin B, which is consistent with the effectivity against H. pylori growth and CagA 
translocation (compare with Figure 35). Strikingly, aurachin C exhibited an even higher 
inhibition than rotenone for lactate respiration. Respiration inhibition by pellasoren A and 
thiangazoles revealed blockage to the same extent as by rotenone (Figure 41E & Figure 42E). 
Similar results were also detected for the SPECS hits (Figure 41F & Figure 42F) that 
inhibited oxygen consumption similarly to H. pylori growth or CagA translocation (compare 
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Figure 37).  
Results observed with α-ketoglutarate and succinate as energy sources were basically similar 
to those described above, although oxygen consumption after injection was only weakly 
induced (data not shown).  
 
 
Figure 41: Influence of NCL and SPECS hits on oxygen consumption with pyruvate as substrate 
H. pylori was incubated with the indicated compounds in nutrient-free buffer (PBS), 7 mM pyruvate was 
injected after 4 minutes (indicated by an arrow), and oxygen consumption was monitored. Experiments were 
performed in Oxoplates that have integrated fluorescence-sensitive oxygen detectors. Values indicate mean 
values of at least three independent measurements with standard error of the mean. ANOVA referring to 
untreated controls (two-way, Bonferroni post hoc test), *: p<0.05, **: p<0.01, ***: p<0.001. 
A) Influence of known respiratory chain inhibitors on oxygen consumption as control. 
B) Influence of antibiotics on oxygen consumption as control. 
C) Influence of NCL-1a, cruentaren A and icumazole A on oxygen consumption. 
D) Influence of aurachins on oxygen consumption. 
E) Influence of pellasoren A and thiangazoles on oxygen consumption. 
F) Influence of selected SPECS hits on oxygen consumption. 
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Figure 42: Influence of NCL and SPECS hits on oxygen consumption with lactate as substrate 
H. pylori was incubated with the indicated compounds in nutrient-free buffer (PBS), 7 mM lactate was injected 
after 4 minutes (indicated by an arrow), and oxygen consumption was monitored. Experiments were performed 
in Oxoplates that have integrated fluorescence-sensitive oxygen detectors. Values indicate mean values of at 
least three independent measurements with standard error of the mean. ANOVA referring to untreated controls 
(two-way, Bonferroni post hoc test), *: p<0.05, **: p<0.01, ***: p<0.001. 
A) Influence of known respiratory chain inhibitors on oxygen consumption as control. 
B) Influence of antibiotics on oxygen consumption as control. 
C) Influence of NCL-1a, cruentaren A and icumazole A on oxygen consumption. 
D) Influence of aurachins on oxygen consumption. 
E) Influence of pellasoren A and thiangazoles on oxygen consumption. 
F) Influence of selected SPECS hits on oxygen consumption. 
 
In general, effects were comparable between pyruvate and lactate, although with the latter 
substrate, oxygen was consumed much faster. This effect can be explained by the conversion 
of lactate to pyruvate by H. pylori lactate dehydrogenase [227]. Within this reaction, 
additional reduction equivalents are produced and fed into the electron transport chain, 
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leading to higher respiratory rates. 
Since the inhibitory concentrations for respiration of the investigated NCL and SPECS hits 
were similar to those for CagA translocation and growth inhibition (compare Figure 35 and 
Figure 37), these anti-H. pylori effects were suspected to result from respiration inhibition.  
 
4.5 Determination of cytotoxicity and evaluation as potential drug 
candidates 
The data obtained in the previous chapter strongly indicated an action of the investigated NCL 
and SPECS hits on the H. pylori respiratory chain. As various anti-H. pylori effects were 
present applying only very low concentrations, the respective substances could be potential 
therapeutic drug candidates to treat H. pylori infection. Hence, the most promising candidates 
were examined regarding their cytotoxicity against eukaryotic cells.  
The most effective and specific anti-H. pylori compounds from the NCL library comprised 
NCL-1a, pellasoren A and thiangazoles. However, highly cytotoxic effects (in the nanomolar 
range) of pellasoren A [221] and thiangazoles [228, 229] have been described in prior studies, 
while no exact cytotoxic concentration for NCL-1a has been recorded. Thus, NCL-1a as well 
as the most potent SPECS hits (SLH4, SLH6, SLH8) were tested for their cytotoxic effects in 
mouse fibroblasts (L929), as summarized in Figure 43.  
 
 
Figure 43: Determination of cytotoxicity and therapeutic indices 
Cytotoxicity in L929 cells was determined via an MTT assay. Experiments were repeated three times and IC50 
values were calculated by non-linear regression analysis. Values highlighted in grey are derived from Figure 35 
and Figure 37 and serve as an orientation for effectivity against H. pylori. The therapeutic index (right column) 
was calculated by dividing the toxicity IC50 values by the IC50 of H. pylori growth inhibition. 
 
The most potent cytotoxic effects were detected for NCL-1a (IC50 of 1.8 µM), followed by 
SLH4 (IC50 of 26.1 µM), whereas the IC50 values for SLH6 and SLH8 were out of the 
determined range (>100 µM). Although cytotoxicity of NCL-1a seemed to be relatively high, 
the compound also exhibited very strong effects on H. pylori CagA translocation and growth 
(data on growth also summarized in Figure 43). To better compare the substance 
concentration needed to cause a therapeutic effect (inhibition of H. pylori) to the 
concentration that causes cytotoxicity, therapeutic indices were calculated referring to the IC50 
Compound Cytotoxicity Growth inhibiton of H. pylori Therapeutic index
IC50 MIC IC50 Cytotoxicity (IC50) / Growth inhibition (IC50)
NCL-1a 1800 nM 3.9 nM 1.5 nM 1200
SLH4 26.1 µM 0.5 µM 0.15 µM 174
SLH6 >100 µM 16 µM 3.7 µM >27
SLH8 >100 µM 1 µM 0.25 µM >400
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values of growth inhibition (right column, Figure 43). In this regard, NCL-1a showed a broad 
therapeutic window when comparing the cytotoxic concentration with that needed for growth 
inhibition. In addition, SLH8 exhibited the highest therapeutic indices, as compared to SLH4 
and SLH6. Following this, NCL-1a and SLH8 are highly recommended to be further 
investigated in future studies including more detailed target identification examinations, 
additional cytotoxicity determinations as well as animal studies to evaluate the in vivo effects 
of compounds for eradication of H. pylori infection. 
118 RESULTS  
  
 DISCUSSION 119 
IV. DISCUSSION 
The bacterial pathogen H. pylori colonizes the gastric mucosa of half of the world´s 
population and is the causative agent of gastritis, peptic ulcers as well as gastric 
adenocarcinoma. Due to increasing antibiotic resistance rates, therapeutic treatment of 
H. pylori infection becomes a major challenge to public health. One key event in the 
induction of the above-mentioned malignant disorders is the delivery of the oncogenic CagA 
protein via type IV secretion into host cells. Hence, studying the exact mechanism of CagA 
translocation is relevant to find possibilities to inhibit this process and to prevent CagA-
induced pathogenesis. Hitherto, the analysis of CagA translocation was time-consuming as 
well as labor-intensive. During this work a novel reporter assay, based on a β-lactamase 
(TEM-1) fusion to CagA (TEM-CagA), has been developed which overcomes these 
limitations. This TEM-CagA assay was applied to study various aspects of CagA 
translocation dynamics and recognition processes by the Cag type IV secretion machinery. 
Moreover, this assay was downscaled to screen various small compound libraries to identify 
potential CagA secretion blockers. Besides two promising specific Cag-T4SS inhibitors, these 
screenings revealed various eukaryotic respiratory chain inhibitors with high efficacy and 
specificity against H. pylori growth, which were further analyzed for their action on H. pylori 
respiration. 
 
1. The novel TEM-CagA reporter assay: fast, specific and 
quantitative analysis 
CagA is delivered into host cells via a type IV secretion-mediated process. Once inside, CagA 
gets phosphorylated immediately at distinct tyrosine residues (EPIYA motifs) by cellular 
kinases [74-76]. For many years, CagA translocation has been routinely determined via 
Western blot analysis of this specific phosphorylation event. But this method is labor- and 
time-intensive, and thus not suitable for high-throughput applications. During this work, a 
novel phosphorylation-independent CagA translocation reporter has been developed. This 
new assay is based on fusion of an E. coli β-lactamase (TEM-1) to the N-terminus of the 
CagA protein. After translocation of the respective TEM-CagA fusion protein into target 
cells, the enzymatic activity of TEM-1 is measured via conversion of the fluorescent β-lactam 
derivative CCF4. The cleavage product of CCF4 differs in its fluorescence signal from the 
intact substrate, resulting in a shift from green to blue fluorescence (see detailed description in 
Figure 8). During this work, it could be convincingly demonstrated that the blue-to-green 
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fluorescence ratio corresponds to translocated TEM-CagA protein. Hence, various cell lines 
infected with TEM-CagA-expressing mutants exhibited high and reproducible blue-to-green 
fluorescence ratios. Moreover, it could be shown that TEM-CagA is translocated by a T4SS-
mediated process, such that a mutant, which is deficient in the Cag-T4SS but expressing 
TEM-CagA, did not evoke a blue-to-green fluorescence signal increase, even after over-night 
incubation with the CCF4 substrate. In addition, co-expression of wild-type CagA and the 
TEM-CagA fusion resulted in mutually reduced translocation of both proteins, suggesting a 
competitive recognition by the Cag-T4SS. The high specificity of the assay was further 
proven by the fact that treatment of host cells with TEM-CagA lysates did not result in a blue-
to-green fluorescence increase, providing evidence for CCF4 conversion exclusively by 
translocated TEM-CagA inside the host cytosol. The high sensitivity of the assay was 
highlighted by detecting very low translocation rates of distinct CagA variants, which was not 
verifiable via CagA phosphorylation analysis in prior studies. In addition, translocation was 
observable after infection at low multiplicities of infection (~6), as well as after very short 
infection durations (about 15 min). In previous studies, CagA phosphorylation was visible 
after 20 to 30 minutes and increased over time, but quantification by immunoblotting is 
complicated [230-232]. Therefore, various aspects demonstrated the applicability of the TEM-
CagA assay as a quantitative tool, and the blue-to-green fluorescence ratio correlated with the 
amount of translocated CagA protein. The fluorescence ratio increased dependent on infection 
duration as well as on MOI, finally resulting in a signal saturation. In addition, a gradual 
decrease of TEM-CagA translocation after sequential truncation of the CagA C-terminal 
secretion signal was maintained, in compliance with the CagA phosphorylation analysis 
presented here, or as previously reported [131]. The blue-to-green signal strengths observed in 
different cell lines, for example in Kato III and J774.1, were also in accordance with the lower 
CagA phosphorylation levels in J774A.1 compared to Kato III cells reported elsewhere [233]. 
Finally, the assay was suitable to titrate the dose-dependency of various inhibitors on CagA 
translocation, supporting the quantificability of the method. In line with this, a reliable 
correlation of translocated TEM-1 and CCF4 turn-over was demonstrated by the delivery of 
TEM-1 fusion proteins via the Legionella pneumophila Dot/Icm T4SS [234]. The principle of 
using TEM-1 fusions for secretion analysis has been originally adapted from Charpentier et 
al., who applied the assay to type III secretion analysis of E. coli [174]. Since then, the 
reporter system was adapted to study bacterial effectors of type III secretion, for example in 
Yersinia pestis [185], as well as of type IV secretion of the Dot/Icm T4SS of L. pneumophila, 
as already mentioned above [186, 235]. For the Cag-T4SS, Suzuki et al. applied TEM-CagA 
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fusions to study translocation of CagA variants. However, these TEM-CagA variants were 
plasmid-encoded and not evaluated for quantitative analysis [236]. Previously applied cagA 
complementation plasmids often yielded variable or low CagA expression levels [131]. In 
contrast, within the work presented here, a chromosomal cagA reconstitution system was used 
which allowed stable (TEM)-CagA expression as well as the expression of diverse variants 
with only introducing minimal changes compared to the wild-type situation. Hence, 
quantitative translocation analysis of these TEM-CagA variants was achieved in a fast and 
reproducible manner. 
 
The TEM-CagA-mediated conversion of fluorescent CCF4 was measurable by various 
fluorescence-assisted devices, including flow cytometry or fluorescence photometry. While 
FACS analysis enables precise quantification of secretion on a single-cell level, plate reader 
applications offer the advantage to be less labor-intensive, because measurements are 
conducted directly in CCF4 solution and do not require washing steps. This raised the 
possibility to miniaturize the assay to a 384-well format and to use it for medium-throughput 
screening of various compound libraries. In this respect, the Z´-factor, a widespread measure 
for the quality or power of a high-throughput screening (HTS) assay [200], confirmed a high 
validity of the TEM-CagA assay for HTS applications. This is in agreement with prior 
studies, which successfully applied the same reporter principle to identify type III or type IV 
secretion system inhibitors in other bacteria [234, 237], and advocates usage of the TEM-
CagA assay in further, ideally automatized, compound library screenings.  
 
As emphasized above, the novel TEM-CagA assay outperforms the validity of the tyrosine 
phosphorylation assay. During the studies presented here, the analysis of CagA 
phosphorylation of distinct variants was hampered by the common blot background which 
complicates analysis of putative phosphorylation bands, especially of weakly expressed CagA 
variants. This finally distorted phosphorylation rates compared to the TEM-CagA assay 
results in some cases (see as an example Figure 21). Moreover, the TEM-CagA assay is 
phosphorylation-independent, which permitted analysis of TEM-CagA variants lacking the 
EPIYA region as well as in the presence of kinase inhibitors. The tyrosine phosphorylation 
analysis might additionally misjudge or overestimate CagA translocation rates, because 
phosphorylation does not follow a linear process but is rather dependent on a multistep 
activation of the Src and c-Abl kinases, and more than one EPIYA motif can be 
phosphorylated simultaneously [232]. In addition, human gastric epithelial cell lines exhibit 
different expression and activation levels of Src and c-Abl kinases, which influences the 
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intensity of CagA phosphorylation [238]. In order to avoid an EPIYA motif-dependent 
analysis, a phosphorylatable GSK-tag was fused to CagA in prior studies [131]. But the 
subsequent immunoblotting still constituted a labor- and time-intensive procedure with 
limited sensitivity and quantifiablity. Comparing IL-8 induction analysis to the TEM-CagA 
assay, CagA-mediated IL-8 induction did not detect minor changes in translocation rates, 
although IL-8 measurement guaranteed a reliable proof for T4SS functionality (e.g. for the 
sequential C-terminal truncations, see Figure 18). As for CagA phosphorylation analysis, IL-8 
secretion is influenced by host cell-specific factors that vary depending on the cell line [238]. 
Moreover, CagA-induced IL-8 secretion depends on the H. pylori strain [189]. In conclusion, 
the read-out of the TEM-CagA assay directly reflects the CagA translocation rate and is not 
influenced by cellular effects in comparison to CagA phosphorylation and IL-8 secretion 
analysis.  
 
Nevertheless, the TEM-CagA assay should not be applied for interaction studies of CagA 
with host cellular proteins or respective signal transduction analysis. Although TEM-CagA 
induced IL-8 secretion was comparable to that induced by wild-type CagA, no hummingbird 
phenotype was observed upon infection. Induction of this phenotype is dependent on 
phosphorylation of at least two EPIYA motifs [135, 232], and indeed, tyrosine 
phosphorylation of TEM-CagA was difficult to detect. This might be due to the generally low 
expression level of TEM-CagA, or the phosphorylation efficiency might be disturbed by a 
steric hindrance of tyrosine kinase interaction with CagA because of the TEM-1 portion. Such 
a spatial obstruction could also be imagined for a complex formation of TEM-CagA with 
other cellular target proteins, e.g. those that are critical for hummingbird phenotype induction 
as the SHP-2 phosphatase [142, 144].  
 
Apart from that, the TEM-CagA assay offers novel possibilities to decipher Cag type IV 
secretion activity. Up to date, CagA is the only translocated effector protein of the Cag-T4SS. 
Fusion of TEM-1 to other putative translocated proteins might lead to the identification of 
further effector proteins, and the discovery of various type IV secretion bacterial effector 
proteins was achieved by fusion of TEM-1 to candidate proteins [239-242]. Moreover, FACS 
analysis allows investigation on a per-cell basis and in this regard, infected cells shifted 
depending on the amount of injected CagA protein. Hence, cells could be classified into high 
and low CagA-injected populations. Performing this principle for Y. pestis type III secretion, 
mutants could be characterized that did not only affect the translocation rate of Yops (Yersinia 
outer proteins), but also the fidelity of Yop secretion [243]. Another application constitutes 
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the transfer of the assay to in vivo animal models, as previously reported for Y. pestis type III 
secretion [185]. In this study, mice were infected with Yersinia strains carrying TEM-1 
fusions of Yops. Afterwards, different cell types derived from these animals were analyzed 
for TEM-1-mediated conversion of CCF4. In this way, it was discovered that Y. pestis 
primarily targets cells of the innate immune system. Since then, this technique was extended 
for in vivo secretion analysis of various bacteria [235].  
 
In summary, lots of information can be obtained from previous bacterial translocation studies 
applying TEM-1 fusions. The TEM-CagA assay established here enables investigation of 
Cag-T4SS activity in more detail, as well as various in vivo applications. 
 
2. Type IV secretion-mediated CagA translocation: new 
functional insights 
Applying the novel TEM-CagA reporter system, various aspects of Cag type IV secretion 
system functionality and requirements for substrate recognition were investigated, and are 
discussed in the following sections.  
 
2.1 Contribution of specific Cag components to type IV secretion 
system functionality 
The Cag-T4SS is evolutionarily related to the A. tumefaciens VirB/VirD4 T4SS and 
composed of various Vir homologues which are likely to fulfil similar tasks. However, the 
Cag-T4SS harbors many further Cag-specific components whose functions are only partly 
clarified. Up to date, functional insights are mainly derived from studies analyzing the 
influence of respective Cag deletion mutants on CagA phosphorylation, IL-8 induction and 
bacterial pilus formation (see also Table 1) [87, 88]. This knowledge was extended by 
analyzing the direct influence of partially uncharacterized Cag-specific components (CagH, 
CagG and CagP) on CagA translocation via the TEM-CagA assay. Because the Cag-specific 
component CagI was intensively studied before and shown to be indispensable for CagA 
phosphorylation, IL-8 secretion as well as pilus production [103, 106], a cagI deletion mutant 
was used as a translocation-deficient control. As expected, the cagI deletion mutant did not 
reveal a translocation signal applying the TEM-CagA assay. Investigation of an isogenic 
cagH deletion mutant also exhibited a deficient TEM-CagA translocation, which was in 
accordance with prior studies where no CagA phosphorylation was observable with a cagH 
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mutant [115, 116]. As previously reported [103], lack of CagH caused a hyperpiliated 
phenotype with elongated and thickened pili compared to the wild-type. However, these 
abnormal pili did not seem to fulfil a functional role since an abolishment of IL-8 induction 
could also be observed in the cagH deletion mutant [103]. It has been speculated that CagH 
might regulate pilus dimensions by terminating pilus assembly. Indeed, CagH is involved in a 
subassembly with CagI and the putative integrin ligand CagL, both involved in pilus 
biogenesis, and the complex has been localized on the bacterial surface [103]. However, pilus 
location could only be demonstrated for CagL, but not for CagI and CagH, so far [113]. Apart 
from that, CagH is supposed to be integrated in the inner cytoplasmic membrane [93] and 
thought to interact with the membrane-associated CagI as well as CagL at the periplasmic 
face. Moreover, this CagH-CagI-CagL subcomplex was suggested to be important for later 
stages of pilus assembly [106]. The cagG gene is genetically organized together with cagH, 
cagI and cagL [121], and a functional connection between the gene products has been 
proposed [106]. CagG contains an N-terminal signal peptide and is thus supposed to be 
transported to the periplasm, and an interaction of CagG with multiple Cag proteins has been 
observed in yeast-two hybrid screening approaches [94]. Moreover, cagG deletion decreased 
CagI and CagL protein levels [106], supporting an interplay with the periplasmic CagI, CagL 
and CagH subcomplex. In a prior study, CagG has been revealed to fulfil functions as a 
supportive component as its absence attenuated CagA phosphorylation as well as the IL-8 
phenotype [115]. Applying the TEM-CagA assay, a clear reduction in CagA translocation 
could be confirmed upon cagG deletion, further proposing a role of CagG for Cag type IV 
secretion activity. Besides, deletion of cagG partially abolished gastric inflammation via 
reduced colonization of Mongolian gerbils [244]. Another rather understudied component is 
the CagP protein. Upon cagP deletion, the TEM-CagA translocation rate dropped to 
approximately 10%. This is in discrepancy to prior data, where full CagA phosphorylation 
was observed, although cagP was deleted [115]. However, in the prior study a different 
H. pylori strain was used, and just recently a strain dependency of CagP function was 
discovered (K.T. Pham, F. Schindele, E. Weiss, R. Haas, W. Fischer; unpublished data). Of 
note, the predominant gene product of the cagP locus is an upstream non-coding RNA, the 
CncR1 sRNA [121, 122]. CncR1 transcript levels correlated negatively with bacterial motility 
and positively with adhesion, attributing to this sRNA a major regulatory role [122]. It was 
even supposed that the CagP protein itself is not expressed at all, because cagP mRNA 
transcription levels were very low [122]. Nevertheless, the TEM-CagA/ΔcagP deletion 
mutant used in this work still harbored the CncR1 sRNA and exerted an effect on CagA 
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translocation efficiency. Moreover, this mutant exhibited reduced expression of CagI and 
CagL proteins (data not shown), which might be an indirect reason for the decreased 
translocation rate. The particular role of CagP has to be elucidated, though it seems to have a 
regulatory rather than a structural function. For many other Cag-specific compounds, no 
specific function is known, although Cag-T4SS activity is reduced (e.g. CagN). Intriguingly, 
some Cag components only have accessory functions and their absence does not affect Cag-
T4SS function, e.g. Cagζ or CagS. These proteins might be different translocated effector 
substrates and could be addressed in future studies by fusion with the TEM-1 reporter tag. 
 
2.2 Recruitment of CagA to the translocation machinery 
In many T4SS, chaperones serve as interaction partners for effector protein stabilization as 
well as for efficient binding by the coupling protein. During this process, secretion substrates 
might undergo partial unfolding to expose secretion signals for recognition and also to fit 
through the translocation channel [77]. For the Cag-T4SS, CagF has been identified as the 
stabilizing chaperone of CagA. Consequently, the TEM-CagA fusion protein was 
significantly less expressed in the cagF deletion mutant compared to the wild-type, as 
previously described [119]. CagA and CagF are both located at the inner membrane, and it is 
proposed that CagF assists CagA with recognition by the Cag-T4SS. Hence, lack of CagF 
abolishes CagA phosphorylation [118, 119], and as expected, no TEM-CagA translocation 
was observed in the cagF deletion mutant. Early studies identified a tight interaction of CagF 
with an N-terminal CagA fragment [118] and with a region adjacent to the C-terminal 
secretion signal [119]. Recently, Bonsor et al. reported that CagF binds five different domains 
of CagA with high affinity, creating a broad interaction surface. It was suggested that multiple 
copies of CagF form these contacts to maintain the labile CagA in a translocation-competent, 
protease-resistant conformation [120]. Hence, the removal of the N-terminal CagA D1 
domain drastically decreased the strength of the CagA-CagF interaction, as shown by co-
immunoprecipitation experiments, and in consequence, significantly reduced the CagA 
translocation efficiency. The CagA-CagF interaction surface contains the EPIYA region as 
well, but the co-immunoprecipitation analysis performed here showed no decrease of CagF 
binding to the CagAΔEPIYA variant, and the expression level of the CagA variant was 
comparable to the wild-type protein. In addition, full translocation of a TEM-CagA variant 
lacking the EPIYA region was observed. Hence, the stabilizing CagF function seems to be 
compensated by the remaining interaction surface. Furthermore, a competition of CagF 
binding to different CagA molecules is suggested by the experiments with mutants co-
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producing TEM-CagA and a translocation-deficient CagA variant (CagAΔ20C). The TEM-
CagA of this mutant was initially expected to be translocated with an efficiency of 100% but 
the actual rate reached only 74%. Hence, it can be speculated about a competitive CagF 
binding by the two CagA variant proteins. Likewise, a competition for recognition by the 
coupling complex could be assumed. This recognition complex is supposed to be composed 
of the coupling protein homologue Cagβ together with CagZ [95]. Within this assembly, 
CagZ stabilizes Cagβ, and the cytoplasmic part of Cagβ interacts and recognizes CagA. 
Accordingly, both coupling components fulfil, as the CagF chaperone, a function in CagA 
recruitment to the T4SS, because the absence of each single component only affects CagA 
translocation but not Cag-T4SS system functionality [115, 116]. Generally, coupling proteins 
confer substrate specificity to their cognate translocation system as these proteins recognize 
distinct areas of the effector proteins. For type IV secretion systems, signals in the C-terminus 
have been identified to be relevant for recognition [77]. For example, VirB/D4 substrates of 
A. tumefaciens (e.g. VirF) are dependent on C-terminal clusters of positively charged arginine 
residues [190], and substrates of the L. pneumophila Dot/Icm T4SS (e.g. RalF) on C-terminal 
hydrophobic residues or blocks of acidic residues [191, 245]. Also, for the Cag-T4SS, a prior 
study could demonstrate that deletion of the last 20 amino acids rendered the CagA protein 
translocation-deficient [131]. In the work presented here, various efforts were made to further 
characterize this C-terminal secretion signal. Substitution of lysine residues with alanines 
within the last 20 amino acids did not exert an effect on the translocation rate. Furthermore, a 
CagA variant with exchange of all charged amino acids within the last 20 amino acids still 
exhibited a translocation rate of 77%. Hence, a substantial role of C-terminal charged amino 
acid residues onto translocation, as described for other T4SS, could not be demonstrated, 
confirming the results of a prior study [131]. Whereas A. tumefaciens VirF or L. pneumophila 
RalF do not tolerate the removal of more than two C-terminal amino acids [190, 245], the 
elimination of up to six C-terminal amino acids did not affect CagA translocation at all. A 
complete abrogation of translocation was only achieved after removal of the last ten C-
terminal amino acids (CagAΔ10C). Intriguingly, CagA translocation could be reconstituted 
after fusion of arbitrary tags to CagAΔ10C. In a previous study, exchange of the last twenty 
amino acids with the C-termini of VirB/VirD4 A. tumefaciens effectors or T4SS-associated 
relaxase motifs (conferring substrate specificity in conjugation systems) reconstituted CagA 
translocation as well, whereas exchange with rather arbitrary CagF, CagS and CagO C-
terminal amino acid residues did not result in translocation competence. Hence, it was 
speculated that a common conserved secretion signal beyond T4SS reconstituted CagA 
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delivery [131]. However, these prior data were generated via CagA phosphorylation analysis, 
and in the context of the translocation of TEM-CagAΔ10C extended with arbitrary tags (e.g. 
TEM-CagAΔ10C-Myc), it is likely that translocation of the reconstituted C-terminal CagF, 
CagS and CagO extensions were below the detection limit of Western blotting. Consequently, 
for recognition by the Cag-T4SS, not a defined C-terminal amino acid composition seems 
crucial but rather a minimal length of the C-terminal tail. Even so, exchange of the last 10 
amino acids of CagA with diverse tags reconstituted translocation with different efficiencies, 
and site-specific exchange of C-terminal charged amino acids significantly reduced the 
translocation rate. This still suggests an impact of the amino acid composition though not of 
specific residues. It is tempting to speculate that binding of the intrinsically disordered CagA 
C-terminus to the coupling protein or to the CagF chaperone confers a secondary structure to 
the C-terminus. Respective variations in the C-terminal amino acid composition might 
modulate this induced conformation, hindering recognition by the coupling protein complex, 
and ultimately have a different impact on translocation efficiency. In compliance with a 
previous study, C-terminal elongation of full length CagA with arbitrary tags was tolerated as 
well [131]. Notably, the C-terminal extensions in the study presented here reduced the 
translocation rate to the same extent, although the amino acid composition of the distinct tags 
clearly differed. The C-terminal elongations may not directly participate in the recognition 
process, but modulate the proposed C-terminal secondary structure similarly, leading to an 
equally decreased CagA translocation rate. 
 
However, TEM-1 solely fused to the last 195 amino acids of CagA was not translocated 
(TEM-CagAC195, data not shown), suggesting that the C-terminus alone is not sufficient for 
CagA translocation, which was also concluded previously [131]. In contrast, merely 19 C-
terminal amino acids of VirF (A. tumefaciens) and 15 C-terminal amino acids of RalF (L. 
pneumophila) enabled reporter protein translocation [190, 245]. One reason for the 
translocation deficiency of TEM-CagAC195 might be the necessity for other N-terminal or 
internal recognition motifs in addition to the C-terminal secretion signal. Prior data indicated 
a contribution of the foremost CagA N-terminus to translocation, and various N-terminal 
deletion mutants did not exhibit a CagA phosphorylation signal [131]. However, the data 
presented here convincingly demonstrated that neither the first 17 N-terminal amino acids, 
nor the N-terminal D1 domain or the internal EPIYA region are needed for CagA delivery. 
These contradictory results might be caused by the detection limit of prior CagA 
phosphorylation analysis in comparison to the highly sensitive TEM-CagA translocation 
reporter. Moreover, previous CagA variants were only weakly expressed, further questioning 
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the results of phosphorylation analysis [131]. No predicted signal sequence is present in N-
terminal CagA, e.g. for sec-dependent secretion across the inner membrane. Accordingly, the 
full translocation ability of CagA lacking the first 17 amino acids clearly proved the absence 
of an N-terminal secretion signal. Nevertheless, after removal of the N-terminal D1 domain, 
CagA translocation efficiency was strongly affected. This decline in CagA delivery was 
mainly contributed to the lacking CagF stabilization for CagA [120]. Besides, the N-terminal 
D1 domain may be important for interaction with host cell proteins rather than being required 
for translocation. According to the CagA structure, the D1 domain forms a single compact 
domain [127, 130], and various studies showed direct interaction of D1 with host cell proteins 
causing the degradation of tumor suppressors [148, 149]. In addition, the first 200 N-terminal 
amino acids of CagA act as another membrane-binding site, which targets CagA to different 
cell compartments and regulates CagA activity [246, 247]. 
 
Notably, the TEM-CagA variant lacking the N-terminal D2 and D3 domains (TEM-
CagAΔD2-D3-EPIYA) was defective for translocation. It could be speculated that this N-
terminal part of CagA constitutes a supportive second recognition sequence for docking to the 
translocation channel. Such a recognition mechanism has been described for translocation of 
Beps (Bartonella-translocated effector proteins) by the Bartonella VirB/VirD4 T4SS. Beps 
contain a bipartite secretion signal, which is composed of a positively charged C-terminus and 
at least one internal “BID” (Bep intracellular delivery) domain [248]. Moreover, the structural 
fold of the N-terminal CagA domain could contribute to substrate recognition as previously 
described for various relaxases. For example, the TraIR1 relaxase requires an intact C-terminus 
together with specific internal motifs, only present in the folded protein, for T4SS-mediated 
DNA transfer [249]. Another explanation for the involvement of both the N- and C-terminus 
for CagA translocation could be a two-step delivery mechanism. Type IV secretion is often 
considered as a one-step transport process, where the substrate is directly delivered through a 
channel spanning both membranes [82]. Indeed, this route has been biochemically shown for 
the T-DNA transfer through the A. tumefaciens VirB/D4 T4SS [83]. Of note, recent structural 
analysis of the T4SS core complex from plasmid R388 of E. coli revealed no continuous 
transfer channel [86]. Hence, a two-step translocation mechanisms could be imagined as well, 
where substrates would access the secretion chamber from the periplasm. This mechanism is 
also supposed for the pertussis toxin of the B. pertussis Ptl T4SS or some substrates of the A. 
tumefaciens VirB/D4 T4SS [250, 251], which enter the periplasm via sec-dependent systems 
or Vir components, and traverse the outer membrane in a second step. Accordingly, the core 
complex VirB9 component of A. tumefaciens seems to harbor a substrate recognition domain 
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for crossing the outer membrane [252]. Following such a theory, the C-terminal signal 
sequence of the CagA protein would be required for recruitment to the inner membrane 
complex and subsequent transfer across the inner membrane, while the N-terminus would be 
recognized in a second step by outer membrane components for translocation. Whether CagA 
accumulates in the periplasm has not been shown yet. Moreover, both one- and two-step 
mechanisms might work in parallel.  
 
The most obvious reasons for the translocation deficiency of TEM-CagAΔD2-D3-EPIYA 
might be additional aspects, which are decisive for CagA transfer. These include an overall 
reduced interaction surface with the stabilizing CagF chaperone [120], no interplay with the 
putative host cell α5β1 integrin receptor via the D2 single layer β-sheet [114, 127] as well as a 
missing host cell phosphatidylserine association of CagA via the D2 domain [129]. Taking the 
host cell receptor and host membrane interplay into account, a mechanism can be assumed in 
which the delivery of CagA across the host cell membrane requires the N-terminus for 
physical target cell contact, whereas the C-terminal secretion signal is exclusively responsible 
for the initial recruitment and delivery through the Cag-T4SS.  
 
2.3 Impact of active bacterial and cellular processes 
Monitoring TEM-CagA translocation provided novel insights into Cag-T4SS translocation 
dynamics. In time-course experiments CagA translocation stopped after approximately two 
hours irrespective of the MOI applied. Although these observations might be biased in 
comparison to the situation in vivo, it could be assumed that CagA translocation is a self-
limiting process to protect the host cell from the pathophysiological effects of CagA to a 
certain degree. CagA translocation was visible after very short infection durations, which 
indicates that, immediately after addition to the cell culture, the bacteria swim to the cells and 
initiate CagA translocation. As direct host cell contact is required for T4SS-mediated transfer 
of CagA, one could assume that adhesion to the cells triggers assembly of the Cag-T4SS 
and/or initiates translocation. Intriguingly, a regulatory sRNA encoded by the cagPAI, the 
CncR1 transcript mentioned above, constitutes a switch between motility and adhesion to the 
cells [122]. Moreover, observations from the work presented here suggest a major role of de 
novo protein synthesis for CagA translocation competence. First, a CagA and TEM-CagA co-
producing mutant translocated both CagA proteins to the same extent, although basal CagA 
expression levels differed significantly. Second, translocation was immediately inhibited upon 
protein synthesis blockage, which further supports a model in which only freshly synthesized 
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CagA is recruited by the Cag-T4SS. In addition, it could be assumed that the Cag apparatus 
itself has to be newly synthesized. Host cell contact might activate the expression of H. pylori 
T4SS components, as it has been reported for the type III secretion system in Yersinia species 
[253]. In contrast, activity of the Legionella Dot/Icm T4SS is independent of de novo protein 
synthesis [234]. Reliance on freshly synthesized protein might be specific for the Cag-T4SS, 
but not for the functionality of type IV secretion systems in general.  
 
Data presented here suggests that only a small proportion of the CagA protein pool is injected 
into the host cell, which is in accordance with a recent study [193]. However, the CagA 
protein is highly abundant also without host cell contact [254]. One explanation would be that 
the high basal CagA expression level is caused by the in vitro culture conditions and does not 
reflect CagA amounts present in vivo. Another possibility could be that CagA fulfils a 
physiological role. In fact, expression of cagA is upregulated upon iron starvation without any 
host cell contact [255]. Moreover, in vitro iron depletion induced coccoid morphologies in 
strains lacking cagA [195]. H. pylori usually exhibits an elongated and spiral morphology, 
while coccoid phenotypes are induced in context of environmental stress, proposing a major 
role of CagA in iron acquisition. Hence, under iron-limiting conditions, cagA deletion 
mutants showed a reduced ability to colonize Mongolian gerbils [256]. Further data from 
animal and epidemiological studies indicated an inverse correlation of iron levels and the 
severity of H. pylori-induced diseases [125]. The same study could demonstrate that the Cag-
T4SS assembly as well as CagA expression levels increased upon iron limitation, which 
resulted in an augmented translocation rate and higher IL-8 induction levels [125]. It was 
proposed that iron limitation induces, in addition to higher CagA expression levels, an 
increased CagA translocation for proper iron acquisition, facilitating colonization. Within the 
work presented here, this iron limitation was aimed to be modeled by using an iron chelating 
reagent. But an augmented TEM-CagA translocation in response to iron sequestration could 
not be observed. Reasons for this discrepancy might be that in the experiments presented here, 
incubation times to achieve iron depletion were relatively short and the iron concentration in 
the media may be too high to be complexed by the chelating agent. In contrast, the prior study 
investigated strains that were either isolated from iron-depleted animals or long-term cultured 
under iron-limiting conditions [125]. An influence on bacterial translocation competence has 
also been reported upon zinc depletion. In response to bacterial infection, in vivo zinc 
sequestration is mediated by calprotectin, a neutrophil-produced metal ion chelator. Infection 
of calprotectin-deficient mice with H. pylori resulted in lower bacterial burdens and an 
increased inflammation compared to wild-type animals. It was concluded that calprotectin 
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represses the pro-inflammatory activity of the Cag-T4SS in vivo, hence contributing to 
bacterial immune evasion and establishment of the chronic infection [126]. Consistently, 
sequestration of zinc by the metal ion chelator TPEN significantly reduced CagA 
phosphorylation, IL-8 induction as well as Cag-T4SS pilus biogenesis in the prior study 
[126]. In this work, zinc depletion via TPEN also resulted in a reduced TEM-CagA 
translocation, but this inhibition clearly correlated with an anti-H. pylori growth effect. 
Contrarily, the effects on Cag-T4SS activity in the prior study were observed applying a non-
antibacterial TPEN concentration. These discrepant results could be caused by different 
culture conditions, but a reduced fitness of H. pylori upon zinc depletion, which resulted in 
less Cag-T4SS activity, seems obvious as well. However, regarding the simulation of zinc and 
iron depletion, the expected effects on TEM-CagA translocation might have been overlooked, 
because the complexity of the gastric environment and interactions with host responses were 
not included in these in vitro experiments. 
 
The energy requirement for Cag-T4SS activity is another aspect which is poorly understood. 
In general, energy conserved in the form of ATP seems to be indispensable for type IV 
secretion functionality, and the Cag-T4SS incorporates three proteins with a putative ATPase 
activity: the coupling protein Cagβ and the inner membrane complex-associated components 
CagE and Cagα [87, 88]. Although a catalytic activity has been experimentally proven only 
for Cagα so far [96], the absence of Cagβ leads to CagA translocation deficiency and lack of 
CagE as well as Cagα completely abrogates Cag-T4SS functionality. Hence, it is assumed that 
these ATPases convert energy for the translocation process and for biogenesis of the Cag 
apparatus or pilus, respectively. Here, additional evidence for this ATP dependency was 
obtained by the high susceptibility of H. pylori towards various respiratory chain inhibitors, 
which were detected during the screenings for CagA translocation inhibitors. The respiratory 
chain generates a gradient across the bacterial inner membrane, called the proton motive force 
(PMF), which drives ATP generation (oxidative phosphorylation). The PMF is composed of 
two components: an electrical gradient (Δψ or membrane potential) and a proton 
concentration gradient (ΔpH). As expected, exposure of H. pylori to the respiration inhibitors 
induced a shutdown of the membrane potential and a drastic drop in bacterial ATP content, 
which resulted in a translocation inhibition. However, the subsequent growth inhibition of 
H. pylori could also be indirectly responsible for this effect. In addition to ATP hydrolysis, 
transport across membranes often requires the PMF in biological systems [257]. For example, 
the PMF is necessary for the activity of the flagellar type III secretion system (T3SS) 
apparatus, which functions as a proton-driven protein exporter [258]. As a result, CCCP (a 
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proton carrier discharging both the electric potential and the concentration component of the 
PMF) inhibited Y. enterocolitica flagellar T3SS (motility) as well as the Ysc T3SS (Yop 
secretion) [259]. TEM-CagA translocation levels were also drastically reduced upon direct 
inhibition of the PMF via CCCP, or indirectly via the above-mentioned respiratory chain 
inhibitors. However, it is difficult to conclude that the PMF is required for CagA 
translocation, because breakdown of the PMF was immediately coupled to decreased ATP 
levels (data for CCCP not shown). The essentiality of ATP for general physiological 
processes might disturb Cag-T4SS activity as a secondary effect, and, as mentioned above, 
the CagA translocation process itself seems to depend on ATP. Charpentier et al. investigated 
the influence of the PMF on the Dot/Icm T4SS of L. pneumophila, and detected an effector 
translocation inhibition upon CCCP treatment was well [234]. As this inhibition was 
reversible and the bacterial ATP pool was only slightly reduced, the authors speculated about 
a partial contribution of the PMF to the ATP-dependent translocation process. This may be 
the case for T4SS in general, but deciphering a relative involvement of PMF and the directly 
linked ATP levels is highly sophisticated.  
 
Apart from the ATP-dependent CagA delivery via the Cag-T4SS machinery, energy-
dependent host cellular processes are also involved in CagA uptake into the host cytosol 
[129]. Hence, upon depletion of ATP from the host cell, via exposure to various respiratory 
chain inhibitors or CCCP (CELLapproach), the levels of translocated CagA were reduced, 
which is in agreement with previous experiments [129]. Furthermore, the contribution of the 
eukaryotic cytoskeleton on CagA translocation was examined. Upon inhibition of the actin 
cytoskeleton, the CagA translocation rate was clearly reduced, consistent with prior data 
[129]. This effect was not only observed applying common actin polymerization inhibitors, 
but also with natural products of the chondramide class [208], which were thus detected 
during the screening for CagA translocation inhibitors. For the first time, a slight influence of 
the eukaryotic microtubule system on CagA delivery could also be demonstrated. This impact 
was also proven with a common microtubule system inhibitor and with the so-called 
tubulysins [210], which were also identified during the translocation inhibitor screenings. 
Although the cytoskeleton seems to have a major role in CagA uptake, a prior study showed 
that no classical endocytotic processes are involved [129]. In addition, cholesterol in lipid 
rafts (microdomains in the eukaryotic membrane) is important for efficient CagA 
translocation, and cholesterol sequestration decreased CagA phosphorylation [114, 129, 197]. 
The data presented here extended prior findings by demonstrating that inhibitory effects on 
translocation were strongest when cholesterol was constantly depleted from the lipid rafts 
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during infection (SCREENapproach). Of note, the putative target receptor of the Cag-T4SS, 
the α5β1 integrin, is raft-associated as well [113, 114], and a constant raft dissociation by 
cholesterol depletion might be the reason for the strong translocation decline. Moreover, 
H. pylori has been shown to actively recruit lipid raft components to the sites of its host cell 
attachment and to metabolize host cholesterol, which has been additionally linked to Cag-
T4SS-associated activities and CagA-mediated signaling [260]. Besides, binding of CagA to 
host membrane phosphatidylserine (PS) is crucial for its uptake. Interestingly, PS are 
transiently externalized to the outer leaflet of the plasma membrane at the site of bacterial 
attachment, which represents a further contribution of active host processes to CagA 
translocation [129]. Although the exact mechanisms of CagA cellular uptake are unknown, 
one can speculate that upon binding of CagA or the T4SS to the host cell membrane – either 
via lipid raft and integrin interaction, phosphatidylserine binding or everything in parallel – a 
structure originates (e.g. a membrane pore or channel), which requires specific actin and 
tubulin rearrangements.  
 
3. In search of a pathoblocker: specific CagA translocation 
inhibition 
CagA, once inside the host cell, exhibits a tremendous pathophysiological activity leading to 
gastric diseases including cancer development. Hence, for treatment of H. pylori infection, 
inhibition of CagA translocation would be a promising issue. During this work more than 
4000 compounds were tested for inhibition of CagA translocation, using the TEM-CagA 
assay. Finally, two chemically related compounds, LLH-1 and LLH-2, were identified in 
follow-up studies to specifically inhibit CagA translocation.  
 
The TEM-CagA assay proved to be a valuable tool for high-throughput applications. 
However, in the primary screening procedure various unspecific CagA translocation 
inhibitors were detected, and showed that several follow-up studies are necessary to confirm a 
specific action on translocation. As a bactericidal compound activity directly correlates with 
CagA translocation competence, such a secondary inhibitory effect could be quickly 
identified by a subsequent secondary screening monitoring bacterial growth. For hit 
confirmation of the primary TEM-CagA assay screening, three different washing protocols 
(BAC, CELL, SCREENapproach) enabled a precise analysis whether compounds act on H. 
pylori, the eukaryotic cells, or the interplay of both. Hence, substances that unspecifically 
caused translocation blockage due to a cytotoxic effect (e.g. chondramides) could be 
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identified. Finally, the orthogonal CagA phosphorylation assay provided an independent 
demonstration of translocation inhibition. This proof was of major importance, as some 
substances had an impact on the TEM-1 reporter system resulting in false-positive hits (e.g. 
cinnachinon-hydroxymethyl). Although the exact inhibition mechanisms on the TEM-1 
reporter system were not clarified, those false-positive hits might have acted as CCF4 
fluorescence quencher, or exhibited an autofluorescence or inhibited the enzymatic activity of 
the TEM-1 β-lactamase. However, the observed compound-mediated blocking of CCF4-AM 
loading of cells (e.g. by cantharidin) allowed a quick identification of cytotoxic activities, and 
compounds could be immediately excluded from further studies. 
 
The source of the libraries screened in this work covered a broad spectrum ranging from 
chemically synthesized substances to various secondary metabolites. As natural products 
generally exhibit a higher bioactivity and increased hit rates in HTS compared to synthetic 
compounds, the applied concentration of natural compound libraries was lower in the 
screening [261]. Even so, the compound concentrations in the screenings were fixed 
beforehand, and future studies should adapt the hit output by a preceding concentration 
optimization [200]. The two identified CagA translocation inhibitors with activities in the µM 
range, LLH-1 and LLH-2, belong to the same class of chemically synthesized substances. 
Speculating about a mechanism of LLH-1/2-mediated inhibition, a specific impairment of the 
CagA delivery process itself is likely, because Cag-T4SS functionality, as determined by IL-
8-inducing capability, was maintained in the presence of the compounds. Moreover, the 
inhibitory effects were only detectable when LLH-1/2 were present during infection, and 
neither pre-treatment of bacteria nor of cells diminished CagA translocation, which suggests 
either a reversible inhibition or a direct blockage of the bacteria-host interaction.  
 
Generally, monitoring CagA translocation inhibition in a cell culture infection model is a 
promising screening approach. Using such a read-out, various possibilities to inhibit the 
translocation process are covered, including the Cag-T4SS assembly per se, various protein-
protein interactions (e.g. CagH-CagI-CagL) or general enzymatic activities relevant for the 
translocation process (e.g. Cagα), as well as obstruction of H. pylori-host interaction. 
Experimental approaches, where the read-out was based on in vitro or even in silico inhibition 
of enzymatic activities or protein assemblies, regularly yielded highly active substances, 
which exhibited a specific inhibition without off-target activity (e.g. antibacterial). But 
subsequent application of those hit compounds in living organisms often produced no effect 
because the substances were simply not delivered to their targets (e.g. due to a failure in 
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compound uptake or due to metabolic conversion). Such a scenario was the case for a set of 
highly potent imidazo[1,2-α]pyrazines. These compounds inhibited the Cagα ATPase in vitro 
[262], but did not affect CagA phosphorylation when tested in a cell culture infection 
experiment (W. Fischer, personal communication). The TEM-CagA screening mode 
overcomes the limitations of those experimental settings. 
 
Secretion systems are used by various bacteria to exert pathogenic effects, and hence are 
favored targets for development of anti-virulence drugs. Screening approaches, as presented 
here, serve as a valuable tool to increase the chance of detecting specific inhibitors. 
Substantial efforts have been made for blocking type III secretion, leading to the identification 
of compounds targeting a relatively broad range of pathogens including Yersinia, Salmonella 
and Pseudomonas species. Nonetheless, successful eradication of pathogens in animal models 
due to a specific T3SS inhibition has not been shown yet [167, 168]. HTS were applied to 
identify inhibitors of the Brucella abortus T4SS assembly factor VirB8 [263], E. coli T4SS-
mediated conjugation [264], as well as the H. pylori Cag-T4SS relevant Cagα ATPase [265]. 
Similar to the above-mentioned study [262], the latter study of Hilleringmann et al. initially 
investigated the inhibition of in vitro enzymatic activity of purified Cagα. But in this study, a 
series of thiadiazolidine-3,5-diones was discovered showing an in vivo activity as well [265]. 
The most potent compound CHIR-1 reduced Cag-T4SS function including an abrogation of 
CagA phosphorylation and diminished gastric colonization of H. pylori in a mouse model. 
However, pre-treatment of bacteria with CHIR-1 was necessary for these effects, excluding 
the compound as a potential therapeutic pathoblocker. Recently, Shaffer et al. identified two 
synthetic small molecules, C10 and KSK85, which disrupted Cag-T4SS activity [123]. Both 
compounds contained a central peptidomimetic 2-pyridone motif and were previously 
reported to inhibit type I pilus biogenesis in E. coli [266]. The work of Shaffer et al. proposed 
that KSK85 inhibited biogenesis of the Cag-T4SS pilus, while C10 interfered with Cag-T4SS 
activity without affecting pilus assembly [123]. However, no animal studies were presented to 
demonstrate an in vivo effect of the two small compounds. For the applicability of LLH-1/2 as 
pathoblockers, various investigations have to be conducted as well. According to the data 
presented here, a specific translocation inhibition can be assumed, but the exact mechanism of 
action has to be elucidated. Moreover, a structure-activity relationship of LLH-1/2 and further 
related compounds as well as a detailed cytotoxicity determination has to be performed. 
Ultimately, the efficacy of the most potent LLH-1/2 derivatives against CagA-induced 
pathologies and gastric colonization success in an in vivo model of infection has to be 
investigated.  
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Apart from the role of T4SS machineries in translocation of proteins, these systems mediate 
the spread of virulence factors and antibiotic resistances via T4SS-mediated conjugation 
among bacteria. Especially the dissemination of antibiotic resistances is a major threat to 
public health, and leads to increasing treatment failures, also regarding H. pylori infection. In 
addition, the selection pressure by excessive antibiotic usage even accelerates this process 
[267]. Specific T4SS inhibitors are expected to stop this antibiotic resistance spread and 
impose only a weak selective pressure at the same time. Consequently, a perfect Cag-T4SS 
inhibitor would target a broad spectrum of T4SS including other H. pylori-expressed T4SS. In 
particular, besides T4SSs enabling conjugation [78], H. pylori encodes another T4SS for 
exogenous DNA import [79]. Hence, a general T4SS inhibition would also diminish the high 
adaptability of H. pylori. Accordingly, future studies should also investigate the inhibitory 
capabilities of LLH-1/2 against other T4SS. The Cag-T4SS inhibitors discovered by Shaffer 
et al. blocked interbacterial T4SS-mediated DNA transfer in E. coli and T-DNA delivery by 
VirB/D4 T4SS of A. tumefaciens [123]. However, both compounds were not demonstrated to 
inhibit DNA transfer or uptake by further H. pylori T4SSs. Additionally, various unsaturated 
fatty acids, shown to inhibit conjugative systems of various pathogens (Escherichia, 
Salmonella, Pseudomonas and Acinetobacter spp. [264, 268]), could be tested for their action 
against H. pylori T4SSs.  
 
Most people tolerate H. pylori infection without any adverse effects, and after establishment 
of a therapeutic Cag-T4SS inhibitor, only persons at high risk for developing malignancies 
should be treated. Moreover, H. pylori infection might protect against allergies and other 
chronic inflammations [14, 166]. Hence, potential beneficial effects of H. pylori infection 
could be preserved applying a personalized treatment with specific Cag-T4SS pathoblockers. 
In addition, the gut microbiota would be preserved in comparison to treatment with 
antibiotics. Inhibition of CagA translocation might reduce the bacterial load in the stomach, as 
it has been proposed that injection of CagA into host cells provides a colonization advantage 
for H. pylori. Translocated CagA allows H. pylori to exploit the surface of gastric cells as a 
replicative niche and for provision with iron [256, 269]. Furthermore, a functional Cag-T4SS 
has been shown to be relevant for successful colonization in a rodent model of infection 
[152]. But cagPAI-negative strains colonize the human stomach as well, although causing 
milder pathologies. Thus, Cag-T4SS inhibitors are not expected to induce a bacterial 
clearance, and a life-time medication with the translocation inhibitor would be required for 
therapeutic treatment. However, combination therapies of antibiotics with T4SS inhibitors 
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could be imagined to increase the efficacy of antibiotics as well as to decrease resistance 
development. Various highly specific H. pylori respiratory chain inhibitors were identified 
using the screening method described in this thesis, and the validity of these possibly novel 
antibiotics will be discussed in the next section.  
 
4. The H. pylori respiratory chain: a potential drug target? 
During the screenings for a CagA translocation inhibitor, various compounds were 
discovered, which exerted specific and efficient inhibition of H. pylori growth, presumably by 
inhibiting respiration. This section discusses whether these compounds could serve as novel 
specific anti-H. pylori antibiotics with respiration as target. For a better understanding, the 
H. pylori respiratory chain is briefly introduced (reviewed in [222, 270]), and a respective 
schematic is presented in Figure 44.  
 
Bacterial respiratory chains are generally composed of different complexes that transfer 
electrons while pumping protons from the cytoplasm to the periplasm. In a first step, reduced 
substrates are oxidized via various membrane-bound or membrane-associated 
dehydrogenases. H. pylori possesses a dehydrogenase with homology to the mitochondrial 
complex I (NADH-ubiquinone oxidoreductase), the NDH-1 dehydrogenase. Despite a 
quinone reductase activity and a proton pumping function, NDH-1 lacks the region involved 
in oxidizing NADH, and the nature of the electron donor to NDH-1 has yet to be identified. 
Accordingly, the complex is rotenone-insensitive for NADH oxidation, but Nagata et al. 
showed that the overall respiration was sensitive to rotenone, indicating a rotenone-sensitive 
complex I-like structure in H. pylori [223]. Interestingly, H. pylori exhibits higher respiration 
rates for NADPH than NADH, suggesting NADPH as the physiological electron donor, from 
which electrons might be transferred via an intermediate to the respiratory chain. Recent data 
also suggests flavodoxin as the main reductive equivalent [271]. Moreover, H. pylori 
possesses an integral Ni-Fe-type hydrogenase (Hyd) which extracts electrons from molecular 
hydrogen, and various further dehydrogenases (Dehyd), e.g. a D-lactate dehydrogenase, 
malate-quinone dehydrogenase, or the recently identified D-amino-acid dehydrogenase [272, 
273]. From all these (de)hydrogenases, reducing equivalents are fed into the quinone pool, 
which is located in the lipid bilayer of the inner membrane and consists exclusively of 
menaquinone-6 in H. pylori. Electrons are then transferred via intermediate electron carriers, 
the integral cytochrome bc1 complex and the periplasmic cytochrome c553, to a single terminal 
cb (cbb3)-type cytochrome c oxidase, for which oxygen is the electron acceptor. Accordingly, 
138 DISCUSSION  
H. pylori is an obligate microaerophilic bacterium. However, there is also evidence for 
anaerobic respiration with a fumarate reductase (Frd) catalyzing electron transfer from 
menaquinone to fumarate as terminal acceptor. In addition, H. pylori encodes a cytochrome 
c551 peroxidase and S- or N-oxide reductases, indicating hydrogen peroxide and N- or S-
oxides, respectively, as further terminal electron acceptors (not depicted in Figure 44). The 
established proton gradient across the inner membrane, the proton motive force (PMF), is 
converted via an F0F1-ATP synthase into ATP (oxidative phosphorylation). Notably, when 
H. pylori is exposed to the low stomach pH, the periplasmic pH is strictly regulated and 
buffered by urease activity to a pH of 6.2. This allows H. pylori to maintain an optimum pH 
gradient across the membrane and preserve the essential PMF [274].  
 
 
Figure 44: Overview of the H. pylori respiratory chain 
Dashed red arrows depict electron flow, dashed black arrows the proton flow. bc1: cytochrome bc1 complex, c553: 
cytochrome c553, cbb3: cb-type cytochrome c oxidase, Dehyd: dehydrogenase, F0F1: F0F1-ATP synthase, Frd: 
fumarate reductase, Hyd: Ni-Fe-type hydrogenase, IM: inner membrane, NDH-1: NADH-ubiquinone-like 
oxidoreductase complex, OM: outer membrane, PMF: proton motive force. Adapted from [222, 270]. 
 
Within this work, several efforts were made to confirm the action of various compounds on 
H. pylori respiration. These included determination of their impact on the PMF (measured as 
membrane potential), the bacterial ATP content, as well as oxygen consumption in response 
to the substances. As concentrations for H. pylori growth inhibition correlated with those 
detected for effects on respiration, a specific inhibition of the respiratory chain was assumed. 
In addition, many of these compounds exhibited a specific growth inhibition of H. pylori, but 
did not affect growth of E. coli, S. aureus or C. jejuni. Besides natural compounds derived 
from myxobacteria (NCL-1a, aurachins, cruentaren A, icumazole A, pellasoren A and 
thiangazoles) also partially uncharacterized chemically synthesized compounds derived from 
the SPECS library (SLH4, SLH6 and SLH8) were discovered to target H. pylori respiration. 
Most of the myxobacterial products were described earlier as respiration inhibitors, and more 
efficient in inhibiting H. pylori respiration than the chemically synthesized compounds. This 
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is in line with expectations, as compounds derived from myxobacteria are known for their 
bioactivities in the nanomolar range, and an important source for potent lead structures in 
drug discovery [207]. The work presented here is not the first study which reports on 
respiration inhibition of H. pylori. For example, Nagata et al. demonstrated inhibition of 
respiration by the proton pump inhibitor lansoprazole in a similar action to rotenone [223]. 
Additionally, a preceding study showed a specific inhibition of H. pylori by lansoprazole and 
analogues while 27 further bacterial species were not affected [275], which is in accordance 
with the inhibitory pattern detected for the respiration inhibitors here. But why does H. pylori 
exhibit such a high sensitivity towards respiration inhibitors? Unusually for a bacterium, 
H. pylori possesses a rather simple respiratory chain and a single terminal oxidase, whereas 
most aerobic or microaerophilic bacteria contain branched respiratory chains with a variety of 
electron donors and alternative electron acceptors [222, 270, 276]. The overall arrangement of 
the H. pylori respiratory chain is very similar to mitochondrial respiration. As mentioned 
above, H. pylori possesses a rotenone-sensitive NDH-1 dehydrogenase which is a homologue 
to the mitochondrial complex I. In contrast, other bacteria encode up to three different types 
of such NADH dehydrogenases. The complex III-like cytochrome bc1 complex is sensitive 
for antimycin A, which targets mitochondrial complex III as well, and further pinpoints a 
similarity. The only terminal oxidase of H. pylori is related to mitochondrial complex IV, 
while other bacteria, e.g. C. jejuni, have additional terminal oxidases of classes specific for 
prokaryotic electron transport chains. This simple arrangement and homology to 
mitochondrial respiration might be the reason, why H. pylori turned out to be highly sensitive 
to (eukaryotic) respiration inhibitors during this work. In addition, H. pylori exhibited a 
general sensitivity towards small compounds, and for example various antibiotics against 
gram-positive bacteria also influenced H. pylori growth. The relatively high in vitro 
susceptibility of H. pylori, compared even to closely related bacteria such as 
Campylobacter ssp., has been described earlier [277]. This high responsiveness might be due 
to various unspecific transport systems of H. pylori, which the bacterium presumably encodes 
to overcome its limited capacity for biosynthesis [28]. One descriptive example for this is 
rotenone, which inhibited H. pylori in a highly specific and efficient manner, while E. coli 
growth was not affected. Interestingly, rotenone has been shown to inhibit the purified 
complex I of E. coli [278]. This suggests that rotenone is not able to enter E. coli and reach its 
target. Furthermore it could be assumed, that the highly branched respiratory chain of E. coli 
can compensate for the blockage by rotenone while the rather simplified electron transfer of 
H. pylori cannot.  
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For most of the myxobacterial respiration inhibitors, a strong cytotoxic effect was described 
before. Finally, solely NCL-1a revealed a potential therapeutic window as a drug candidate, 
exhibiting a slight cytotoxicity, but with potent and specific action against H. pylori growth. 
Among the SPECS library hit compounds, SLH8 had the best inhibitory profile without a 
cytotoxic effect within the determined range and specific anti-H. pylori activity. For the 
chemically synthesized SPECS hits earlier descriptions on activities are lacking and preclude 
speculations on a defined target within the respiratory chain. The identified myxobacterial 
products were studied before, and hence, possible targets in H. pylori together with their 
therapeutic potential will be discussed next. The most promising compound, NCL-1a, was 
previously shown to inhibit mitochondrial complex I in the micromolar range, comparable to 
the cytotoxic activity against L929 mouse fibroblast within this study. In contrast, H. pylori 
respiration and growth was inhibited in the nanomolar range. Speculating that the substance 
also targets H. pylori NDH-1, it seems to do this with much higher effectivity than for 
mitochondrial complex I, which justifies the application of NCL-1a as a therapeutic inhibitor. 
In addition, NCL-1a specifically inhibited H. pylori growth with high efficiency, but did not 
affect the growth of other bacteria, although minor activities against fungi and gram-positive 
bacteria were previously reported. Also, various aurachins were characterized to have a major 
impact on H. pylori respiration. Aurachins exhibited not only strong anti-H. pylori effects, but 
also S. aureus growth was inhibited, which is in accordance with a prior study [215]. In 
addition, C. jejuni growth was influenced by aurachin A. Regarding the target, aurachins have 
been shown to inhibit mitochondrial and bacterial complex I, mitochondrial complex III in an 
antimycin-like manner as well as the bacterial cb-type cytochrome c terminal oxidase [216, 
278, 279]. In the case of H. pylori all three complexes might be targeted by aurachins. Due to 
the rather unspecific effects and the variety of targets that seem to affect eukaryotic cells and 
other bacteria, aurachins were omitted as potential drug candidates. The class of thiangazoles 
specifically inhibited H. pylori within these studies, and a general inactivity against bacterial 
growth is known from prior studies [220]. Thiangazoles were reported to inhibit 
mitochondrial as well as purified bacterial complex I, and this blockage was at similar 
concentrations observed for H. pylori in the work presented here [220, 278]. Thus, an action 
on the H. pylori NDH-1 complex is likely. However, an application as a therapeutic drug is 
excluded because prior studies revealed an extremely high cytotoxicity due to mitochondrial 
inhibition in the nanomolar range [228, 229]. Interestingly, aurachins and thiangazoles, as 
described above for rotenone, have been shown to inhibit the complex I of E. coli [278], but 
also for these compounds, no growth inhibition of E. coli has been observed during this work 
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as well as in prior reports [215, 220]. This indicates, as for rotenone, that H. pylori seems to 
be more prone for substance uptake and/or fails in compensating the inhibition of complex I. 
The definition of a distinct target for icumazole A is rather speculative. Prior data ascribed an 
antifungal action to this compound, due to mitochondrial NADH oxidation inhibition [219], 
and here, a high efficiency against H. pylori growth as well as weak activities against C. 
jejuni and S. aureus were observed. Moreover, icumazole A exerted strong effects on CagA 
translocation when only cells were in contact with the compound (CELLapproach), which 
also implies a major activity against human cells. Hence, a rather conserved target within the 
respiratory chain might be responsible for the icumazole A effects, which excludes the 
substance as a potential drug. No specific mode of action has been described yet for 
pellasoren A. However, Jahns et al. discovered a highly cytotoxic activity against human 
colon cancer cells at nanomolar concentrations, comparable to those active against H. pylori 
respiration [221]. This indicates the same bacterial and mitochondrial target but restricts the 
usage of pellasoren A as an anti-infective at the same time. Cruentaren A was described 
earlier as a potent inhibitor of mitochondrial F0F1-ATP synthase, but restricted to eukaryotes 
because no effect on a purified E. coli F0F1-ATP synthase was observable [217, 218]. In 
contrast, the data presented here in fact indicates an inhibition of H. pylori F0F1-ATP synthase 
because cruentaren A drastically reduced the bacterial ATP concentration while the oxygen 
consumption, which is independent of ATP synthase activity, was not affected. Accordingly, 
IC50 values of mitochondrial F0F1-ATP synthase inhibition were in the same range as 
inhibition of H. pylori ATP content, which suggests a similarity of this component to those in 
mitochondria. Intriguingly, the membrane potential of H. pylori was also inhibited by 
cruentaren A. This suggests that the H. pylori F0F1-ATP synthase has an ATPase function, 
thus operating reversely as an ATP-driven proton pump as well. This seems reasonable, as a 
strict regulation of proton import and export in or from the periplasm is required to maintain 
the afore-mentioned pH homeostasis for PMF preservation in the acidic stomach niche [274]. 
Indeed, a functional F0F1-ATP synthase was reported to be essential for H. pylori for survival 
at low pH [280]. However, due to its high cytotoxic potential, cruentaren A has no drug 
potential [217, 218], and, in this study, exerted weak effects on C. jejuni and S. aureus as 
well. 
 
According to the data presented here, inhibitors targeting H. pylori respiration often exerted 
major effects on human respiration due to a similar electron transport chain arrangement. 
Thus, the question arises whether the respiratory chain is a suitable therapeutic target at all. 
Potential targets of H. pylori antimicrobials have to fulfill four requirements: they have to be 
142 DISCUSSION  
essential in vivo, constitutively expressed, present in all strains and to have unique 
characteristics different from those of the host [281]. Respiration components match the first 
three preconditions, the latter reflects again the doubtful suitability of H. pylori respiration 
inhibition. Hence, drugs have to target either unique components or target the respiratory 
complexes at sites that differ from those in mitochondria. General suggestions for the 
inhibition of respiration in pathogenic bacteria are energetic machines where no mammalian 
homologue exists, such as NDH-2 (not encoded by H. pylori), cytochrome bd oxidase (not 
encoded by H. pylori), or a hydrogenase [276]. Indeed, as mentioned above, H. pylori 
possesses such a hydrogenase (HydABC), and H2 oxidation is proposed to be responsible for 
a large proportion of electron flux through the respiratory chain [282]. Moreover, this 
hydrogenase is essential for virulence, further suggesting it as a potential drug target [276]. 
Another suitable target might be the putative terminal electron acceptor fumarate reductase 
(Frd), which has been shown to be essential for colonization of the mouse stomach and is 
absent in mitochondria [283]. Targeting the quinone pool or even inhibiting biosynthesis of 
menaquinones might be also a promising approach [276]. Accordingly, the quinone analogue 
ibedenone specifically inhibited H. pylori growth by acting on respiration [284]. As the 
inhibition of H. pylori was accompanied by ibedenone reduction, it was suggested that the 
analogue sequestrated electrons more efficiently than the intrinsic menaquinone. In this work, 
NCL-1a and SLH-8 constituted the most promising candidates with only minor cytotoxic 
effects. Although for NCL-1a an inhibition of the NDH-1 complex seems likely, the exact 
inhibitory activity of both compounds cannot be concluded from this data. Hence, further 
studies have to confirm a specific target, for example by examining the compound effects in a 
cell-free system with purified respiration complex components, as described elsewhere [273]. 
In addition, a metabolome analysis of H. pylori upon exposure to the inhibitors could be 
conducted. In this case, besides the elucidation of a distinct target, further insights in the 
rather understudied respiration of H. pylori might be obtained. Finally, an in vivo activity of 
NCL-1a and SLH8 against H. pylori should be verified.  
 
New drug targets are urgently needed to address the emergence of drug-resistant H. pylori 
strains and the associated treatment failures. One major advantage of a specific respiration 
inhibition of H. pylori would be constituted by a decreased risk for resistance development. 
Antibiotic resistances often develop by mutation of the genes encoding the bacterial target, 
but it is challenging to modify the respiratory chain, as this functional entity has evolved to a 
high complexity. Accordingly, no resistances could be identified upon long-term exposure of 
aurachins and rotenone to H. pylori within this work (data not shown). In addition, potent 
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respiration inhibitors were found to specifically inhibit H. pylori with high efficiency, which 
might enable a preservation of the gut microbiota upon treatment. Although targeting 
H. pylori respiration is critical due to putative toxic effects, a prior study demonstrated that 
the quinone 1,4-di-hydroxy-2-naphthoic acid abolished H. pylori infection in mice without 
exerting adverse effects on the host [285]. This demonstrates that respiration inhibitors could 
be successfully applied for H. pylori eradication. Interestingly, bismuth compounds, which 
have been used in the bismuth quadruple therapy for decades, also exert an inhibition on 
H. pylori respiration [224]. Thus, respiration inhibitors might have been used for years for 
H. pylori treatment but only with minor attention.  
 
5. Conclusion and Outlook 
This work presents a novel Cag-T4SS reporter, the TEM-CagA assay, which allows fast, 
sensitive and quantitative analysis of CagA translocation. Applying this assay, the impact of 
partially uncharacterized Cag-T4SS components on the translocation rate was quantified, and 
the stabilizing effect of CagF on CagA reconfirmed. With respect to the signal recognition 
mechanism of CagA, it was shown that the C-terminal secretion signal is more dependent on a 
minimal length than on its amino acid composition for efficient recruitment by the Cag-T4SS. 
While an influence of utter N-terminal regions on CagA translocation was excluded, several 
internal N-terminal regions are of further importance for CagA delivery. It was demonstrated 
that CagA translocation is dependent on a functional protein synthesis machinery, and 
moreover, efficient CagA uptake is strongly influenced by active host cellular processes. 
Besides, the TEM-CagA assay was successfully applied for identification of specific CagA 
translocation inhibitors, which will serve as valuable tools to investigate T4SS-functionality, 
assembly and delivery mechanisms. Transfer of the TEM-CagA assay into animal models of 
infection will enable analysis of Cag-T4SS activity in vivo.  
In addition, two novel strategies to treat H. pylori infection were investigated. First, two 
specific CagA translocation inhibitors were identified, which could prevent CagA-triggered 
carcinogenesis, and also hold the potential to block the T4SS-mediated spread of antibiotic 
resistances. Second, respiration inhibitors of H. pylori were discovered, which are promising 
future antibiotics due to their high and specific efficiency. Future studies have to further 
evaluate these hit candidates as therapeutic drugs, and an ultimate determination of an in vivo 
action against H. pylori infection would be a big step towards the usage as a new medication. 
Importantly, both approaches overcome the disadvantages of the current antibiotic treatment 
and would preserve the gut microbiota as well as exhibit a low risk for resistance 
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development. As H. pylori is the major risk factor for development of gastric cancer due to 
the oncogenic CagA activity and H. pylori eradication increasingly fails, new strategies to 
combat infection are urgently required. This work did not only contribute to basic research of 
Cag-T4SS activity, but also made promising steps towards future ways for treatment of 
H. pylori infection.  
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